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Abstract
The overall goal of this study was to develop an integrated program of
RTI/STD clinical services within two family planning clinics in urban-harbor, lowincome neighborhoods. Multiple training programs to introduce a standardized
clinical evaluation for the detection, treatment and management of RTI/STDs were
conducted. Prior and subsequent to training, observations of health care provider
(HCP) and client interactions were conducted to evaluate the behavior changes of the
HCP. Each consenting client received a standardized reproductive health history,
pelvic exam, and provided specimens for laboratory testing to detect the RTIs of:
Candida albicans, Bacterial Vaginosis, Trichomonas vaginalis, Chlamydia
trachomatis, Neisseria gonorrhoeae, and Treponema pallidum. On site laboratories
performed microscopic evaluations of combined Gram stains and wet mounts. The
Gram stains were validated by a referral lab at the national infectious disease
hospital. Endocervical & serology specimens were sent to the referral lab for final
confirmation. Of the 478 clients who presented to one of two family planning clinics
within the 12 weeks, 89% (425) were willing to become study participant. A total
of 53 clients refused to participate due to fear of the exam and not enough time, and
113 clients were excluded from participation due to current menstruation or
antibiotics use. The final study sample was 312. Findings indicate that through
universal screening of the participants by an STD referral laboratory, 24.7% (n=77)
of the participants were confirmed to have one or more RTI while 13.8% had one or
more STD (9 women had two diagnoses). The following disease prevalences were
found: chlamydia cervicitis 10.3%; candidiasis 6.7%; trichomoniasis 5.4%; bacterial
vaginosis 5.1%; and gonococcal cervicitis 0.3%. No positive blood tests for syphilis
were detected. HCPs were observed by trained research assistants who recorded an
itemized evaluation of HCP behavioral components. The results of this 70 item
observation tool showed a preference for performing physical examination tasks,
and a reluctance to perform history taking, education, partner treatment plans
and prevention counseling skills.
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Executive Summary
With support from HAPP/AIDSCAP and the Population Council, an eight
month program funded by USAID to improve reproductive health services for
“ordinary housewives” was undertaken. This program included the incorporation of
RTI/STD clinical services into the menu of routine services offered in two family
planning (FP) clinics in North Jakarta. The two study settings included FP clinics at
a 202 bed district hospital, and at a community level primary health center (PHC or
Puskesmas). The primary target group of this study were the health care providers
(HCP) who received the intervention. Five HCPs participated fully in all components
of the study three doctors from the hospital and two midwives from the PHC. The
clientele of these two FP clinics formed the secondary target group of the study. The
clientele were in general married, multiparous, low income women whose primary
risk of acquiring a sexually transmitted infection was via sexual intercourse with their
spouses. The majority of these women, despite being long time consumers of
contraceptive services, had never previously received pelvic examination or been
tested for the presence of RTI/STDs.
Baseline data from the study area of North Jakarta were gathered by use of
multiple interviews with local providers, a retrospective medical record review, and
extensive observations of health care facilities and HCP/client interactions to
determine the feasibility of incorporating RTI/STD clinical services into the family
planning clinical setting. Despite evidence of an acceptable level of resources and
facilities to begin RTI/STD care at the two study settings, there was very minimal
prior experience among the staff in diagnosing or treating specific RTI/STDs.
The existence of an adequate infrastructure combined with the absence of
RTI/STD case recognition pointed to the HCPs as the target group for intervention
activities of this project. The primary intervention was a series of educational
activities for the HCPs on RTI/STD diagnosis and case management. The main study
objective was to assess the feasibility and acceptability of improving FP provider
skills in provision of STD services in the two selected FP clinics. An advisory board
of national experts and leaders from the fields of public health, dermatovenereology,
obstetrics and gynecology, served as editors for the clinical protocols, instructors
during the training, and role models for the HCPs. The basic study design was a
quasi-experimental evaluation comparing the ability of HCPs to recognize and
appropriately respond to RTI/STDs within their population of FP clients before and
after the training intervention. A broad range of data were collected during the course
of this evaluation.
The baseline assessment data and initial educational workshops were
valuable inputs for the development of a standardized clinical evaluation flowsheet
and clinical protocols for use in PHC family planning settings. The standardized
procedures on the flowsheet included obtaining an RTI/STD risk assessment history,
performing a pelvic examination, obtaining laboratory specimens to screen for the
presence of six selected treatable RTI/STDs, selecting a nationally approved
vii

treatment for identified infections, and providing client education with partner
treatment for future disease prevention.
Each presenting FP client during the twelve week post intervention
observation period was individually advised of the main purpose of the study and
given a complete description of the clinical evaluation procedure by a trained
research assistant (RA). Their consent was then requested with an assurance of
voluntary participation and an option to withdraw from the study at anytime without
compromising family planning benefits. All prospective participants were informed
that the examination, laboratory testing and any necessary treatment would not
require any additional charge. Additional project funding for the express purpose of
purchasing medications to treat identified infections was obtained from the Jakarta
chapter of the American Women’s Association (AWA). An additional donation
procured through the Indonesia ObGyn Association (POGI) Jakarta chapter
consisted of 75 single dose anti-fungal treatments for non-pregnant women. No other
incentives to participate were given. The content of this client disclosure was
recorded on an informed consent form. This informed consent form also doubled as
a record of the client’s requested follow-up notification procedure in the case that
final laboratory results indicated the need for additional treatment for either herself
or her partner(s).
Of the majority of clients, 89% of 478 who presented to the two FP clinics
during the twelve week observation, were willing and eager to participate. The
requirement of a full pelvic examination did not discourage the level of participation.
On the contrary, the clients’ desire to learn about their reproductive health status
might have been influenced by the desire to receive “free” medical care and
treatment. The 53 clients who refused to participate cited fear of the exam and not
enough time as the most common reasons, and another 113 clients were excluded
from participation due to current menstruation or antibiotic use. The final number
of study participants was 312. Day-to-day direct post-intervention observations were
conducted in both sites for a twelve week period between February 17 and May 9,
1997. During that period, the 312 client evaluations were observed and a supervisory
medical checklist was used to record progress and behavioral changes among the
five HCPs. Biological samples from the vagina, endocervix, and blood were
obtained to determine the prevalence of six treatable RTI/STDs. Three sociodemographic variables were gathered for all participating clients: age, current
contraceptive use and marital status. Eleven additional potential risk factors for
RTI/STD infection were also explored with each participant. Among those clients
with a confirmed RTI, no risk factor was found to occur at a significantly higher rate
than among uninfected clients, and none of the risk factors had predictive value.
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Through universal screening of the participants by an STD referral
laboratory, 24.7% (n=77) of the participants were confirmed to have one or more RTI
and 13.8% (43) had one or more STD (9 women had two diagnoses). The following
disease prevalences were found: chlamydia cervicitis 10.3%; candidiasis 6.7%;
trichomoniasis 5.4%; bacterial vaginosis 5.1%; gonococcal cervicitis 0.3%. No
positive blood tests for syphilis were detected. HCPs were asked to evaluate and
record on the flowsheet the presence or absence of seventeen separate clinical signs
of infection. Presence of cervical mucopus and cervical inflammation occurred at
higher rates among women who were eventually confirmed to have an RTI but the
difference was not statistically significant. As with the risk factors, no clinicals signs
were found to be predictive of final diagnosis.
Through the standardized history taking/risk assessment and physical
examination procedures, HCPs were encouraged by the trainers to attempt an
accurate clinical/syndromic diagnosis for each client. Doctors were much more
likely to attempt an initial client diagnosis (including negative) than the midwives
(98%.vs 68.5%), and were much more likely to be accurate (41% vs. 35%). 56
women (18%) did not receive an initial diagnosis. Of those 256 women who did
receive a syndromic diagnosis, 7% of women received correct initial positive
diagnoses and 31% received correct negative diagnoses. Thus a total of 98 (38%)
women received a correct initial diagnosis, ie. concurrent with the final diagnosis.
The most common initial diagnosis was a false negative (44%). Concurrence
between initial and final diagnoses improved at the hospital but not at the PHC. By
the end of the observation period (May 9, 1997), 73% of clients with non sexually
transmitted RTIs had received appropriate treatment for their confirmed infections,
and 73.5% (36) of clients with STDs had received appropriate treatment. The
remaining women were not treated as they did not return to the clinic. No one was
treated with inappropiate medication due to pre-packaging and labeling of
medications for the study. Furthermore, only 55% (27) of the sexual partners of STD
positive participants received treatment for infections, potentially exposing 9 of the
treated STD clients to the risk of reinfection.
This low partner treatment rate reflects the level of HCP interpersonal
communication skills found overall. It was found that 62% of the time, the midwives
“smiled and greeted the client respectfully”, while doctors did so only 3.5% of the
time. Only with one client did one HCP (a midwife) review the health effects of
RTI/STDs and make a connection to birth control. Eight clients received information
about the diagnosis and only two clients received any mention of condoms. Only 26
of 63 clients receiving prescriptions were warned of possible side effects (24 of them
by a midwife). Client counseling was generally neglected and risk assessment was
largely delegated to the research assistants which indicated that it was undervalued
by the HCPs who were mostly unwilling to take the time or to ask such personal
questions.

ix

Findings on infection control varied. In only 2 out of 312 examinations did
the HCP not use visibly clean instruments, and for 79% of pelvic examinations, a
new/disinfected glove was used. However, rates of hand washing before and after
the exam were low, about 20% each over the (post-intervention) observation period.
A six month retrospective medical record review (July 1 to December 31,
1996) showed that essentially it is a non-existent practice to categorize gynecological
problems with a disease specific diagnosis. At Koja Hospital, more than 100
diagnosis each of vaginitis and cervicitis were made, but no further diagnoses or
records of counseling were made. Also there was no evidence of a standardized
prescriptive regimen. At Cilincing, a monthly disease report revealed a total of three
RTI/STD diagnoses, all for gonorrhea. These could not be linked to medical records
to assess treatment or interventions as no client identifiers were included.
The main findings revealed that the provision of medical care by the HCPs
and return rate of laboratory results from the referral lab were the greatest constraints
to service integration. Both doctors and midwives were willing to perform
standardized clinical physical examinations with the collection of laboratory
specimens from the vagina and endocervix. However, they were not as consistent in
performing education and partner treatment plans for RTI/STD positive clients. The
referral laboratory could not provide a consistent rate of turn around time for final lab
reports. The actual length of time between initial evaluation and final lab reports
varied from one to four weeks. Future studies of RTI/STDs should strive to improve
diagnostic microscopy skills that have a more rapid final report rate which do not
need to be sent to a referral laboratory.
Another side-product of this study is a RTI/STD treatment formulary, which
was selected after reviewing the costs and benefits associated with each treatment
regimen included in the recently published national STD Treatment Guidelines
(Daili, et al., 1996). Medications were purchased and individually prepackaged for
the six treatable infections that all clients were screened for.
Future efforts to improve reproductive health and STD services for clients
of family planning clinics must also investigate strategies to strengthen or supplement
the skills of the HCP in conducting risk assessment and providing counseling and
partner treatment for clients discovered to be STD positive. The widely held HCP
belief that factually informing a client of the discovery of an RTI/STD would cause
emotional distress was not validated during a single encounter with a client,
according to the RAs. Additional exploration of the client’s and affected partner’s
perceptions of participating in such a program would be invaluable in developing
future strategies to overcome the reluctance of HCPs to see the truth, and speak the
truth about RTI/STDs in the real lives of ordinary housewives.
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I.

Introduction and Literature Review

I.A.

Introduction

In the national workshop on Reproductive Health (RH) last May 1996,
representatives from the Indonesian Ministry of Health (MOH or DepKes), the
National Family Planning Coordinating Board (NFPCB or BKKBN), other public
sector programs, NGOs, professional organizations, and donor agencies, agreed on
four services which will become the main components of the new Essential
Reproductive Health Care (ERHC) Package at the primary health care (PHC) level.
These components are: a) Safe Motherhood; b) Family Planning; c) Management of
Reproductive Tract Infections/Sexually Transmitted Diseases (RTI/STD); and d)
Adolescent Reproductive Health.
This ERHC initiative is a major step towards the implementation of the
International Conference on Population and Development (Cairo, 1994). The ICPD
platform recommended that family planning (FP) services be expanded to include the
prevention and treatment of sexually transmitted diseases (STDs), including
HIV/AIDS, in a reproductive health context, aimed largely at reducing reproductive
morbidity from RTIs in women (Jain, 1995; Zizic, 1994). The HIV epidemic has
made the prevention and treatment of RTI/STDs a high priority on the world's
reproductive health agenda.
Unfortunately, despite the formulation of the ERHC package one year ago,
Indonesia’s MOH currently has no reproductive health program. The maternal and
child health (MCH)/FP programs and STD control programs deliver their services
independently, with the latter targeted primarily at men and high risk groups. This
vertical structure poses potential obstacles to service integration, although
conceptually it seems to be a natural union (Fox, Williamson, Cates and Dalabetta,
1996). The high disease burden of STDs, both in terms of morbidity and mortality,
demand that family planning and infectious disease control programs work together.
I.B.

Literature Review

I.B.1

RTI/STD in Low Risk Populations and Women

RTIs include: (1) STDs, such as chlamydia, gonorrhea, trichomoniasis,
syphilis, chancroid, genital herpes, genital warts, and HIV infection; (2) endogenous
infections caused by overgrowth of organisms in the genital tract of healthy women,
such as bacterial vaginosis and vulvovaginal candidiasis; and (3) iatrogenic
infections, which are brought about by medical procedures (Wasserheit and Holmes,
1992:7). All these infections are preventable or treatable, but current health and FP
programs give them low priority.
Women are more often asymptomatic and thus more difficult to diagnose
than men, but their health is also more seriously threatened by STDs than men. STDs
1

can cause pelvic inflammatory disease (PID) and tubal infertility, and several STDs
can be passed perinatally to infants (Fortney, 1995:6). Women are also more
vulnerable to STD transmission from men than vice versa (Fox et al., 1996). In
addition, women suffer more social stigma associated with sexual morbidity (Fortney,
1995:8). Thus, special attention is needed to alert women to RTI/STDs, encourage
them to seek treatment, use more effective barrier methods that they can control, and
notify their sexual partners so that they too can be treated and prevent reinfection of
the woman.
Worldwide, the most common STDs are trichomoniasis, genital chlamydia,
human papilloma virus, gonorrhea, and genital herpes (Fox, et al., 1996). Estimates
from selected studies of low-risk populations (FP/prenatal clients and adults in
population-based studies) show that among these women, risk of STD/HIV is largely
determined by the behavior of their male partners (Fox et al., 1996:131). Studies in
developing countries indicate that among prenatal clinic attendees, gonorrhea rates
are 10 to 15 times higher, chlamydia rates 2 to 3 times higher, and syphilis rates 10
to 100 times higher than among comparable women in developed countries. Risk
assessment surveys in FP clinics found that 25% of clients report behaviors that put
them at increased risk for STDs (Cates and Stone, 1992:125).
I.B.2

RTI/STD/HIV/AIDS in Indonesia

The magnitude of the HIV/AIDS epidemic in Indonesia is still unknown
because of the lack of a well-monitored surveillance system. Based on a passive
recording and reporting system, 413 HIV(+) cases including 132 AIDS cases were
recorded in 21 out of the 27 provinces of Indonesia, as of May, 1997 (Yayasan Pelita
Ilmu, 1997). Over one-third (31.4%) of these cases were residents of Jakarta. The
first HIV+ baby was announced on October 5, 1996 (the Jakarta Post, October 5,
1996).
In Indonesia, there is precious little data on STDs in non-high risk
populations. In 1994, the Kusuma Buana Foundation (YKB, an NGO working in the
FP and HIV fields) announced a disturbing finding of nearly 29% STD prevalence
among 6,666 women aged 25-45 years who came for Pap-tests at six clinics in
Jakarta and were also tested for STDs (cited in Daili, Nuning and Asri, 1994:4-5).
Another study among 695 women presenting for menstrual regulation (abortion) in
1987 and 1988 at an urban clinic in Bali, found that 53% had one or more RTI/STD,
including 16.3% bacterial vaginosis, 15.5% candidiasis, 7.3% trichomoniasis and
5.2% chlamydia, among others (Susanti, 1993). While 67% of these women were
unmarried, they did not fall into any high-risk group category. A review of studies
and articles on STDs in Indonesia
published between 1988 and 1994 found that the two most frequently mentioned
were gonorrhea (16% to 58%) and non-gonorrheal urethritis (24% to 54%) (Daili,
2

Masjkuri and Adisasmita, 1994:2-6). The reviewers suspected that these data were
limited by the availability of diagnostic facilities (ibid).
Although anyone may be infected, RTI/STDs tend to be diseases of poverty.
Conditions of economic deprivation, social disenfranchisement, and gender
inequality, have a detrimental impact on women’s reproductive health from a very
young age (see Sadli, et al., 1994:6). In general in Indonesia, women seeking care
at a primary health center, or Puskesmas, tend to be of lower socio economis status.
They are not informed or asked about STD/RTI risks when they present themselves
for FP services, and do not receive appropriate information or referrals even if
presenting with potential RTI symptoms. A survey needs assessment on reproductive
health among 318 women (96% married) in rural Bali found that 53.5% of the
women had ever experienced an adverse symptom, including discolored discharge
(36%), odorous discharge (17%), itchiness (34%), genital sores (4%), dysuria (9.5%)
and lower abdominal pain with fever (13.5%). Women were more likely to have
experienced symptoms if they were pill or IUD users or if their husband’s work
required him to travel frequently or live elsewhere. 70% of the afflicted women
sought health care for the problems, 55% of them at a puskesmas. However 53% of
the participants expressed some form of dissatisfaction with the available services
and only 35% had ever received any form of information on STDs (Susanti and
Patten, 1996). There is a great need to address prevailing undiagnosed RTI/STD
problems among poor or rural women.
Clearly Indonesian women are vulnerable to RTIs including STDs and
HIV/AIDS, infertility, and reproductive tract cancers. There is an unmet demand and
need for services and information. A study on women’s perspectives of RTI’s quoted
a Jakarta woman's complaint, "if we go to the doctor and ask whether this [vaginal
discharge] is serious or not, the doctor always answers 'no problem'" (Hull,
Widyantoro and Fetters, 1996).
Why, then, has the primary health care system in Indonesia been incapable
of addressing RTI/STDs? There are four possible answers: (1) women are generally
unaware of RTI/STDs symptoms and do not seek care; (2) only STD clinics offer
STD diagnosis and treatment, and women do not go to STD clinics, thus they are not
approachable; (3) health care providers at the FP clinic (or MCH) fail to recognize
RTI/STD symptoms; and (4) health care providers who recognize RTI/STD do not
inform the client, record the case, nor report it in the monthly statistics.
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I.B.3

Family planning and STDs

Clearly there are differences in clientele and training orientation between FP
and STD services. Unlike STD clinic clientele, FP clients are typically women
seeking contraceptive services who are generally unaware of STDs. FP providers are
more physiologically oriented than microbiologically, and are trained to offer a
choice of options (not a strict treatment regimen). Furthermore, the most common
FP methods have no value for STD prevention, and FP providers are not trained to
ask personal questions about sexual behavior.
In Indonesia, at the hospital and subdistrict health center (Puskesmas) level,
there are very few records of STD diagnoses among FP clients. This is not only due
to a lack of medical and laboratory facilities, but also because FP providers prefer not
to take on uncomfortable topics, such as STDs and extramarital transmission.
Providers avoid confronting the reality of STDs and the need for partner notification
and treatment in their efforts to help patients “save face”.
At the PHC level, there is little evidence of counseling on effectiveness,
advantages and disadvantages of available FP methods, or careful screening of
potential IUD users by history and pelvic examination. All in all, there is a broad
lack of the communication skills (e.g., risk assessment, education, counseling) and
clinical examination skills that are necessary in providing both FP and STD/RTI care.
Professional re-training is needed because the FP and other primary health
care providers are not uniformly aware of STD diagnosis, tests and treatment
regimens. Currently, even in areas with high STD and HIV prevalence rates, many
FP workers are not aware of or equipped to address the risk behaviors of their clients.
On the other hand, the existing STD interventions are not targeted at women in
general, but at high risk groups. FP providers can be trained to make a diagnosis
based on a standardized clinical evaluation, or at the very least, to do a risk
assessment, provide education and make a referral for care.
Risk assessment tools for use with all FP clients can be developed to include
STD risk issues for little additional cost (Fox et al., 1995:131), thus opening the door
for discussion of prevention and counseling. Even just a commitment to offer simple
advice from the FP provider on condom and spermicide use can provide protection
against STDs (Cates and Stone, 1992:122), and is a step up from STD services
available from many FP clinics.
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I.B.4

Costs of FP and STD integration

The costs of adding STD services are always a concern to FP programs. A
recent cost study on RTI management services in India used a production process
analysis model to analyze inputs, processes and outputs, looking at both fixed and
variable costs. It was found that costs vary widely by level of utilization, level of
infection and existing capability of health centers in terms of facilities and staff.
Laboratory testing and treatment costs were found to be high, pointing to an
emphasis on prevention a vital cost-saving strategy in the long term. The authors of
this study recommend that program managers need “to examine both initial and
continuing costs to examine the quality and sustainability of RTI case management”
in the context of the entire reproductive health package (RamaRao, Townsend and
Khan, 1996).
I.B.5

Feasibility, Sustainability and Risks

If women in the general population are to get STD services, public and
private FP/MCH programs are the most logical place to provide them, as they are
women’s primary contact with the health care system. Ideally, FP providers should
be able to understand client needs and be capable of advising clients on methods for
prevention of both pregnancy and STD transmission when needed. So far, FP clients
in Indonesia have not been receiving such information. The decision to expand FP
programs to include STD/HIV prevention or treatment services in accordance with
the ERHC package, involves studying client needs, assessing program capacity and
potential resources, estimating costs and also determining the availability and
acceptability of alternative STD services.
Sustainable integration of FP and STD services also requires that providers
of the two types of services support the integration initiative. There may be
resistance due to the possibility that FP activities may be weakened and human
resources may be spread thin. Training of FP providers in the basics of STDs and
counseling techniques may not automatically bring changes in attitude or practice,
especially if they feel overburdened with new responsibilities or lengthy procedures.
This resistance must be acknowledged and addressed by discussion of the common
service goals and potential for significant and much needed improvement in the lives
of Indonesian women.
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I.C.

Project Summary

In the interests of working towards integrating STD/RTI services into FP
services in Indonesia, as outlined in the MOH’s 'Essential Reproductive Health Care
Package', the Population Council attempted to run a pilot-test in a real primary health
care environment. The study aimed at identifying and attempting to address barriers
to the integration of STD services into FP services in two selected pilot FP clinics.
The intervention involved initial and on-going training of five Health Care Providers
(HCPs) and a follow-up twelve week observation of their attitude and behavior
changes in the delivery of RTI/STD services to 312 consenting client participants.
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II.

Description of Subproject

II.A.

Background

This study is part of the Indonesian Ministry of Health HIV/AIDS prevention
project (HAPP) coordinated by Family Health International/AIDSCAP in
collaboration with U.S. Centers for Disease Control (CDC) and the Government of
Indonesia. The overall goal for year 1 of the HAPP project was to facilitate the
development and implementation of national policies supportive of HIV/AIDS
control and surveillance. This study, by the Population Council Jakarta, as a
subcontracted executive agency has conducted a study focusing on integrating
clinical services for reproductive tract infection and sexually transmitted disease
(RTI/STD) into two different family planning (FP) clinics, one at the primary health
center and one at a public hospital. As the entry point to primary health care for the
majority of women seeking reproductive health services. The FP setting was seen as
the ideal place to prevent and control RTI/STDs.
The two study sites in the target area of North Jakarta include (1) the outpatient FP clinic of the Koja District Public Hospital (Rumah Sakit Umum Daerah
Koja or RSUD Koja), and (2) the Primary Health Center (PHC or Puskesmas) at
Sub-District (kecamatan) Cilincing. Koja (11.3 Km2) and Cilincing (42.6 Km2) are
two of the seven sub-districts in North Jakarta. These two sites are in Jakarta’s
harbor area on the Java sea which is the main port for the commercial shipping and
fishing industries of a metropolitan area of more than 12 million people. Like most
major urban ports, the surrounding neighborhoods are primarily low income. The
predominant occupations in both Koja and Cilincing are sailors, laborers, ship
loaders, fishermen and vendors. In this densely populated area, the average level of
education is middle school level, with only 15% of residents finishing high school
and 3% going on to higher education (North Jakarta Health Office, 1995). The
average number of family members per household is 13.8 in Koja, and 6.7 in
Cilincing (North Jakarta Health Office, App. Table 2). Only 44% of Koja households
have piped water, and even fewer in Cilincing 25% (ibid, App. Table 9 A). The
highest rates of STDs are generally found in urban men and women in their most
sexually active years, ages 15 to 35 (Over and Piot, 1996).
There were two separate target groups in this study. The primary target
group was the health care providers (HCPs) in the two FP clinics who provided the
clinical services. The secondary target group was women who presented as their
clients for FP services. They were selected because the majority of FP/MCH health
care clients are of reproductive age and sexually active. Coincidentally, most of these
women are married, and monogamous sexual behavior for married women is the
cultural norm. This target group was also deliberately chosen as women who were
not necessarily perceived as being at high risk for STD infection. The target group
and the area in North Jakarta make an optimum environment to study the integration
RTI/STD services into the existing venue of FP clinics for reproductive health care.
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According to data from the 1990 census, the total population of the North
Jakarta district was almost 1.6 million, with 341,786 people living in the sub-district
of Koja, and 262,677 people living in Cilincing. The estimated total number of
women of reproductive age between 15 and 44 years was 97,458 in Koja and 74,900
in Cilincing (North Jakarta Health Office, 1995:Table IA). According to the annual
report for 1995 from the North Jakarta Health Office, the total couples of
reproductive age (PUS) seeking family planning clinical services in Koja was 24,068
and in Cilincing 24,364 people (ibid, Table 21A). Koja Hospital received 21 clients
per week, and Cilincing Health Center 19 clients per week, during the observation.
A breakdown of the types of contraception given to these clients reveal that very few
of these sexually active women use a method that is a barrier to the acquisition of
STDs (see Table 1).
Table 1:

Contraceptive Choices in the Two Subdistricts

Contraceptive Method

Koja

Cilincing

Injectable Hormones

36 %

42%

Pills

34%

33%

Intrauterine Device (IUD)

21%

14%

Sterilization

5%

5%

Norplant

2%

4%

Condoms

2%

2%

Source : North Jakarta Health Office. Health Profile for the District of North Jakarta. 1995:
App. Table 21A

The surveillance of reported STDs by the local District Health Office for the
studied area only includes diagnoses of Neisseria gonorrhoeae and syphilis. As a
baseline of reported STDs, Table 2 presents annual cases of STDs recorded by all the
Puskesmas and Hospitals in North Jakarta. However, clearly, this represents an
inadequate recognition of actual disease and incidence rates.
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Table 2:

Rates of Reported STDs by Cases and Total Percentage of Clinic
Visits Diagnosed in Out-Patient Health Care Facilities in 1995 in
North Jakarta.

Out-Patient
Clinic at:
District Health
Center
District
Hospitals

STD Diagnoses

# of Cases

% of Total Visits

gonorrhea

63/417,819

0.015

syphilis

20/417,819

0.005

gonorrhea

299/16,322

1.83

syphilis

15/16,322

0.092

Source : North Jakarta Health Office. Health Profile for the District of North Jakarta. 1995:
Table 10A and 10B

A recent RTI/STD prevalence study among a similar target group of women,
conducted during 1994-1995 in four Puskesmas in urban Jakarta and rural west Java,
performed a total of 1,136 laboratory examinations using wet mount microscopy and
Gram stains to detect bacterial vaginosis, candidiasis, trichomoniasis, gonorrhea, and
Non-specific genital infections (leukocytosis). Based on the results of this study, the
authors cite a combined RTI/STD prevalence rate of 40-45% (Pratomo, Kodim, et
al., 1995: 66-67). Since microscopy is a subjective analysis infections for gonorrhea
and chlamydia, the actual STD prevalence rates may differ from the findings of this
study.
In an attempt to gather additional data illuminating the local consequences
of untreated RTI/STDs, such as ectopic pregnancies and tubal infertility, secondary
data from the infertility clinic of Harapan Kita private hospital was requested. The
percentage of infertility due to tubal factors was 38.5% for 725 women who sought
in-vitro fertility (IVF) treatment between 1991 and 1995. Diagnoses were based on
hydrosalphingography and laparoscopy procedures.
Additional data was also gathered from the WHO Laboratory for Matched
Reagent Program in Immunoendocrinology of the Faculty of Medicine, University
of Indonesia (Makmal Terpadu Immunoendokrinologi, FKUI ). These data recorded
serological markers for past infections with a variety of pathogens that could be
related to auto-immune induced spontaneous abortions (SABs). The prevalence rate
of serological markers for Herpes Simplex Virus (HSV) was 68.9% among 3,475
serological samples and for Chlamydia, 67.7% among 3,821 specimens, all from
women who sought care for SABs between 1994-1996.
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Primary data collection at the pre-intervention stage covered the following
four areas:
1. Study site facility (logistic) observations
2. HCP knowledge, attitudes and acceptance of integrated RTI/STDs into
FP services
3. The level of recorded RTI/STD from FP services in a six month
retrospective medical record review
4. Observations of the content of actual HCP and client clinical interactions.
In summary, the findings from the above four areas of inquiry revealed that
the two selected sites were adequate to support RTI/STD program integration, and,
at the same time revealed specific HCP clinical and record keeping practices that
overlook the possibility of RTI/STD in FP clients. These identified deficiencies
served to guide and direct the development of standardized protocols and training
curricula for use as the study intervention. Results of overall needs assessment
directed attention to problematic health practices that had not been anticipated, such
as infection control and the client education process, and this led to future
adjustments in the original work plan.
II.B

Scope of Work

II.B.1 Objectives
The overall goal of this study was to strengthen the skills of FP providers in
appropriate and feasible methods of RTI/STD clinical practices that would lead to an
effective identification and treatment of women who were infected with certain
RTI/STDs in the family planning clinic setting at the PHC and hospital levels.
During the needs assessment phase, the study design evolved to include the following
specific objectives:
1.

To determine the prevalence of specific RTI/STDs: candidiasis, bacterial
vaginosis, trichomoniasis, gonococcal cervicitis, chlamydia cervicitis, and
syphilis, among women presenting for routine FP services in two FP clinics
in North Jakarta who gave informed consent to participate in this study;

2.

To study possible associations between the presence of infection and the
women’s socio-demographic characteristics, and sexual and obstetric/
gynecological history;

3.

To study the practice of infection control in daily family planning services;

4.

To assess the clinical and laboratory skills of doctors and midwives in the
diagnosis of RTI/STDs in female clients levels;
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5.

To assess the compliance of doctors’ and midwives’ RTI/STD
prescriptive recommendations with the national STD treatment
guidelines;

6.

To assess the interpersonal communication skills of doctors and midwives
for effective RTI/STD risk assessment and client counseling;

7.

To study the quality of the existing RTI/STDs recording and reporting
system.

II.B.2 Study Design
A quasi-experimental design using a single pre-intervention observation and
repeated measurement of post-intervention observations in 12 weeks was employed.

_________________ time ( 16 weeks)
O1 X O2 O3 O4
O1

was the pre-intervention observation of the study measures, which were
conducted between December 1996 - January 1997;

X

was the intervention consisting of various workshops for FP HCPs on:
a) diagnostic clinical and laboratory skills;
b) RTI/STD treatment regimens;
c) interpersonal communication skills;
d) recording and reporting; and
e) infection control practices.

O2-4

were repeated post-intervention observations for twelve weeks between
February 17 and May 9, 1997.

II.B.3 Eligibility Criteria of Study Participants
All clients who attended the FP clinic in either Koja Hospital or Puskesmas
Cilincing during the twelve week period of study were advised that a study to
improve the detection and treatment of RTI/STDs was seeking interested volunteers.
The FP staff, doctors at Koja hospital and midwives at the Puskesmas Cilincing,
presented an introductory discussion of contraceptive options and their link to
RTI/STDs. Those clients choosing to participate received standardized information
for informed consent and then were briefly interviewed by the HCP to determine their
eligibility. All consenting FP clients were considered eligible to participate unless:
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C
C

they were menstruating at the time of the exam (in which case they were
invited to return to the clinic two weeks later for evaluation) ;
they had taken antibiotics in the past 14 days.

It was anticipated that a population of both symptomatic and asymptomatic
clients would be gained by including all presenting FP clients as potential
participants. There was no extra compensation for the clients to participate.
II.B.4 Diagnostic Model
The syndromic STD case management algorithms from the World Health
Organization (WHO) require an evaluation that is dependent on the primary symptom
of vaginal discharge to start the diagnostic process (WHO, 1993). Previous
investigations using a hierarchical syndromic algorithm to evaluate RTIs in
asymptomatic populations have not found such algorithms to be highly sensitive
specific for the detection of RTI’s, and in particular, the cervical infections of
gonorrhea and chlamydia (Vuylsteke, 1993; Behets, 1995; Thomas, 1996).
Therefore, all participants were evaluated by risk assessment, physical examination
and laboratory testing.
II.B.5 Physical Examination and Specimen Collection
The physical examination included 17 separate steps and the collection of
five separate lab specimens, all of which were sequentially recorded on the clinical
evaluation form (Appendix A). The examination of the abdomen and skin included
visual inspection for rashes that might be related to secondary syphilis infections.
The abdomen and inguinal area were palpated for organomegally and
lymphadenopathy, respectively.
Examination of the vulva and vagina noted the presence or absence of
inflammation (erythema), ulceration or abnormal lesions of the vulvovaginal mucosa.
Recording a written description of abnormal findings was encouraged. The
following three lab-diagnostic tests were conducted on vaginal discharge:
(1)

(2)
(3)

Gram stain for the presence of an elevation (above 30) of
polymorphonuclear leukocytes (PMNs), suggestive of inflammation,
hyphae and/or pseudo hyphae (candidiasis), and clue cells (bacterial
vaginosis);
Wet mount microscopy with normal saline for the detection of motile
trichomonads;
A positive amine odor when combined with 10% potassium
hydroxide (KOH).

After removing cervical discharge with a cotton swab, the cervix was
visually inspected for signs of ectopy, erythema, mucopus and friability. Another
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three lab-diagnostic procedures were applied to the endocervical specimen :
(1)

(2)
(3)

inoculating a modified Thayer-Martin medium plate with immediate
placement in a candle extinction jar prior to transport to the referral
lab where each plate was then incubated at 37 degrees Celsius for 24
to 48 hours;
heat fixed Gram stain for the detection of gram negative intracellular
diplococci (GNID);
chlamydia ELISA screen, by using a sterile dacron swab in the
endocervix for a minimum of 10 seconds and rotating the swab in the
endocervix three times before placing in a chlamydial transport
medium.

Isolates for N. gonorrhoeae were identified by the referral laboratory on the
basis of typical colonial morphology and oxidase reaction. C. trachomatis was tested
®
from endocervical specimens by enzyme-linked immunoassay or ELISA (IDEIA
from DAKO Diagnostic Ltd, UK).
All consenting participants also had a 5 ml sample of blood (aseptically)
drawn for syphilis serology using the non-treponema RPR as a screen. In the event
that an RPR tested positive, the same sample of blood would have been re-tested for
confirmation by TPHA. The Gram stains, cultures, and ELISAs and serology
samples were transported daily at noon to the referral laboratory at a medical
teaching hospital, Rumah Sakit Cipto Mangunkusumo (RSCM). This referral lab is
in the Department of Dermatovenerology, which is the primary STD clinical training
program in Jakarta. The department head also acted as a member of the advisory
committee for this study. He also chairs the National STD working group who
recently published the first National Treatment Guidelines for RTI/STDs (Daili et al,
1996). The referral laboratory at RSCM hospital re-screened the Gram stains for
verification of initial microscopy diagnoses, and also performed the reading and
reporting of culture, ELISA and serology results.
To complete the physical examination, a bimanual examination was
performed to assess for cervical motion tenderness (CMT), and to rule out uterine
enlargement or adnexal mass. The results of all clinical examination findings were
documented on the study’s standardized clinical evaluation form (see example in
Appendix A).
II.B.6

Sample Size

Five HCPs participated in this study as our primary target group for
intervention. These five participated in all phases, from the pre-intervention needs
assessment interviews, to the intervention trainings and follow-up evaluative
observation of client interactions by research assistants. These five HCPs consisted
of three out of the four doctors in the FP clinic at Koja Hospital, plus two of the three
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midwives at the FP clinic at Cilincing PHC. The midwives were both female, but of
the three doctors, two were male. The other doctor and midwife also participated in
the training, but not the other study components. This is also true of the one doctor
at Cilincing PHC (the head of Puskesmas), three doctors at Koja Hospital ( two
clinical pathologist and one ObGyn, head of ObGyn unit), and two lab technicians
at each site. Therefore, 19 people received training, but only five were targeted for
full participation; two midwives at Cilincing, and three doctors at Koja.
The secondary target group were the FP client. A total of 312 women were
participated in the study between February 17 and May 9, 1997; 144 women at Koja
Hospital, and 168 women at Puskesmas Cilincing (see section III. D. Findings and
Results for exclusions, etc).
II.B.7

Data Collection Methods and Patient Management Policy

Every health care interaction between provider and client was observed by
a trained research assistant using a coded observation checklist (see Appendix G).
The checklist involved noting the presence or absence of the following HCP
behaviors:
C
C
C
C
C
C
C

exhibited positive communication skills
obtained a standardized gynecological and sexual history
maintained infection control practices
performed a standardized physical examination
provided diagnostic laboratory specimens
provided client education and follow-up for client and partner(s) if an
RTI/STD was diagnosed
wrote a correct prescription for infections that were clinically diagnosed
in accordance with National STD Guidelines

Analysis of laboratory specimens used a separate documentation tool.
Clinical assessments were compared with on-site laboratory diagnoses of Gram stains
and partial wet mounts. Subsequently, on-site Gram stain laboratory reports were reevaluated by
the RSCM reference laboratory to confirm the diagnosis of the on-site laboratory
staff. This same report served to report the results of testing for gonorrhea,
chlamydia and syphilis, which were performed at the referral laboratory.

The clinical evaluation, which included history, exam and lab findings as
well as the HCPs teaching and client recommendations, along with the observations
of the HCP/client interaction were all recorded and checked for completeness on a
daily basis by the project officer before the data was entered into the computer.
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Standard double entry procedures and consistency checks were used to ensure that
the data set was clean prior to analysis. Client records used new assigned ID code
numbers, so that individual identifiers were minimized in the data files.
II.B.8

Data Processing and Analysis

The data used here are taken from observations of 1) client provider
interactions; 2) client background, including behavior, medical histories, and
examination; and 3) results of laboratory tests. The software used to enter these data
allowed for both numeric and character responses. It also included automatic
checking for invalid and inconsistent responses. The data was organized in such a
way that each client has a complete set of the three types of data mentioned above.
Preliminary analyses included univariate descriptive statistics to obtain a
simple data description of all variables under study. This established how the cases
were distributed across the various categories of each variable, the number of missing
values per variable, and the shapes of the distributions of key variables.
Bivariate analyses using two variables for sub group comparisons were used
for a descriptive presentation of some preliminary findings. They were also used for
the preliminary analysis of the association between dependent variables (STD disease
status -with or without gonorrhea, syphilis, and chlamydia) and selected disease
markers as independent variables. Cross tabulations described the distribution of
key variables of interest, such as disease status across various client’s backgrounds
behavioral characteristics, medical histories and results of physical examinations. An
unadjusted odds ratio was calculated to assess the individual or gross effect of
selected markers on the dependent variables.
A two way contingency table was employed to test the validity of some
disease markers for predicting an STD infection. In this case, the results of RSCM’s
laboratory works were used as the standard.
II.B.9

Major Activities

A multitude of activities took place to accomplish the various objectives of
this study. This project was not a singular intervention to study disease prevalence,
but also a broader plan to study the feasibility of sustainably incorporating RTI/STD
clinical services into the existing family planning services. The actual
implementation of these activities closely followed the plan established in the original
HAPP FHI/AIDSCAP Logframe of Activities (see Appendix B). The sequence of
project activities started with pre-intervention data collection and needs assessment.
These pre-intervention baseline findings contributed to the development of clinical
protocols and HCP training curricula, followed by the clinical observation of each
client and HCP interaction. During the study there was on-going coaching and
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refinement of HCP skills, as observations and program monitoring revealed the need
for additional and continuous strengthening of HCP skills.
II.B.10 Key Collaborators
The key collaborators and members of the advisory committee were
recruited early on in the preparatory stage as experts who also initially served as
facilitators for training activities (intervention). These collaborators were selected
for their positions of leadership, not only for training skills and also for their ability
to supervise the HCPs and laboratory personnel who would be trained to perform
clinical care. This cadre of leaders were also able to serve as mascots for ensuring
that HCPs and laboratory staff would attend and participate fully in training activities.
The list of policy makers/program managers selected at the central level is as follows:
C
C
C
C
C
C
C

Head, Subdirectorate of ObGyn - Family Health, Ministry of Health
(MOH)
Section Head, Subdirectorate of STDs and Yaws - Centers for Disease
Control (CDC), MOH
Chairman, The Indonesian ObGyn Association (POGI) - Jakarta
Chapter
Chairman, The Indonesian STD Working Group & Department. of
Dermatovenerology, Faculty of Medicine, University of Indonesia.
Member, The Indonesian STD Study Group
Head, Subdirectorate Surveillance, Directorate Epidemiology at PHC CDC, MOH
Head, Subdirectorate of Mental Preventive Health - Family Health,
MOH
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III.

Subproject Implementation

III.A

Management

With the exception of the position of the Project Officer during the first
quarter, all staff positions were filled in the beginning of the project and continued
through the entire period of study. The final project staff included:
Project Manager
OR Fellow
Project Officer
Data Analyst
Health Consultant
Research Assistant

:
:
:
:
:
:

Dr. Meiwita B. Iskandar, Ph.D
Subadra Indrawati, MPH
Dr. Siti Nurul Qomariyah
Djoko Hartono, Ph.D
Cathy Vickers, RN, BSN, CNP
Lila Amaliah, SKM1*
Zakianis, SKM
Eti Sulaeha, SKM
Milla Herdayati, SKM

The selection of advisory board members reflected diplomatic negotiations
for the operational integration of two traditionally distinct programs (FP and STD
management) to establish the desired outcome of a more comprehensive reproductive
health care delivery system. To support this goal, leaders from divergent programs
were approached. Many of them have been used to working in strictly vertical and
well defined MCH programs. The concepts of teamwork and collaboration, although
unfamiliar to some, were critical element of the board functions. As a consequence,
there were times when an individual member had very strong opinions about the
composition of the advisory committee, or the group of trainers. This collaboration
required many compromises in implementing the final protocols and delivery of
actual training programs.
A strong consensus among project staff, advisory board members, and
clinic site HCPs was that women with treatable infections detected during the course
of the study should be provided with medications for themselves and their partner(s).
Due to the budgetary prohibition of medication purchases, it was necessary to seek
funding from an additional source for the procurement of these medications. A
proposal for funds to purchase medications was submitted to the American Women’s
Association (AWA) of Jakarta. This organization awarded a grant of 5 million
Rupiah to the Population Council for the acquisition of RTI/STD treatments. An
additional donation procured through the Indonesian ObGyn Association (POGI)
Jakarta chapter consisted of 75 single dose anti-fungal treatments for non-pregnant
women.

*SKM is Public Health Graduate
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III.B.

Accomplishments

A series of operations research (OR) products and findings emerged from
the activities and may be of future help for efforts to improve reproductive health for
women in Indonesia. An unanticipated accomplishment was that the MOH
Directorate of Family Health recognized this study as a “model development
project”. This led to the invitation of the program manager to present the results of
the field work to the Ministry of Health on April 5, 1997 in a seminar devoted to
recommendations for the future integration of STD program planning into PHC at the
national scale. This national meeting was attended by MOH representatives from
multiple provinces. Of greatest interest to the MOH advisory board members was the
fact that the protocols for STD case management were comprehensive, yet concise
and manageable for the FP clinicians. The program manager was informed by the
Head of the Subdirectorate of ObGyn-Family Health at this April 5th presentation,
that the MOH intended to incorporate some parts of the Population Council’s
protocols into future MOH planning guidelines to integrate RTI/STD clinical services
into broader FP/MCH programs in Indonesia (see Appendix C for a report of this
MOH meeting). An MOH pilot test is going to be implemented in two health centers
in Bali, under AusAID funding.
III.B.1

Pre-Intervention Needs Assessments: Health Facility Observations

Observation at the two clinical sites, Koja Hospital and Puskesmas
Cilincing, revealed an adequate existing infrastructure for the provision of RTI/STD
detection services without the need for significant additional equipment.
Observations also revealed the need for enhanced written instructions, particularly
in the protocols of infection control and education and counseling.
The most significant difference in clinic resources between the hospital and
the PHC was the absence of an autoclave for sterilization of speculums at Puskesmas
Cilincing. The method of disinfection used in this facility was to wash with water,
then dry them, and place them in a container with formalin tablets. This toxic and
potentially dangerous practice was immediately addressed with a recommendation
to use safer disinfectants. This procedural problem was addressed in the second
training program which placed a greater emphasis on infection control procedures.
Supplies for hand washing and instrument disinfection were purchased and
distributed as needed. The Puskesmas staff did not use disposable gloves for pelvic
examination, therefore, disposable gloves were also purchased for the health center.
Koja District Hospital is presently a class “C” hospital, but expects to be
promoted a class “B” facility this fiscal year. Koja hospital is a 202-bed hospital
covering 18,000 square meters of land. Within the hospital, there are 13 specialty
clinics, run by 55 doctors, 4 dentists, 10 midwives, 142 nurses and 14 nursemidwives. The PHC at Cilincing is a coordinating subdistrict (kecamatan) health
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center (Puskesmas), with 9 subsidiary village (kelurahan) health centers. The four
story building covers 1,500 square meters and was established in 1994. Cilincing
employs a physician as medical director and 3 midwives for MCH/FP clinical
services. Besides FP/MCH, the Puskesmas offers multiple medical services including
inpatient deliveries, general medical, dental and optometry services.
III.B.2 Pre-Intervention Needs Assessment: Health Care Provider (HCP)
Knowledge Attitudes and Practices (KAP)
Five in-depth interviews were conducted prior to the training intervention
to obtain a baseline assessment of HCP experience, knowledge, and acceptance about
the provision of RTI/STD services within the FP clinic. Three doctors were
interviewed at Koja hospital and two midwives were interviewed at Puskesmas
Cilincing, using a verbally administered structured questionnaire. Doctors were
interviewed by the project officer (a physician), and midwives were interviewed by
the research assistants. All of the interviewers attempted to employ a non-threatening
manner. They conveyed a sense of informality in their verbal interviews to limit the
appearance of scrutiny. Interviews were conducted after the clients had all been seen
for the morning clinics. Unfortunately, both of these study sites are also used for
another RTI/STD study sponsored by HAPP. This created a crowd of researchers
obtaining baseline data through observations and interviews of clinical staff in the
same time period. Consequently there was frustration among the clinical staff about
repetitive questions from different interviewers. Fortunately for this study, our
research assistants were the first to access the Puskemas and were able to interview
fresh staff.
The length of employment for doctors in the hospital ranged from 10 to 23
years, with an average of 15 years of employment in the FP clinic. The two midwives
had a much shorter duration of employment in their clinics, ranging from one month
to two years. None of the five HCPs were able to give an estimate of the average
number of FP clients seen in one month.
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All of the five HCPs reported that they had not diagnosed a single STD
in the last six months. Two of the doctors had referred an FP client to the STD
clinic in the past six months. One described the number of clients referred to the
STD unit as “just a few”. The other referring physician reported referring three
clients to the STD clinic in the last six months.
The comparatively new midwives were unable to estimate or rank the most
common RTI/STDs encountered in their clinical practices. All three of the doctors
chose candidiasis and trichomoniasis as frequently encountered infections, with
two choosing bacterial vaginosis and gonorrhea as the next most common
infections seen in the FP clinic.
Two distinctly different perceptions of the main barriers to RTI/STD
identification emerged from the midwives in contrast to the doctors. The midwives
felt that FP clients were uneducated about signs of infection as well as being
embarrassed to provide an accurate sexual history. Both midwives also felt that the
lack of laboratory diagnostic procedures was a barrier to disease recognition. The
three doctors did not attribute lack of disease identification to inherent qualities of
the clients. One physician, despite a self-reported track record of not diagnosing any
RTI/STDs in the last six months, believed that there were no existing barriers to
disease recognition. This doctor believed that a disease recognition system
producing an accurate rate of infection already existed in the clinic. A second doctor
believed that there was not enough time in the busy daily schedule of FP services to
include the additional work involved in STD detection. One reason cited was the
difficulty in locating clients for follow-up since culture or serological results were not
available until after the clients had left the clinic. Another perception of barriers to
disease identification was that most FP clients could not afford to pay for additional
laboratory diagnostic tests for diagnosis of RTI/STDs. The third physician felt that
relatively rare use of laboratory tests was sufficient to support routine clinical
recognition of RTI/STDs.
No significant deficits in actual facilities were discovered in either site
for the performance of pelvic examinations. However, the existence of
microscopes, incubators, reagents, and cultures did not translate to a perception
of access among the staff.
For a hypothetical female client complaining of genital discharge, no
consistent pattern of ordering or performing wet mount microscopy to determine the
causative organism for the vaginitis was evident from interviews. Only 1 of 5 HCPs
acknowledged wet mount microscopy as a rapid diagnostic practice available and
appropriate for such a clinical presentation. This HCP felt that the determining factor
in whether or not this simple, inexpensive laboratory test was performed, was the
economic status of the client.
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Doctors, in particular, embraced the conviction that their experience, and
superior education superseded the need to include an etiological investigation of
pathogens that caused vulvovaginitis. Actual patient interactions with these same
doctors revealed that they never recognized more than one pathogen from an
approach that only included listening to the client’s description of the discharge,
or less frequently, an investigation of the history and a visual examination of the
vaginal environment.
In a related, but not directly measured indicator of reproductive health in
this study, the HCPs were asked under what clinical circumstances they would order
a Pap smear. A comparison of their responses follows:
Midwife #1 -

Midwife #2 Doctor #1

Doctor #2

Doctor #3

-

Client is 35 years old;
Client complains of abnormal discharge;
Spotting;
Contraceptive use longer than 5 years.
Never (no experience)
Abnormal discharge;
Abnormal cervix;
Age 35-40 years.
Vaginal discharge;
Cervical erosion;
Age 35 years, obtain once a year;
Age 40 years, obtain twice a year.
Rarely uses the speculum, only when asked to by client.

The above pattern of using a Pap smear for clinical presentations of vaginal
discharge, indicates a misunderstanding of the purpose of cytological screening and
would also increase the probability of false positive cytological results from
inflammatory atypia.
The frequency of recommending that a cervical culture be obtained for the
detection of gonorrhea was very low. Only one doctor recommended obtaining a
culture if a client presented with vaginal discharge and also admitted any risk
behavior in the history taking. This same doctor used these two indicators for
recommending that serology be obtained for the detection of syphilis. Another doctor
reported never using serology for syphilis in Koja hospital, but in other facilities he
would do so if there was evidence of genital ulcers. The third doctor honestly
admitted a lapse of memory on how to diagnose syphilis. Both of the midwives
reported never recommending a test for syphilis. All 5 HCPs were unanimous in
never having recommended that a client be tested for HIV infection.
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An analysis of medication prescription practices for candidiasis,
gonorrhea, and chlamydia yielded vague responses reflecting a lack of knowledge
among family planning HCPs. HCPs were asked to describe the drug of choice
and the recommended dosage, frequency and duration of use for each regimen.
The majority of the responses only included a name of the drug and not a precise
measure for how much, when, and how long it should be taken for. The drugs
mentioned were often not appropriate for the suspected organism.
Only 2 of the 3 doctors were able to refer to a specific antifungal medicine
by name. One of these doctors also included a traditional regimen of “sirih” leaf
water for some of the clients with candidiasis. One of the midwives was unable to
cite a drug for the treatment of a yeast infection. The other midwife used a dual
regimen of Metronidazole, which is not effective for eliminating candidiasis, along
with a local cream “Albothyl”, which is a condensation of metacresol sulfonic acid
and methanal. In its undiluted state, Albothyl is a caustic agent that can debride
wounds.
When the drug selections did have therapeutic efficacy for a targeted
organism (such as Thiamphenicol for gonorrhea), were lacked knowledge of a
standardized dosage and administration schedule. In reference to the practice of
automatically providing additional treatment for chlamydia when a diagnosis of
gonorrhea is made, none of the HCPs reported this to be a standard practice. One
doctor consistently relied on the “economic status” of a client as a determinant for
whether or not a prescription was offered. One of the midwives was unaware of the
correct regimen for gonorrhea, and the other midwife mentioned the outdated and
ineffective regimen of Ampicillin.
A frequent and resonating theme mentioned by both doctors and midwives
was the difficulty of educating clients about reproductive tract infection, especially
sexually transmitted infections. An investigation of the HCPs perceptions on the
utility of educational resources such as flip charts, brochures, posters, etc. did not
reveal a consensus on the utility of materials. The midwives who perceived their
client’s level of awareness as an important diagnostic determinant, were more
inclined to think that all resources could be helpful for educating clients. Only one
of the three doctors felt that brochures and pamphlets would be helpful. Two doctors
specifically felt that written information was not helpful, and felt that direct
communication was the best method of client education with regard to STD
prevention. Although these two HCPs valued direct communication, they both felt
that client education was a difficult and time consuming clinical practice.
HCPs were asked if they provided condoms with instructions to clients who
were diagnosed with STDs. Two of the doctors responded that they never did this.
One doctor responded that “occasionally” condoms were given. One midwife did not
provide condoms, the other reported that she always provided condoms if the
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husband had a history of dysuria. A general feeling expressed by all HCPs was that
it was unrealistic to expect an “ordinary housewife” to convince her spouse to use
condoms. Both midwives also agreed that condoms promote immoral sexual
behavior. Only one of the HCPs reported being “comfortable” discussing STDs with
clients. All the other providers admitted that it was very difficult to be open about
RTIs with their FP clients. One of the doctors felt that condoms were not efficacious
in STD prevention, because they were uncomfortable and interfered with men’s
sexual pleasure. Two other doctors felt that good qualities condoms were helpful if
used correctly. Another doctor expressed a strong belief that “condoms don’t prevent
STDs as effectively as abstinence”.
This same physician who felt condoms were not effective againts STDs
expressed many other opinions about STD management. He was candid about his
habit of never telling a female FP client that she had an STD because it would make
her feel uncomfortable and cause problems with her spouse. He also felt very
confident making an etiological diagnosis based only on a history and visual exam.
He felt that any pruritic vaginal discharge was a fungal infection, and any milky
discharge with a bad odor and dysuria was Trichomonas vaginalis. He agreed that
trichomoniasis was sexually transmitted, and would prescribe Metronidazole for both
the client and her spouse. He would tell the women to give her husband the pills
with the explanation that they would increase his sexual potency and performance.
This same physician articulated the perception that RTI/STD case management was
not connected to FP clinical care.
With the general level of discomfort among HCPs in discussing STDs
with their clients, it was not surprising to learn that these same providers were not
well informed about which STDs required concurrent treatment of the sexual
partner. Both midwives in the Puskesmas reported that they did not know which
infections should also include partner treatment. Since their job experience did
not include the detection of STDs, they did not hesitate to say that they did not
know.
Each HCP was specifically asked which of the 10 infections (candidiasis,
trichomoniasis, bacterial vaginosis, gonorrhea, chlamydia, chancroid, syphilis, HSV,
HPV and HIV) require partner treatment. One of the doctors responded that all
clients with any signs of infection should have their partner evaluated at a clinic.
Another doctor only identified trichomoniasis as an infection requiring partner
treatment. The third doctor correctly identified trichomoniasis and gonorrhea as
infections requiring partner treatment along with an incorrect identification of
candidiasis and bacterial vaginosis in the same category.
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III.B.3 Standardized Clinical Evaluation
Based on the results of pre-intervention assessment, the development of a
comprehensive, but pragmatic clinical evaluation procedures was necessary to
standardize the intervention. This also served as a template for HCPs to absorb
minimal quality of care behaviors integral to the performance of a pelvic examination
for the detection of RTI/STDs. However it was necessary to minimize changes in
HCP practice, limiting changes to those that are essential for both RTI/STD case
management and contraceptive care. According to the World Health Organization
guidelines (WHO, 1994:2), comprehensive STD case management should include:
C
C
C
C
C

correct diagnosis
effective treatment
education on risk reduction and treatment
promotion and provision of condoms
clinical follow-up where appropriate.

These five components of STD case management were included in the
standardized clinical evaluation. Two comparable clinical evaluations were studied
during the course of this instrument development. The final clinical evaluation was
a one page format that included essential RTI/STD evaluation elements (see
Appendix A), although a four page evaluation was drafted. This four page draft
provided more socio-demographic data and a thorough contraceptive history
investigation. It was decided to use the abbreviated one page tool for HCP
acceptability.
Unlike common RTI/STD prevalence studies where the history and risk
assessment is obtained by field research staff, this study attempted to sharpen the
skills of the HCP in obtaining an accurate history. Thus, in order to limit the
demands on the busy HCP, who was also often culturally and professionally
predisposed to avoiding candid sexual histories, an abridged sexual history form was
used.
This study employed a non-hierarchical inventory of risk factors, clinical
symptoms and signs, accompanied by serology and vaginal and endocervical
specimen collection. This diagnostic investigation was etiological and not
syndromic. It allowed for the determination of prevalence rates since all
consenting clients were universally screened. It further allowed for comparison
of sensitivity, specificity and positive predictive values among the various
assessments that all clients were screened with (i.e., clinical assessment versus lab
tests).
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III.B.4 Clinical Practice Protocols
Nine separate clinical protocols were developed to merge RTI/STD case
management into the context of the family planning clinic setting (see Appendix D).
These protocols served as the framework for training activities to help the HCPs
develop the ability to introduce the subject of RTI/STDs to the FP client, and then
proceed with examination, diagnosis, treatment and interventions. These protocols
address the following contents areas:
Protocol
I
II
III
IV
V
VI
VII
VIII
IX

Title
Contraceptive Education
Diseases of Women’s Reproductive Organs
Taking an Effective Reproductive Health History
Providing a Reproductive Health Physical Exam
Laboratory Tests
Diagnosis and Case Management
RTI/STD Treatment Guidelines
Client Education and Counseling
Infection Control

III.B.5 Training Programs
Training family planning HCPs to expand their awareness and normal
clinical routine to include a vigilant consideration of RTI/STDs in every single client
demanded large scale professional consciousness-raising.
This demand could not be met by a single training event, but rather
required close project monitoring and post-training supervisory trouble-shooting
activities.
HCPs were induced to participate in training activities by multiple
incentives, including:
C
C
C
C

attendance of department head and institution management at major
training activities;
attendance of outside professional “mascots” which were also project
advisory board members at training programs;
financial reimbursement for “missed opportunity costs” due to
attendance;
the chance to improve professional expertise by gaining applied
knowledge for enhancing private practice.

25

The following summary of the training process shows the scope and
diversity of training efforts. The pre-intervention collection of baseline data on HCPs
knowledge, attitudes and practices (KAP) revealed a strong aversion among the
specialists/ physicians to the concept of training and the amount of time it would
require. This aversion was not expressed by the midwives. To accommodate the
perception that training was not needed by "expert/experienced HCPs", and should
not last as long as originally proposed, a new semantical and temporal approach was
pursued. Instead of offering training on the clinical aspects of RTI/STD case
management, a "Round-Table Discussion" was conducted as the initial training
activity. Instead of the original five day presentation, the curriculum was presented
in multiple half-day doses. The published time schedule of a total of four hours per
day, transformed in reality to a six-hour day of "discussion" to include all the
learning objectives targeted in the original plan (see Table 3) and Appendix E :
Workshop Reports, includes a greater description of these training activities.
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Table 3:

Training Activities Summary, January-April 1997

Date

Workshop
Topics

Length

Trainers

Site

Personnel
Trained

Jan
24-25

Round Table
Discussion

2 days

Combined Advisory
Board

Koja Hospital
Conference
Room

Combined FP
staff from Koja
Hospital &
Cilincing PHC
(Doctors,
midwives, & lab)

Jan
28-29

Clinical
specimen
collection & lab
analysis

2 half
days

RSCM STD clinic staff,
led by
Dr. Sjaiful F. Daili,
DSKK

Cilincing PHC

Cilincing PHC
midwives & lab

Jan 31

Lab testing
procedures

half day

RSCM STD clinic staff

Cilincing PHC

Cilincing PHC
lab

Feb 5

Refreshing HCP
clinical skills
on counseling
and infection
control

half day

Dr. F. Sumampouw, DAJ,
MPH &
Dr. Djajadilaga, DSOG

Koja Hospital
dormitory
classroom

Combined from
Doctors,
midwives Koja
& Cilincing

Feb 5

Clinical
specimen
collection &
preparation

half day

RSCM STD clinic staff

Koja Hospital
FP clinic

Koja Hospital
medical staff

Feb 7

Lab testing
procedures

half day

RSCM STD lab staff

Koja Hospital
lab

Koja Hospital
lab staff

March
21

RTI/STD case
management
update

quarter
day

Dr. Iskandar &
C. Vickers

Cilincing PHC

Cilincing PHC
midwives and
lab staff

March
25

RTI/STDcase
management
update

quarter
day

Dr. Iskandar &
C. Vickers

Koja Hospital

Koja Hospital
medical & lab
staff

April
21

Communication
& infection
control skills

quarter
day

Dr. F. Sumampouw, DAJ,
MPH & Senior Midwife
Coos Leiwakabessy

Cilincing PHC

Cilincing PHC
midwives, lab &
nursing staff

RSCM = referral laboratory at Cipto Mangunkusumo Hospital

The initial "Round-Table Discussion" conducted in two parts on Friday,
January 24th and Saturday, January 25th at Koja Hospital initiated the series of
training activities. This was the longest and most formal training program of the
project. The hospital contributed a large conference room with audiovisual
equipment, tables, chairs, and microphones. It also provided valuable feedback from
the HCP participants about their reactions to the protocols and the expectations of the
research. This process of collaboration and feedback was important to instill a sense
of ownership among HCP and the project Advisory Board.
Providing small-dose training sessions over a long period meant that
trainers and investigators periodically visited the sites and could observe problems
27

and successes with the implementation of the new protocols. This allowed for
remedial instruction in subsequent training, as well as refinement of the protocols
prior to data collection on clients. The process of utilizing members of the advisory
board as trainers allowed for supervisory visits as envisioned in the original work
plan. However, rather than doing a checklist style of supervision, the supervisor used
the RAs records on HCP/client interaction to guide discussions. The checklist
inventory was given to each HCP as a tool to assess their own progress in integrating
the written protocols and formal instruction with actual client care (see Appendix F
for the itemized HCP skills inventory that was utilized throughout the supervisory
visits).
An evaluation of the impact of the training activities on actual HCP
behavior change was designed through the daily observations of each HCP/client
interaction (see Appendix G). An additional gauge of the impact of the training is
the comparison of pre-training rates of RTI/STD disease recognition (determined
through the retrospective six month medical record review), and the rates of
confirmed positive findings obtained during the course of the study. The results of
these analyses are discussed in section III.D. Findings and Results.
III.B.6 Advisory Board
The creation of the advisory board as described earlier in section III.A
(Management), was simultaneously an accomplishment and a constraint. It was
anticipated in the design of this study that the feasibility of integrating additional
work and services into an already well-established and busy FP program would
require broad support from leaders in influential positions. It was also a carefully
considered choice to utilize persons with leadership and solid clinical expertise in the
practice of reproductive health in Indonesia as training instructors. As a result, these
advisory board members brought credibility and expertise in family medicine,
obstetrics & gynecology, public health, mental health and dermatovenereology to the
training program. This diverse constituency of successful practitioners set a new
standard and simultaneously lent a “reality-check” to the tone of the training
sessions.
A frequently expressed concern by more than one member of the HCP
trainee group during the first workshop was the inherent difficulty in discussing the
need for partner treatment for STDs. The advisory board of instructors possessed the
professional authority and experience to acknowledge the difficulty while
emphasizing the primacy of not neglecting realistic partner treatment plans for every
client diagnosed with an STD.
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III.B.7 RTI/STD Treatment Formulary
Three sources were used to compare and contrast RTI/STD treatment
guidelines; (1) the national guidelines, as recently published by the MOH for the
Republic of Indonesia (RI), (2) the 1993 STD Treatment Guidelines as published by
the Centers for Disease Control in Atlanta Georgia (MMWR, 1993), and (3) the
guidelines recommended by the World Health Organization (WHO, 1994). The
final treatment guidelines used by this project were the guidelines from the MOH for
the RI (Daili, et al., 1996) (see Appendix H for a summary of the contrasted
regimens from the MOH, CDC, and WHO). Pharmaceutical supplies were
purchased and pre-packaged for individual distribution as indicated either by the
initial clinical diagnosis or the final laboratory diagnosis. Table 4 displays the final
RTI/STD formulary used in this project.
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Table 4:

RTI/STD Treatments

Drug

Infection

Dose/per person

Pregnancy

Metronidazole

Trichomoniasis
* & Bacterial
Vaginosis

2 grams- oral single
dose- (tablets)

Contraindicated
in 1st Trimester

Clotrimazole
(Canesten
SD®)

Candidiasis

500 mg. per day
single dose
(vaginal suppositories)

Not a
contraindication

Fluconazole
(Diflucan®)

Candidiasis

150 mg oral single dose
(tablet) contraindicated
in liver disease

Contraindicated
in pregnancy &
lactation

Ciprofloxacin

Gonorrhea*

500 mg oral single dose
(tablets)

Contraindicated
in pregnancy
use
Spectinomycin

Spectinomycin
(Trobicin®)

Gonorrhea*
for pregnant
women

2 grams IM single dose
(Injection-divide dose in
half for each buttock
must use 2 needles &
syringes)

Not a
contraindication

Doxycycline
(Vibramycin®)

Chlamydia*

100 mg oral twice a day,
for 7 days (tablets)

Contraindicated
in pregnancy
Use
Erythromycin

Erythromycin

Chlamydia*
for pregnant
women, and
Chancroid*

500 mg.- oral four times
a day, for 7 days
(tablets)

Not a
contraindication

Benzathine
penicillin G

Syphilis*
(Must do
follow-up
exams & titered
serologies to
test Rx 3 & 6
months after
Rx)

2.4 million Units IM,
single dose if confirmed
primary case, or
3 weekly doses if
duration is longer than 2
years, or of
undetermined duration.
(Injection)

Not a
contraindication

* These RTI/STDs MUST include treatment for the client & her partner(s). A specific note was given
to HCPs stating the following warnings: “If you do not provide a treatment for the partner(s), your client
will become reinfected. Remember to always check the medical history for a possibility of allergies,
pregnancy, or other medical conditions before choosing a treatment”.
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III.B.8 Treatment Cost Implications
A market survey of current prices for individual treatments for each
treatment regimen was conducted. This was not a full cost analysis, but just a quick
survey to determine the actual cost of one complete treatment for all of the
recommended RTI/STD regimens included in the National Treatment Guidelines
from Indonesia. The results of this market survey are included in Appendix I.
III.B.9 IEC Development
Although the original proposal did not include the development of IEC
materials, the need to use a quick “Ice Breaking” visual symbol to introduce the
topic of RTI/STDs to clients, became apparent. A local laboratory technician, who
is also an artist sketched two cartoons. The content was culturally recognizable to
Indonesian people. He transferred his knowledge of microbiology to blend with
well-known colloquialisms to represent individual STDs. This cartoon also served
as a teaching aids to describe possible symptom a women might experience if she
were infected. The cartoons were laminated into a one page tool for the HCP to
introduce this study to clients. The cartoons are shown in Appendix J.
III.C

Constraints

The role of the advisory board of subject matter experts expanded from
advisor to a more intimate involvement as protocol editors and workshop instructors
mascots. This increased programmatic involvement contributed to an increase of
opinions on how to implement RTI/STD into FP services. This team of strong
professionals included members from different professional disciplines, and some
members were strongly opposed to giving equal status as instructors and advisors to
other members. Fortunately, the majority of advisors shared a dedication to the
overall goal of the project and were flexible enough to accommodate less flexible
members. As described in a paper from Family Health International (Hardee
&Yount, 1995) on the subject of integrating previously separate services: "Fear of
takeover and loss of status or career prospects create barriers to effective
collaboration” (see also Laing, 1981).
The different medical disciplines to be integrated (STDs and family
planning) have a different view and set of priorities when looking at the same client,
even when they examine the same organ system. The dermatovenereologist may be
keenly interested in the cervix, and neglect the rest of the uterus in performing a
pelvic exam, because it has diminished diagnostic yield for the detection of STDs.
The family planning specialist on the other hand, performs a bimanual examination
routinely, but may neglect a speculum for visual assessment of the cervix.
The revised plan of performing universal screening for all six selected
RTIs on all consenting clients created an additional ethical requirement of submitting
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the proposal to the Institutional Review Board (IRB) of the Population Council. This
required the inclusion of a formal informed consent procedure. HCPs in the study
sites felt that this was a barrier to gaining maximum client participation in the study.
It did
create another demand on the part of the field staff to do more recording and
reporting. A copy of the individualized consent form, which was also used to
determine a plan for follow-up care is included in Appendix K.
A philosophical constraint was evident among HCPs about the relative
importance of some of the individualized tasks that accompanied the research
process and the detection of RTI/STDs.
It was apparent that the technological update to using a speculum to
perform a bimanual examination and obtaining specimens for microscopy, culture
and serological analysis were easily accepted by all HCPs. The doctors were very
willing to participate in the scientific evaluation process by performing physical
tasks, even though they had not been a part of their prior routine. It was not
anticipated that the greatest HCP resistance would be in the area of provider/client
communication. Specifically, the doctors did not perceive performing client
education as a scientific or medical task.
While the doctors and midwives were very willing to learn and perform the
high-tech evaluative practices, they were also eager to delegate the tasks of obtaining
informed consent, and the standardized thirteen question history to the neutral
research assistants (RAs). Recording and reporting the results of the clinical
evaluation were also perceived as undesirable tasks which these HCPs were eager
to delegate to the RAs or other staff. This resistance shows a devaluation of some
clinical evaluation components. A medical model emerged with two distinct sets of
practices which HCPs were either willing or unwilling to perform depending on the
perceived clinical technology associated with them. This can be summarized as
follows:
HCP Willingness to Perform
High
High
Clinical
Technology
Perceived

C
C
C

Low

Physical examinations
Lab specimen collect
Prescription of medicine

__
C

Low
__

C
C
C

Interpersonal
communication
History taking
Client education
Reporting and recording

Clearly the HCPs placed a greater value on the high-tech evaluative
practices. The challenge of trying to work with this constraint prompted two
workshops in which the less valued areas of practice were discussed. A connection
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between not performing them and a client's likely reinfection (i.e., a reversal of all
their high-tech work of examining, testing and treating) was attempted.
A cultural concern not to cause any loss of face to a client by honestly
disclosing a diagnosis of STD, and the need for partner treatment, far outweighed
any logistical constraints of finances, facilities and supplies. There seemed to be
a professional blindness to the necessity of treating a sexual partner in order to
prevent a reinfection of the index client.
The most illustrative example of this phenomena occurred during one of the
on site clinical training sessions. At the Puskesmas one client who was having her
first pelvic exam, and coincidentally was also four months pregnant, was discovered
to have mucopurulent cervicitis with a Gram stain showing more than 30
polymorphonuclear leukocytes (PMNs) per high power field. The STD specialist
physician who was training the midwives to correctly obtain vaginal and cervical
specimens told this woman she had an infection that required treatment. The doctor
prescribed 500 milligrams (mg) of Erythromycin four times a day for seven days.
The doctor was able to stress the importance of completing the
prescription for the health of the client and her unborn baby. However, the
potential need for treatment of the spouse/sexual partner was not mentioned.
When interviewed by the research staff about not mentioning treatment for both
partners, the reply was: “it is very difficult for us (Indonesians) to talk about
partner treatment”.
Later, the doctor express a high index of suspicion that the cause of this
pregnant woman’s mucopurulent cervicitis was infection with chlamydia trachomatis.
This suspicion motivated the recommendation of the prescription of Erythromycin.
Most experienced STD specialists would agree that a diagnosis of an STD would be
premature at this stage, even though a purely syndromic model of care would justify
such a diagnosis and treatment plan. However, at a minimum, an ethical need to
inform the pregnant client of actions she can take to prevent herself from possible
reinfection via sexual intercourse with a potentially infected partner, prior to
receiving the final laboratory results, seemed called for. The dissonance between
client treatment based on a syndromic diagnosis and a final etiological diagnosis will
be discussed later in section III.D. Findings and Results.
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Even for infections with positive STD lab tests, there was a distinct trend
to provide a prescription for the index client, while not disclosing the need for
concurrent partners therapy. This reluctance was not only evidenced by HCPs
reglecting of document to a treatment plan on the clinical evaluation flow sheet, but
was frequently in evidence during the HCP/client observations audited by the
research assistants.
A logistical constraint prevented getting the laboratory reports back to
the clinic and client in a timely manner, slowing the rate at which a final diagnosis
could be reached. The Koja hospital laboratory would hold the Gram stains until
they had accrued a sufficient “batch” to do group staining and reading. This resulted
in Gram stain reports taking an average of 2-4 hours after the completion of the
clinical evaluation. Since saline wet mount microscopy did not require staining and
did require a quicker interpretation, the only RTI that was ever reported in the
hospital prior to the client departing the site was Trichomonas vaginalis. Wet mount
microscopy reports were returned in ten minutes in the hospital. Although the
Puskesmas did not hold Gram stains for batching, they had a larger number of clients
at each clinic, and could not turn around a laboratory report before the client left the
clinic.
A further constraint in receiving timely laboratory reports was also
encountered from the referral laboratory. During the 12 weeks of observation there
were insufficient chlamydia test kits and gonorrhea culture plates to provide testing
for each study participant. Another constraint at the referral lab was the excessive
demands on the laboratory technician to read all the Gram stains and endocervical
tests for gonorrhea and chlamydia. The head of the STD department required the
technician to submit slides to him for concurrence in the case of a positive judgement
of infection. Thus, whenever the department head was unavailable or out of town,
final reports were delayed until his return. This practice resulted in a turn around
time of one to four weeks for final laboratory reports. The referral laboratory also
pooled chlamydia tests until they had batches of five specimens which added to the
delay in some cases.
In the process of specimen collection, another problem observed was the
high frequency of improper swab placement and insufficient absorption time,
especially in week 1-4. Specifically for gonorrhea, cross-streaking the swab over the
surface of the agar in 3 directions might have been done poorly in the first weeks.
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III.D

Findings and Results

Of the 478 clients who presented to one of the two FP clinics in the 12
weeks, 89% (425) were willing to become study participants. Figure 1 shows the
reasons for the exclusion of a further 113 clients and figure 2 shows the reasons why
53 of the original clients chose not to participate. The final study sample was 312.
Figure 1. Exclusion of Study Participants

Staff
judgement
38%

Menses
38%

Menses

= 43

Antibiotics

= 11

Lack of lab
supply

= 16

Staff pattern/
judgement

= 43

Total

= 113

Antibiotics
10%

Lack Supply
14%

Figure 2. Clients Reasons for Refusing Participation in the Study
Other
13%

Fear
40%

Shame
13%

Fear of exam

Evaluation too
time consuming =13
Wanted spouse
approval

Spouse
approval
9%

Total

= 21

= 5

Pelvic exam too
shame full
= 7

Time
25%

Other

= 7

= 53

By the fourth week of the study period, the RAs observed that additional
new FP clients were presenting to the clinic specifically to obtain the RTI evaluation.
They had heard of the “free” study from their female friends who had already been
evaluated, and expressed a desire to also be examined. Certainly, the provision of
“free”medicine had the effect of drawing more study participants, possibly
introducing self-selection bias into the study.
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Only one women was widowed/divorced. The remainings 311 were all married.
The most common contraceptive method employed by the FP clients in both clinic
study site in North Jakarta was hormonal injection. Table 5 illustrates the breakdown
of contraceptive methods reported by study participants.
Table 5:

Contraceptive Method Use Reported by Clients

Contraceptive Method

Koja
Hospital
N=144
n
(%)

Injectable Hormones

62

(43.0)

Intrauterine Device (IUD)

47

(32.6)

Pills

20

(13.9)

Sterilization

9

(6.3)

Norplant

3

(2.1)

Condoms

3

Other

Puskesmas
Cilincing
N=168
n
(%)
53
(31.5)

Combined
Clinics
N=312
n
(%)
115

(36.9)

34
(20.2)

81

(26.0)

52
(31.0)

72

(23.0)

(0.0)

9

(2.9)

2

(1.2)

5

(1.6)

(2.1)

5

(3.0)

8

(2.6)

0

(0.0)

1

(0.6)

1

(0.3)

Not using contraceptive

0

(0.0)

20
(11.9)

20

(6.4)

Not reported

0

(0.0)

(0.6)

1

(0.3)

0

1

To simplify the history taking procedure and to direct the HCP to consider
history variables that are strongly associated with a risk for STD infection, the client’s
age was coded as being either younger than 25, or 25 and over (see Table 7). For
312 participants, the actual ages ranged between 19 and 52 years, with a mean age
of 32.6 (36 missing values).
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III.D.1 Prevalence Rates of RTI/STDs and Associated Factors
The prevalence level of the six tested RTIs is shown in Table 6. A total of
86 separate RTIs diagnoses in 77 individual clients were confirmed by the referral
laboratory. Nine clients tested positive for more than one RTI. Although a total of
312 women were examined, the full range of specimens was not obtained for some
clients, either due to a lack of test supplies furnished by the referral laboratory, or due
to the client’s refusal to submit a blood sample. Following are the actual counts of
each specimen type: 301 for chlamydia, 309 for gonorrhea cultures and 302 serology
samples for the Rapid Plasma Reagin (RPR) test. Chlamydia trachomatis was the
most prevalent RTI found in 10.3% of the tested participants. Only one client tested
positive for N. Gonorrhoeae, and none of 302 RPR tests were positive for syphilis.
Following is a full list of lab tests performed:
Koja
144
144
143
143
139

Gram stains
Wet Mounts
Chlamydia tests
Gonorrhea cultures
RPR
Table 6:

Reproductive Tract
Infections

Cilincing
168
167
158
166
163

Combined
312
311
301
309
302

Prevalences of Confirmed RTIs in the Two FP Clinics

Koja Hospital
N=144*

Puskesmas
Cilincing
N=168*

Combined
Clinics
N=312*

n

(%)*

n

(%)*

n

(%)*

11

(7.6)

10

(5.9)

21

(6.7)

8

(5.5)

8

(4.8)

16

(5.1)

13

(9.0)

4

(2.4)

17

(5.4)

Gonorrhea

1

(0.7)

0

(0.0)

1

(0.3)

Chlamydia

18

(12.6)

13

(8.3)

31

(10.3)

0

(0.0)

0

(0.0)

0

(0.0)

77

(24.7)

43

(13.8)

Candidiasis
Bacterial Vaginosis
Trichomoniasis

Syphilis
Any RTI

* There were 86 RTI/STDs diagnosed in 77 clients. Multiple infections were confirmed in 9 clients.
Percentages were calculated on the actual number of tests performed for each infection, at the reference
laboratory, RSCM.
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The following diagnostic criteria were used to confirm these RTIs:
1.

Bacterial Vaginosis: Confirmed presence of clue cells visible in the Gram
stain. pH was not measured. Amine odor (KOH) was recorded but not
directive of a diagnosis.

2.

Candidiasis: Confirmed presence of hyphae and or budding yeast visible
in the Gram stain.

3.

Trichomoniasis: Evidence of motile trichomonads seen by clinic site
laboratory staff on normal saline wet mount.

4.

Chlamydia: Confirmed by positive antigen response with ELISA
commercial kit.

5.

Gonorrhea: Confirmed presence of gram negative intracellular diplococci
visualized with Gram stain, and positive growth of colonies on culture.

6.

Syphilis: By use of RPR test, with TPHA re-test for positive findings.

In addition to the three socio-demographic characteristic of marital status,
contraceptive use and age, eleven potential risk factors for RTI/STD were also
recorded for each study participant during history taking. Table 7 presents the
frequency of positives for each risk factor, including age less than 25 as an additional
risk factor (15% of the sample). Since all but one of the women were currently
married and since contraceptive use is not a risk factor per se, these two characteristic
are not included in Table 7.
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Table 7:

Frequency of Positive Risk Findings Obtained During
the History Taking

Positive Risk Findings

Koja Hospital
N=144
n

Puskesmas
Cilincing
N=168

Combined
Clinics
N=312

n

(%)

n

(%)

(%)
1. Age younger than 25 years

22

(15.3)

26

(15.5)

48

(15.4)

2. Past history of STD ever

0

(0.0)

5

(3.0)

5

(1.6)

3. More than 1 sex partner in past
3 months

0

(0.0)

2

(1.2)

2

(0.6)

136

(94.9)

153

(91.1)

289

(92.6)

5. Unusual vaginal discharge (bad
odor/color)

78

(54.2)

106

(63.1)

184

(59.0)

6. Pain with urination

25

(17.4)

26

(15.5)

51

(16.3)

7. Lower abdominal pain

59

(41.0)

69

(41.1)

128

(41.0)

8. Bleeding after intercourse

14

(9.7)

16

(9.5)

30

(9.6)

9. Genital sores or lumps

14

(9.7)

13

(7.7)

27

(8.6)

10. Sex partner with unusual
discharge from penis

4

(2.8)

2

(1.2)

6

(1.9)

11. Sex partner with sores or lumps
on penis

2

(1.4)

2

(1.2)

4

(1.3)

12. Sex partner not monogamous

6

(4.2)

2

(1.2)

8

(2.6)

4. Sexual intercourse without
condoms

Note: All refer to the past three months before the interview, except #1 and #2

It was noticed that clients had great deficits of information about common
STD symptoms. There was a high level of uncertainty among study participants
about the implication of penis discharge, lesions and monogamy, for their partners’
potential STD status. However, during this study, FP clients did not receive any
systematic educational intervention. It was hoped that HCPs would be prompted by
the training to follow the flow chart and provide some counseling and education if
indicated. However, as discussed earlier, this interaction was undervalued and
generally reglected by the HCPs. There remains a great unmet need for information
among this target population (FP clients).
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Turning to the physical examination, the HCPs were asked to record the
presence or absence of 17 separate symptoms and signs. Table 8 presents these
findings.
Table 8:

Positive Physical Examination Findings in Two FP Clinics

Positive Physical Examination Findings

Koja
Hospital
N=144

Puskesmas
Cilincing
N=168

Combined
Clinics
N=312

n

n

(%)

n

(%)

0

(0.0)

1

(0.3)

(%)
1. Skin rashes (includes trunk, palms, soles
of
feet)

1

2. Abdominal masses, organomegally,
tenderness

1

(0.7)

1

(0.6)

2

(0.6)

3. Inguinal lymphadenopathy

2

(1.4)

0

(0.0)

2

(0.6)

11

(7.6)

2

(1.2)

13

(4.2)

5. Urethral discharge

0

(0.0)

0

(0.0)

0

(0.0)

6. External genital ulcers

0

(0.0)

0

(0.0)

0

(0.0)

7. External genital lesions (wart, etc)

0

(0.0)

4

(2.4)

4

(1.3)

8. Vaginal inflammation (speculum)

20

(13.9)

36

(21.4)

56

(17.9)

9. Abnormal vaginal discharge (speculum)

14

(9.7)

90

(53.6)

104

(33.3

10. Vaginal lesion/ulcers (speculum)

1

(0.7)

5

(3.0)

6

(1.9)

11. Cervical ectopy (speculum)

1

(0.7)

0

(0.0)

1

(0.3)

12. Cervical erythema/inflammation
(speculum)

46

(31.9)

55

(32.7)

101

(32.4)

13. Cervical mucopus (speculum)

63

(43.8)

54

(32.1)

117

(37.5)

14. Cervical friability (speculum)

11

(7.6)

8

(4.8)

19

(6.15)

15. Cervical motion tenderness

8

(5.6)

2

(1.2)

10

(3.2)

16. Abnormal uterine size and/or shape

2

(1.4)

1

(0.65)

3

(1.0)

17. Adnexal mass

0

(0.0)

0

(0.0)

0

(0.0)

4. External vulvar erythema/ inflammation

(0.7)

Note : Data were collected between February 17 and May 9, 1997

Approximately one third of women had signs of abnormal discharge,
cervical erythema and cervical mucopus, however, the proportion with abnormal
discharge was far higher at the hospital. Four women had genital lesions/warts and
six had vaginal lesions/ulcers but none had external genital ulcers.
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III.D.2 Parameters Related to Confirmed RTIs
The associations between confirmed RTI diagnoses and client risk factors,
symptoms and clinical signs (as measured by Odds Ratio and p-value) are, shown in
Table 9. The only statistically significant (p= 0.02) association was for vaginal
lesions/ulcers. However, the value of this statistic is limited by the small numbers
of women experiencing this symptom.
Table 9:

Client Characteristic, Risk Factors, Reported Symptom and
Clinical Findings and Measures of Association with Infection
Status
Characteristic

Infected
n = 77
(%)

Uninfected
n = 235
(%)

OR

Age
<25
>25

9
68

(11.7)
(88.3)

39
196

(16.6)
(83.4)

0.66
1

0.29

Marital Status
Never married
Married
Widowed/divorced

0
77
0

(0.0)
(100.0)
(0.0)

0
234
1

(0.0)
(99.6)
(0.4)

-59.30
1

-0.76
--

2
2
72
46
14
33
11
9

(2.6)
(2.6)
(93.5)
(59.7)
(18.2)
(42.9)
(14.3)
(11.8)

3
0
217
138
37
95
19
18

(1.3)
(0.0)
(92.7)
(58.7)
(15.8)
(40.4)
(18.2)
(7.9)

2.05
0.33
1.13
1.03
1.18
1.11
1.88
1.61

0.43
0.6
0.82
0.9
0.63
0.71
0.12
0.27

1
1
2

(1.4)
(1.4)
(2.8)

5
3
6

(2.4)
(1.3)
(2.7)

0.59
1.02
1.03

0.64
0.98
0.97

0
0
0
4
0
0
1

(0.0)
(0.0)
(0.0)
(8.5)
(0.0)
(0.0)
(2.2)
(19.4)
(38.2)
(7.4)
(0.0)
(36.8)
(46.1)
(10.1)
(10.5)
(14.3)
(0.0)

1
2
2
9
0
0
3
43
78
1
1
73
82
12
8
2
0

(0.9)
(1.8)
(1.8)
(8.1)
(0.0)
(0.0)
(2.6)
(23.3)
(42.4)
(0.5)
(0.5)
(32.2)
(35.3)
(5.9)
(11.8)
(13.3)
(0.0)

0.01
0.01
0.01
1.05
n/a
n/a
0.83
0.79
0.85
14.36
0.02
1.22
1.56
1.79
0.88
1.08
n/a

0.81
0.73
0.73
0.93
n/a
n/a
0.87
0.52
0.57
0.02*
0.76
0.47
0.09*
0.24
0.88
0.95
n/a

History (all refer to past 3 month)
Past history of STD
>1 sex partner
Sexual intercourse without condoms
Unusual vaginal discharge (bad odor/color)
Pain with urination
Lower abdominal pain
Bleeding after intercourse
Genital sores or lumps
Sex partner with unusual discharge from
penis
Sex partner with sores or lumps on penis
Sex partner not monogamous
Exam
Skin rashes
Abdominal masses, enlargement, tenderness
Inguinal lymphadenopathy
External genital inflammation
Urethral discharge
External genital ulcers
External genital lessions
Vaginal inflammation (speculum)
Abnormal vaginal discharge (speculum)
Vaginal lesions/ulcers (speculum)
Cervical ectopy (speculum)
Cervical erythema/inflammation (speculum)
Cervical mucopus (speculum)
Cervical friability (speculum)
Cervical motion tenderness
Abnormal uterine size &/or shape
Adnexal mass

13
26
5
0
28
35
7
2
1
0

P

*Statistically significant (<0.05) or boderline significant (<0.1)
Note : n/a = measures of association were not calculated (not applicable) if there were zero values
or very low numbers.
OR = Odds Ratio
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III.D.3 Validation of Diagnostic Approaches for RTIs
Although, of course, no laboratory test is infallible in determining the
presence of each and every RTI, for the purposes of data analysis, the final laboratory
results were used as an indicator of actual presence or absence of an RTI. This study
provided the opportunity to compare initial clinical (or syndromic) diagnoses, made at
the time of the clinical evaluation, with the results of the final confirmatory laboratory
reports, of etiologic diagnosis. The results in Table 10 show a 42.6% of concurrence.
The disparity represents both over- and under- diagnosing at both clinic sites. The
doctors in the FP clinic at Koja Hospital achieved a higher rate of correct initial
diagnoses (47.5%) than the midwives at Puskesmas Cilincing (36.5%). However in
practice it should be noted that the final laboratory results were not used to override the
independent judgment of the HCP if there was strong clinical evidence (multiple signs
and risk factors) of infection after the history and examination had been completed.
Table 10 illustrates the trends observed over the 12 weeks in the prevalence of infection
and the level of concurrence between initial and final diagnoses in each FP clinic. This
shows that while confirmed prevalence remained steady overall at about 25%, the
concurrence rates improved at the hospital but not at the Puskesmas.
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TABLE 10:

Actual STD
Status

Trends and Overall Rates of 1. Prevalence of Any RTI/STD
Diagnosis, and 2. Concurrence Between Initial Clinical
Diagnoses and Final Laboratory Diagnoses
1 st quarter
(weeks 1-3)

2nd quarter
(weeks 4-6)

3rd quarter
(weeks 7-9)

4th quarter
(weeks 10-12)

TOTAL

11/38 (8.9%)

11/34 (32.4%)

14/38 (36.8%)

9/34 (26.5%)

7/33

6/37 (16.2%)

9/46 (19.6%)

10/52
(19.2%)

32/168 (19.0%)

17/71 (3.9%)

23/8 (27.4%)
19/86
(22.1%)

77/312
(24.7%)

1. Prevalence
of any
RTI/STD:
Koja Hospital
Cilincing PHC
Combined Sites

(21.2%)
18/71
(25.4%)

45/144
(31.3%)

2. Concurrence
between clinical
& Lab
Diagnoses:*
Koja Hospital

10/36 (27.7%)

15/34 (44.1%)

13/38 (34.2%)

20/33 (60.6%)

58/141 (41.1%)

Cilincing PHC

7/10 (70.0%)

5/7 (71.4%)

15/47 (31.0%)

13/51 (29.4%)

40/115 (34.8%)

Combined Sites

17/46 (36.9%)

20/4 (48.8%)

28/85 (32.9%)

33/84 (39.3%)

98/256 (38.3%)

* 56 out of the 312 women (17.9%) did not receive any clinical diagnosis (3 at Koja Hospital and 53 at
Cilincing PHC), therefore concurrence can only be assessed in 256 of the cases.
Notes:
Actual Prevalence of RTI/STD was determined by any RTI/STD diagnoses made at the referral
laboratory at RSCM between February 17 and May 9, 1997 (i.e. positive for bacterial vaginosis,
candidiasis, trichomoniasis, gonorrhea and/or chlamydia)
Clinical Diagnoses in general, were based only on history risk assessment and physical examinations.
Concurrence includes (1) matches between positive clinical RTI/STD diagnoses and positive final
RTI/STD diagnoses (note: only if the diagnosis was correct, eg. an initial diagnosis of bacterial vaginosis
for a final diagnosis of candidiasis was not considered correct, but an initial diagnosis of cervicitis and
a final of chlamydia was considered correct); and (2) matches between two negative diagnoses (note:
initial recorded diagnoses which had no relation to potential RTI/STD, such as ammenhorrea or a
problem with an IUD, were also considered negative diagnoses for our purposes here.)

As previously described, universal etiologic testing for six treatable RTIs was
attempted on each client, which allowed the opportunity to compare the initial clinical
diagnosis (or syndromic diagnosis) with the final laboratory confirmed diagnosis (or
etiologic diagnosis).
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Further analyzing the concurrence and discordance of syndormic and
etiologic diagnoses, Table 11 charts the false and correct negatives and positives,
using the etiological diagnoses as the “true” diagnoses.
Table 11:

Comparative Analysis of Syndromic with Etiologic Diagnoses

Accuracy of initial clinical
(syndromic) diagnoses
compared with final
confirmed laboratory
(etiologic) diagnoses
Correct positive diagnoses

Koja Hospital
N=141

Puskesmas
Cilincing
N=115

n

(%)

n

14

(9.9)

5

(%)

Combined
Clinics
N=256
n

(%)

19

(7.4)

(4.3)
False negative diagnoses

54

(38.3)

59

(51.3)

113

(44.1)

Correct negative diagnoses

44

(31.2)

35

(30.4)

79

(30.9)

False positive diagnoses
29
(20.6)
16
(14.0)
45
(17.6)
*Note:
56 out of the 312 women (17.9%) did not receive any clinical diagnosis (3 at Koja Hospital and 53 at
Puskesmas Cilincing ), therefore concurrence can only be assessed in 256 of the cases.
Correct positive = syndromic and etiologic diagnoses agreed - both were positive
False negative = syndromic diagnosis was negative but the correct (etiologic) diagnosis was positive
Correct negative = syndromic and etiologic diagnoses agreed - both were negative
False positive = syndromic diagnosis was positive but the correct (etiologic) diagnosis was negative

A total of 19 clients from both clinic sites (14 from Koja and 5 from
Cilincing), had correct initial positive diagnoses. A total of 79 clients from both
clinic sites had correct “Normal” (negative) diagnoses. This combined diagnostic
accuracy rate yielded a total of 98 clients (38.3%) who were correctly diagnosed
at the time of the initial clinical evaluation.
A higher number of clients received false syndromic diagnoses
(113+45=158) than received correct syndromic diagnoses (19+79=98). The most
likely diagnosis was a false negative (44.1%).
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During the first quarter of the study, there was a high degree of reluctance
by the midwives to render a clinical diagnosis without laboratory confirmation.
The midwives had a much higher rate of making no initial diagnosis (53/168 or
31.5% of cases) compared to their physician counterparts at the hospital clinic
(3/144 or 2.1% of cases). Compared to the doctors, the midwives also had a
lower rate of achieving a correct clinical diagnosis (41.1% vs 34.8%) when it was
attempted. Overall, 56 women (17.9%) did not receive an initial diagnosis.
After this trend of non-diagnosis by the midwives was observed during the
first two weeks, various training and coaching activities ensued to encourage the
midwives to make an initial clinical diagnosis. As a group, the midwives started the
study with less diagnostic experience. This lack of experience, along with all HCPs
struggle to make an accurate initial diagnosis, motivated the development of an
RTI/STD Case Management Manual (see Appendix L). This training manual
utilized the exact case management protocol (see Protocol VI, Appendix D)
previously distributed during the initial “Round Table Discussion” but each RTI
protocol was accompanied with photographs to provide a visual example for future
reference. The photographs were reproduced from slides previously used during an
additional training on “RTI/STD case management” held March 21st for the staff of
Puskesmas and 25 March for hospital staff.
Same day accurate clinical diagnosis could be facilitated by prompt and
accurate microscopy results. Comparisons of the sensitivity and specificity of on-site
lab results with final diagnoses are presented in Table 12 and 13, for bacterial
vaginosis and candidiasis, respectively.
Table 12.

Sensitivity and Specificity of Clinic Site Gram Stains in
Detecting Bacterial Vaginosis

On-site Lab Tests

Confirmation Lab Results

Total

+

-

+

9

29

38

-

7

267

274

Total

16

296

312

The prevalence of Bacterial vaginosis in this population : 16/312 = 5.13%
Reliability of local clinical labs for detecting Bacterial vaginosis :
Sensitivity
: 9/16 = 56.2%
Specificity
: 267/296 = 90.2%
Positive Predictive Value (PPV): 9/38 = 23.7%
Negative Predictive Value (NPV): 267/274 = 97.5%
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Table 13.

Sensitivity and Specificity of Clinic Site Gram Stain in
Detecting Candidiasis

On-site Lab Tests

Confirmation Lab Results

Total

+

-

+

9

15

24

-

12

276

288

Total

21

291

312

The prevalence of candidiasis in this population : 21/312 = 6.7%
Reliability of local clinical labs for detecting candidiasis :
Sensitivity : 9/21 = 42.8%
Specificity : 276/291 = 94.8%
PPV : 9/24 = 37.5%
NPV : 276/288 = 95.8%

Sensitivity and specificity were calculated comparing the clinic site gram
stain microscopy results with the results from the same gram stain read by referral
laboratory at RSCM. Comparison could not be performed for wet mounts to screen
trichomonads, since these had to be performed on site only (before the trichomonads
died). Also the comparison was not made for chlamydia or gonorrhea, as these were
only tested for at the referral lab. We can see that sensitivity and positive predictive
values of these initial on-site diagnoses were limited for both bacterial vaginosis and
candidiasis.
A customary practice of the referral laboratory, independent of this study,
was to include “Non-Specific Genital Infection” (or NSGI) as a laboratory diagnosis,
based on leukocytosis as indicated by more than 30 polymorphonuclear leucocytes
(PMNs) per HPF, both on vaginal and cervical Gram stains. Previous RTI/STD
screening conducted by some of the national working group have used an elevation
of PMNs as a prevalence marker in RTI/STD studies without performing cervical
cultures for N. gonorrhoeae or specific testing for C. trachomatis (Pratomo, Nasrin,
et. al., 1995). However, a study in Zaire stated that the presence of leukocytosis >10
PMN/hpf was not a good predictor of actual STD diagnosis (Vuylsteke, Laga, Alary,
et.al., 1993). Following the universal literature on RTI/STDs, the presence of
cervical leukocytosis was not assigned a diagnostic significance in this study. The
presence of increased PMNs on the cervix was also not interpreted as diagnostic of
an RTI or STD in this study, since universal screening for both gonorrhea and
chlamydia was performed. Since the data on elevated PMNs are available, however,
they are presented in Table 14 in comparison with the lab diagnoses. In brief, Table
14 shows that 36.2% (113) of clients were identified as having cervical leukocytosis,
but 70.8% of them (80/113) had negative final lab results.
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Table 14: Cervical Leukocytosis and Final Laboratory Findings for RTI/STDs

Gram stains indicating cervical
lecocytosis: cervical PMNs
>30/hpf:

Koja
Hospital

Puskesmas
Cilincing

Combined
Clinics

n/N

%

n/N

%

n/N

%

48/144

(33.3)

65/168

(38.7)

113/31
2

(36.2)

Positive lab test for Chlamydia
among
clients with elevated PMNs*/**

11/48

(22.9)

8/65

(12.3)

19/113

(16.8)

Positive lab test for any RTI/STD
among clients with elevated
PMNs***

11/48

(22.9)

6/65

(9.2)

17/113

(15.0)

Positive lab test for Chlamydia
among clients with normal PMNs

7/96

(7.3)

5/103

(4.8)

12/199

(6.0)

Positive lab test for any RTI/STD
among clients with normal PMNs

16/96

(16.7)

13/103

(12.6)

29/199

(14.6)

Elevated PMNs among all clients

PMN = Polymorphonuclear Leucocytes
hpf = high power field
*
11 clients did not have chlamydia tests performed.
**
1 client was positive for both gonorrhea and chlamydia
*** i.e., bacterial vaginosis, trichomoniasis and/or candidiasis (1 client had more than 1 RTI).

The performance of the amine odor (“whiff”) test was originally
recommended at the beginning of the study when wet mount microscopy was the
only microscope test included in the routine. With the adoption of a combined Gram
stain wet mount microscopy procedure, as recommended by the advisory board
member who was the chief of the referral laboratory at Cipto Mangunkusumo
Hospital (RSCM), the method of performing and evaluating the whiff test was
transferred from the HCPs to the Ras. At the Koja hospital, 57 (45.2%) of 144
“whiff” tests were judged as positive, but only eight clients had confirmed clue cells
on their Gram stains. Six of these eight clients had positive “whiff” tests. Factors
that contributed to this low sensitivity and specificity included the manner that the
test was performed and the inexperience of both the HCPs and RAs in integrating this
subjective test into the performance of routine specimen collection.
Inaccurate clinical diagnoses can lead to inappropriate prescription. The
impetus to promote a same day accurate diagnosis came from the fact that many
RTI/STDs will never be treated if treatment depends on the client returning to the
clinic to receive the laboratory results. Follow-up efforts to reach clients who
typically do not have telephones or street addresses are a costly and unrealistic
option for delivery of treatment. As described in Table 15, the medications that were
prescribed as a result of this study’s encouragement to make same day clinical
diagnoses included a broad range of treatment. Some drugs were given in
accordance with the national treatment guidelines and others were inappropriate and
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reflected long standing habits of drug selection by the provider. While it is a
possibility that some of these clients with “negative” laboratory results may have
benefitted from some of the treatments, it indicated a pattern of “over treatment”.
We can see that over the course of the study, this over-treatment declined at the
hospital but not at the Puskesmas (PHC).

Table 15:

Number of Prescriptions Written at Initial Clinical Evaluations
for Clients with Final Negative Laboratory Diagnoses

Prescriptions

Koja Hospital

Puskesmas Cilincing

Combined Clinics

Week
1-4

Week
5-8

Week
9-12

Week
1-4

Week
5-8

Week
9-12

Week
1-4

Week
5-8

Week
9-12

Metronidazole

11

2

8

0

13

10

11

15

18

Doxycycline

9

5

6

0

0

0

9

5

6

Thiamphenico
l

5

4

1

0

0

0

5

4

1

Albothyl

0

0

1

25

29

16

25

29

17

Vitamins

2

2

1

0

0

0

2

2

1

Antifungals*

0

3

2

0

1

11

0

4

13

Ciprofloxacin

4

0

0

0

1

0

4

1

0

Amoxicillin

2

1

0

0

0

0

2

1

0

Tetracycline

0

2

0

3

0

0

3

2

0

Total
Prescriptions

33

19

19

28

44

37

61

63

56

Total Clients
with Negative
Diagnosis

38

29

32

39

50

47

% Receiving
unnecessary
prescription

86.8

65.5

59.4

71.8

88.0

78.7

77

79.2

79

79.7

79

70.9

*Antifungals include Diflucan, Canesten vaginal suppositories and Miconazole cream.

The fact that the study pre-packaged and provided approved treatments, no
doubt, raised the level of compliance and accuracy when selecting an approved
medication. However, this did not eliminate incorrect choices completely, such
as selecting Metronidazole to treat candidiasis.
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The history of using Thiamphenicol for both Gonorrhea and Chlamydia was
accompanied by a strong belief by some of the doctors that it worked well for
cervical bacterial infections. Some physicians expressed concerns that a single dose
therapy such as Ciprofloxacin could not cure a gonorrhea infection in women.
Another long standing prescribing habit in Indonesia that is reinforced by the public
health system is prescribing antibiotics for a three day regimen. Thus, suggested
changes in the length of time a drug is given to either a shorter single dose or a seven
day regimen, was not immediately aceptable to HCPs.
III.D.4 Observations of HCP/Client Interactions
Every one of the 312 clinical evaluations was observed by a trained RA,
who immediately recorded her observations on a coded observation form (see
Appendix G). At first the HCPs were skeptical and guarded about being observed.
The RAs were young, female college graduates from the field of public health. They
had all been trained to be neutral and non-threatening. They had also been very
involved in the writing of the protocols and study instruments. In addition they had
received much RTI/STD training during the pre-intervention portion of the study.
They all intrinsically possess characteristics that make them appealing team members
such as youth, enthusiasm and warm good natures. The final style of the relationship
between the HCP and the RAs was similar to that of a benevolent “boss” to a friendly
junior “assistant”. The HCPs were aware of the knowledge and experience each of
the RAs possessed.
During the initial “Round-Table Discussion” training intervention in
January, the HCPs expressed reluctance towards filing out the clinical evaluation
flow sheet (Appendix A). To promote cooperation, the project manager agreed to
let the RAs function as data recorders for the HCPs. At the hospital, this assistance
was limited to the risk assessment/history portion. The doctors filled out the physical
exam finding themselves. At the health center, partly due to higher case load, the
RAs also completed the physical exam portion, filling in to the findings as assessed
by the midwives. However, in the last month of the study, when the physician
medical director, and a visiting supervisory midwife started performing evaluations
at the health center, the midwives were more likely to fill this out themselves. The
progression of the RAs role as neutral observer to helpful assistant was influenced
by the performance of the HCPs. For some HCPs with weaker clinical skills,
especially among midwives at the health center, the roles were often reversed,
placing the RAs in the position of mentors to HCPs who often sought their advice on,
“what do you think this is?” or, “where should this go?” It should also be mentioned
that during the course of the study, at both the hospital and the health center, trainee
midwives were sometimes brought in to complete the history portion, instead of the
RAs.
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Even with the supportive help and watchful eye of the RAs at each
HCP/client interaction, the HCP’s were not compliant in performing or completing
the final teaching/counseling component of the RTI/STD evaluation procedure. This
has been previously addressed as a very undervalued component of client care.
Table 16 describes the frequency with which targeted HCP behaviors were observed.
The check list of behaviors is based on the clinical protocols. The desired behavior
were repeatly reinforced in each training in a variety of presentations, both written
and oral. The minimal desired behaviors were finally written in the self assessment
checklist, as previously discussed (Appendix F) which was given to each HCP as
a guide to what was expected of them. The observation tool covers optimum history
taking, client teaching, partner intervention and infection control practices, and
directly mirrors the clinical evaluation tasks. Of interest is the frequency with which
the HCPs would direct the RAs to record a negative result on the evaluation form for
a task that was not performed, such as a bimanual examination. In cases where
HCPs completed the physical exam section themselves, HCP/client interaction
observation records can serve as a testimony to what was actually completed, and
what was recorded as being completed.
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Table 16:

Observed Frequency of HCP/Client Interaction Behaviors
Koja
Hospital

Behavior Observed

N=144
Yes
n
(
%)
1.Introduction
Smiles and greets client respectfully
Asks client’s reason for coming to clinic
2.Review of Current Status/Condition
Current contraceptive method
Last menstrual period
Current medications
Allergies to medicine and latex
OB history and potential of current
pregnancy
3. Introductory Education
Reviews RTI/STDs that effect women’s
health
Reviews 7 birth control method & makes a
connection to STD protection
4.Review of Reproductive Health History
Items
Previous history of STD
More than 1 sex partner in past 3 months@
Sexual intercourse without condoms
Unusual vaginal discharge
Pain with urination
Lower abdominal pain
Bleeding after intercourse
Genital sores or lumps
Sex partner with unusual discharge from
penis
Sex partner with sores or lumps on penis
Sex partner not monogamous
5. Infection Control
Washes hands before exam
Uses visibly clean instruments
Puts on new/ disinfected glove before pelvic
exam
If rectal exam done, changes glove prior to
rectal
Washes hands after removing glove

Puskesmas
Cilincing
N=168
Yes
n
( %)

Combined
Clinics
N=312
Yes
n
( %)

5
(3.5)
144 (100.0)*

104
101

(61.9)
(60.1)

109
245

(34.9)
(78.5)

144
143
124
139
140

(100.0)
(99.3)
(86.1)
(96.5)
(97.2)

167
164
137
160
151

(99.4)
(97.6)
(81.5)
(95.2)
(89.9)

311
307
261
299
291

(99.7)
(98.4)
(83.7)
(95.8)
(93.3)

0

(0)

1

(0.6)

1

(0.3)

0

(0)

1

(0.6)

1

(0.3)

144
144
144
144
144
143
144
143
142
143
143

(100.0)
(100.0)
(100.0)
(100.0)
(100.0)
(99.3)
(100.0)
(99.3)
(98.6)
(99.3)
(99.3)

161
166
167
167
167
167
167
167
166
165
164

(95.8)
(98.8)
(99.4)
(99.4)
(99.4)
(99.4)
(99.4)
(99.4)
(98.8)
(98.2)
(97.6)

305
310
311
311
311
310
311
310
308
308
307

(97.8)
(99.4)
(99.7)
(99.7)
(99.7)
(99.4)
(99.7)
(99.4)
(98.7)
(98.7)
(98.4)

11
(7.6)
144 (100.0)

47
166

(28.0)
(98.8)

58
310

(18.6)
(99.4)

143

(99.3)

103

(61.3)

246

(78.8)

0
25

(0.0)
(17.4)

0
44

(0.0)
(26.2)

0
69

(0.0)
(22.1)

6. Physical Exam Steps Performed
Abdomen/skin
144 (100.0)
15
(8.9)
159
Inguinal palpation
144 (100.0)
16
(9.5)
160
Visual external genitalia
144 (100.0) 112
(66.7)
256
Speculum exam
144 (100.0) 166
(98.8)
310
Bimanual exam
18
(12.5)
70
(41.7)
88
* With assistance from hospital midwives who screen clients and always asked
@ All in this section refer to recall period of the past three months, except the first item
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(51.0)
(51.3)
(82.1)
(99.4)
(28.2)

Table 16:

Continued

Behavior Observed

7.Counseling
Explains the diagnosis to client
If diagnosed RTI positive, explains the
disease transmission to client
If diagnosed STD positive, makes verbal
plan for partner treatment & evaluation
8. Instruction for future STD prevention
Discusses abstinence
Discusses monogamy
Discusses Condoms
Offers condoms
Provides instructions for condom use
9. Advice on treatment
Name of medication
How often to take the drug
Length of drug use
Take entire prescription
Potential side effects (alcohol & pregnancy)
Assesses client’s understanding of
instructions
10. HCP demonstrates positive
communication skills
Open and friendly
Uses understandable terminology
Conveys interest in the client
Listens carefully
Is open to the client’s questions

Koja
Hospital

Puskesmas
Cilincing

Yes

Yes
n
%)

n

(%)

7

(6.8)

11

Combined
Clinics
Yes

(

n

(%)

1

(1.1)

8

(4.1)

(25.6)

0

(0.0)

11

(14.9)

8

(24.2)

0

(0.0)

8

( 9.5)

9
0
2
1
0

(21.4)
(0.0)
(4.8)
(2.4)
(0.0)

1
0
0
0
0

(11.1)
(0.0)
(0.0)
(0.0)
(0.0)

10
0
2
1
0

(19.6)
(0.0)
( 4.0)
(2.0)
(0.0)

37
49
39
23
2

(40.6)
(54.4)
(42.8)
(25.6)
2.2)

39
32
29
0
24

(61.9)
(51.6)
(47.5)
(0.0)
(39.3)

76
81
68
23
26

(49.4)
( 53.3)
(44.7)
(18.4)
(17.2)

1

(1.1)

4

(11.7)

5

(4.1)

63
2
2
4
4

(94.0)
(40.0)
(50.0)
(100.0)
(80.0)

167 (100.0)
143
(99.3)
165 (100.0)
79
(98.8)
58
(96.7)

230
145
167
83
62

(98.3)
(97.3)
(98.8)
(98.8)
(95.3)

Note : In this continuation of Table 16, unlike the first portion, denominators vary widely for various
reason, such as exclusions based on diagnosis, HCP/Client interactions that did not happen or were not
observed, and some inconsistencies in the methods of recording observations among RAs.
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The HCPs first task of making a good impression and establishing a rapport
with the FP client at the beginning of the clinical evaluation was observed by any
demonstration of smiling and greeting the client respectfully. The midwives, were
able to achieve this goal more often than their physician counterparts (61.9% vs.
3.5% respectively). Although the doctors were rated as achieving a 100% threshold
of screening the client’s reason for visiting the clinic, this task was delegated to and
performed by the nursing staff who automatically documented the chief complaint
or reason for visit, in an intake before the client actually sees the doctor (Table 16,
section 1). Five separate inquiries about the current status of contraception,
menstruation, medications, allergies, and potential pregnancy were similarly
achieved by both groups of HCPs at a level of 80-100% (Table 16, section 2).
Both groups of HCPs ignored the protocols of providing preliminary health
education on the existence of RTIs and their connection to selected contraceptive
methods (see Table 16, section 3). This step should have preceded the performance
of an STD risk assessment, not just to educate the client, but to also allow the client
more time to adjust to the concept of a frank discussion of STDs, as well as
increasing the opportunity for the HCP to demonstrate his or her particular merits as
a professional deserving of the client’s trust, before the invasiveness of a sexual STD
risk assessment is performed. This step occurred with only one client (by a midwife).

The entire eleven question sexual history was performed 95-100% of the
time in both clinics. However, as described above, the history was actually obtained
almost exclusively by the RAs and sometimes by trainee midwives, but not by the
primary HCP. Doctors in the hospital would review affirmative history responses
with the patient for greater diagnostic clarification.
Five distinct infection control behaviors were itemized with only four
behaviors ever being observed since no rectal exam were actually performed during
the study. Rates of hand washing before (18.6%) and after (22.1%) performing a
pelvic examination were quite low, though higher for the midwives (Cilincing) than
the doctors (Koja). Out of the 312 observed examinations, visibly clean instruments
were used in all but 2 (0.6%) of the exams. Midwives at the Puskesmas were less
consistent than the doctors at Koja in using new or disinfected gloves prior to each
pelvic examination (61.3% vs 99.3%). Prior to the study, the Puskesmas regularly
re-used gloves after disinfecting them. The project purchased disposable
examination gloves for this clinic. In the opinion of the observing RAs, one of the
midwives felt reluctant to throw away “perfectly good” gloves and would recycle
them by simply washing her hands prior to examining the next client.
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The pelvic examination most often included a speculum examination
(99.4%). Other components of the physical exam were performed much less regularly
especially the bimanual exam (28.2%) (see Table 16, section 6).
As discussed early, regarding the low value placed on counseling and
communication, Table 16 shows that rates of performing these behaviors were much
lower than for physical exam procedures. In only 14.9% of RTI positive cases was
the disease transmission explained to the client, and in only 4% of cases were
condoms discussed. Only one client was offered condoms (2%) and no client
received instruction on condom use.
With regard to discussion of medication Table 16, section 9 overall about
50% of the time, HCPs mentioned the name of the drug and described the regimen.
Only 18.4% of the time was emphasized that the entire prescription must be taken
(never mentioned at the Puskesmas), and doctors more often neglected to warn of
side-effects (2.2% vs. 39.3% among midwives at Cilincing ). HCPs almost never
bothered to assess the clients’ understanding of the instructions (4.1%). The final
section of Table 16 presents especially subjective evaluations by the RAs of the
HCPs positive manner and openness. Overall, the results were very high (all, item
over 95% positive), with lower rates among doctors (at Koja) than midwives (at
Cilincing) (see Table 16, section 10).
However, overall for this observation evaluation tool, the highly subjective
nature of many of the items, along with the fact that the RA’s for each site were never
switched and the tool was not tested for interater reliability, limits the reliability and
value of these data.
Proportions of RTI/STD Positive Clients and Partners Treated
The anticipated problem of failing to treat many RTI cases due to requiring
clients to return to the clinic for result of the final laboratory results, was an expected
effect of the decision to perform universal etiologic RTI diagnosis. All those who did
return received appropriate treatment. No inappropriate (wrong medication)
treatment was given. This is because it was decided to prepackage and label all
medications for the study and also, in all cases it was the research assistants who
selected the packages of medication based on the confirmatory diagnosis. Thus, we
can not assess HCP compliance with treatment guidelines (objective 5). An analysis
of return clients visits and appropiate treatments is presented in Table 17 and 18.
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Table 17:

Status of Client Treatment for Non-Sexually Transmitted RTIs

RTIs confirmed in both clinic sites that
are non-sexually transmitted:

Appropriate client
treatment

Client not treated*

n

(%)

n

(%)

(n=21)

16

(76.2)

5

(23.8)

Bacterial Vaginosis (n=16)

11

(68.8)

5

(31.2)

Total

27

(73.0)

10

(27.0)

Candidiasis

(n=37)

* Client had not returned to clinic for final lab results and treatment as of two weeks after study
completion on 5/9/97.

Table 18:

Status of Client and Partner Treatment for RTIS That are
Sexually Transmitted (STDs)

Confirmed STDs at both
clinic sites

Appropriate
client
treatment
(PI6)**

Client not
treated*

Appropriate
partner
treatment
(PI7)**

Partner not
treated*

n

(%)

n

%

n

%

n

%

Trichomoniasis (n=17)

12

(70.6)

5

(29.4)

9

(53.0)

8

(47.0)

Gonorrhea (n=1)

1

(100.0)

0

(0.0)

0

(0.0)

1

(100.0)

Chlamydia (n=31)

23

(74.2)

8

(25.8)

18

(58.1)

13

(41.9)

Total (n=49)

36

(73.5)

13

(26.5)

27

(55.1)

22

(44.9)

*

Client had not returned to clinic for final lab results and treatment as of two weeks after study
completion on 5/9/97.
** These were calculated according to WHO formulas PI6 and PI7, as shown. Since only two clients
received advice on condoms, PI7 was devised to reflect partner treatment alone.

No. of women with STD assessed and treated in an appropiate way
PI6 = ---------------------------------------------------------------------------------- x 100%
No. of women with STD confirmed by referral lab
No.of women with STD who received basic advise on condoms and partner treatment
PI7 = ----------------- -- ---------------------------------------------------------------------------x 100 %
No. of women with STD confirmed by referral lab
source: WHO/GPA/TCO/SEF/94.1-section 2, p.1

For non-sexually transmitted RTI’s, Table 17 shows that approximately one
quarter (26.5%) went untreated due to the client’s failure to return as of two weeks
after the study ended. The rate was approximately the same for STDs 73.5% (36/49
women) received appropriate treatment. However the rate of partner treatment was
much lower; just over half of partners of women with STD’s received treatment
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(55.1% or 27 partners). This leaves nine treated women (36-27) exposed to the
possibility of reinfection from her partner. Rates were approximately equal for
treatment of chlamydia and trichomoniasis. The single case of gonorrhea was treated
but the partner was not.
Broken down by clinic site, at Koja Hospital the doctors provided appropriate
treatment for 84.4% of cases but the midwives did so only 52.9% of the time. This
means simply that the Cilincing clients more often failed to return and perhaps the
midwives were less firm in their explanation of the need for a follow-up visit.
III.D.5. Existing RTI/STD Reporting and Recording Practices
A six month retrospective medical review showed that it is an essentially nonexistent practice to catagorize gynecological problem with disease specific diagnosis.
In review of chronological register of out-patient visits to combined MCH/FP clinics
in the Koja Hospital, there were no recorded reports of trichomoniasis, bacterial
vaginosis, candidiasis, gonorrhea, chlamydia, or syphilis during the six months
between July 1 and December 31, 1996. There were descriptive syndromic
assessment that could very well be sentinels of RTI/STDs. There were 114 diagnoses
of vaginitis, 102 of discharge and 67 of adnexitis, 14 of cervicitis, one of cervical
cancer and two of genital lumps.
The actual medical records, for each client who was diagnoses with one of the
above diagnoses, were reviewed to see if the individual medical recording had a
consistent or more precise diagnosis. The records were also reviewed to monitor
diagnostic and treatment modalities. In none of the actual records reviewed were
there discovered any more etiologically precise labels. A majority (125) of the
prescription written in these medical records were illegible and the hospital did not
have a computer based formulary to double check actual prescribing practices. In no
cases was there any indication that the individual clients were educated on their
diagnosis or given instructions for future disease prevention, or for partner treatment.
The six month retrospective medical review of Puskesmas Cilincing did not
have a chronological daily clinic visit registration report as Koja Hospital. The
medical report were completed by the HCP, who in turn transferred data to a monthly
report for disease. This report only includes the client’s age and disease, and no
client identifiers

that would allow for the retrieval of an individual medical report to survey diagnostic,
treatment and education interventions. The only RTI/STDs include in the report are
gonorrhea and syphilis. For the entire six month period there were only three
reported cases of gonorrhea and no cases of syphilis.
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IV.

Conclusion and Recommendations

A deliberate choice to limit the number of variables used to perform risk
assessment was made to promote a feasible standard of history taking for HCPs who
were also being asked to perform more client care in their busy practices. The
sociodemographic picture of the family planning clients studied in both clinics is
strikingly homogenous. The marital status of clients was 97.3% married, and the age
of the majority of studied women (264 or 85%) was 25 or over. The most popular
contraceptive methods are injectable hormones (36.9% ), IUDs (26.0%) , and pills
(23.0%).
.
The risk assessment history revealed that past histories of STDs (1.6%) and
recent multiple partner exposure (0.6%), were rarely reported. Almost all women
(97.4%) reported the perception that their partner was monogamous. Despite a low
rate of condom use as a contraceptive method (2.6%), a slightly higher percentage
(7.4%) of women used condoms during sexual intercourse in addition to other
contraceptive methods.
Five inquiries were made regarding the woman’s self-reported
symptomatology in three months prior to the exam. Fifty nine percent of women
reported having abnormal vaginal discharge (bad odor, itching or discolored),
41% complained of lower abdominal pain, 9.6% had experienced post-coital
bleeding in the past three months, 8.6% reported genital sores or lumps in the past
three months, and 6.3% reported pain with urination. The woman’s perception of her
partner’s manifestation of RTI symptoms was very low at 1.9% for discharge from
the penis and 1.3% for sores or lumps on the penis.
From the clinical evaluations of the 312 clients , the HCPs reported that
37.5% had cervical mucopus, 33.3% abnormal vaginal discharge, and 32.4% cervical
erythema. Due to the long turn around time for all laboratory reports, except the
saline wet mount exam for trichomonads, performed on site, most clients left the FP
clinic with an unconfirmed clinical diagnosis and were advised to return to the clinic
in approximately two weeks for the final laboratory diagnosis and treatment. In view
of the likelihood that some women would not return for follow-up visits, HCPs were
encouraged to attempt to provide a correct initial clinical diagnosis and treatment
(including treatment for partners) prior to the woman leaving the clinic. This
concentration on providing early and correct clinical diagnoses and treatment plans
was also made in accordance with national and international STD case management
recommendations to interrupt the chain of infection by providing treatment for
treatable infections at the earliest possible point with the ultimate goal of reducing
STD associated mortality and morbidity (Daili et al., 1996 and WHO, 1994).
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Overall, this target group of low-income housewives was a relatively low-risk
group for STDs. However, they self-reported a high rate of genital symptomology,
especially abnormal discharge (59%). HCPs detected signs of infection by speculum
examination in roughly one third of the evaluated clients. Final laboratory
evaluations confirmed a total prevalence rate of 24,7% for any RTI/STD among the
312 evaluated clients. Chlamydia was the most common infection (10.3%). The
prevalence of the sexually transmitted infections (trichomoniasis, chlamydia and
gonorrhea) exceeded the rate of non-sexually transmitted RTIs (candidiasis and
bacterial vaginosis) among the participants (16% vs. 11.8%, respectively). Clearly,
this “low-risk” group has a need for RTI/STD services that remains unmet.
The initial (syndromic) clinical diagnoses based on the history and physical
examination; were compared to the final (etiologic) laboratory results. None of the
twelve variables collected during the history, or the seventeen physical examination
components, were sensitive or specific enough to accurately predict the presence of
these 86 etiologically confirmed infections. The combined rate of correct initial
clinical diagnoses (either negative or positive) for both doctors and midwives was
38.3%.
The result of such a large percentage of inaccurate clinical diagnoses
contributed to inappropriate treatment and missed treatment opportunities. The
wrong clinical diagnosis allows treatable infections to persist and in turn be passed
on to other sexual partners. Furthermore, the cost of incorrect diagnosis for women
who are not appropriately treated, in terms of consequences to their health and well
being, is in itself a compelling reason to direct continued efforts to effectively
identify, treat and counsel women with treatable RTIs. As described by Over and
Piot (1996), health care intervention can achieve benefits in two distinct ways. The
simplest intervention is one that cures or prevents the infection of some people once.
The second type of intervention is a sustained one that alters either the sexual
behavior of the population or the disease specific transmission and duration
parameters. These two interventions of appropriate treatment and risk reduction
education are two functions that are within the scope of services that can be feasibly
provided by both FP clinics in this study. An improvement in delivering these
services to each client should be made.
This study revealed that education for STD risk reduction is a consistently
neglected component of FP client care, even after initial and follow-up HCP training.
The discussion and offering of condoms should be included in every treatment plan
for clients with a confirmed STD as well as for clients who do not use a barrier
method during sexual intercourse and are not certain if they are in an infection-free,
sexually monogamous relationship. This intervention for clients is analogous to
training HCPs in universal precautions, such as wearing gloves before performing
pelvic examinations. This promotion of education and condoms only occurred in two
of the observed HCP/client interactions during the twelve week observation period.
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FP clients with the greatest need for intervention are certainly those clients who are
found to have a confirmed STD. By definition, these infected clients are members
of a core group for STD transmission, including HIV.
Following are recommendations addressing the various areas of study:
1.

Improve risk assessment and counseling

If HCPs are too busy to perform the task of risk assessment and counseling,
and are willing to delegate them to a designated interviewer, resources should be
secured to provide appropriate staff for programs that want to include RTI/STD case
management. Even though risk assessment is not highly specific for the discovery
of RTI/STD’s, it is critical for making an initial clinical judgement about suspected
gonorrhea and chlamydia, which at this time are only reliably diagnosed by
etiologically specific testing. Making a risk assessment requires sensitive questioning
of the client. By delegating the risk assessment to non-medical personnel, the HCP
subjects the client to scrutiny by more people, which may limit the collection of
complete information if the client feels threatened by this. If the sequence of an
evaluation starts with a history performed by non-medical personnel, followed by
physical assessment and specimen collection from the medical personnel, and
concludes with education/counseling from non-medical personnel, care for the client
is fragmented. A more logical point to delegate the labor from “busy”
doctor/midwives to trained disease intervention specialists, is for the final
education/counseling portion of a clinical evaluation.
For history taking, basic communication skills need to be repeatedly
reinforced for all personnel who obtain histories, including how to open-ended
questions and how to probe for relevant responses. For example, the high rate of
claimed abdominal pain (41%) should discriminate between normal (menstrual) and
potentially pathogenic etiologies. Collection of a risk assessment also involves time
management issues, and willingness of an HCP to investigate intimate aspects of a
client’s private life. In order to make the HCP more client oriented, additional
strengthening of HCP communication skills in performing risk assessments should
be a focus in continued studies in Jakarta.
2.

Improve Partner Treatment

The rate of providing partner-treatment for clients with confirmed STDs must
increase from the 55% attained in this study/intervention. Following is a
recommended hierarchy of health care intervention priorities for partner treatment
aimed at breaking the chain of transmission for treatable STDs:
a.
b.

educating & supporting each index client in choosing the best
method of partner(s) notification and treatment;
providing the partner with medication for a treatable STD;
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c.
d.

physically examining the partner to confirm infection and evaluate
for other infections that may coexist;
Providing the partner with STD education and counseling for future
risk reduction.

Confirming a concurrent partner infection is not always reliable or possible,
so examination of the partner should never be a prerequisite for providing treatments.
Education and counseling for risk reduction are important services to offer interested
partners of clients, but they too should not be used as a prerequisite for treatment
Additional strategies to provide follow-up outreach to clients and partners
who do not receive concurrent treatment for confirmed STDs should be explored.
Previous work in Haiti included a verbal plan with the index client to have a health
outreach worker contact partners if they did not present for treatment (Desmormeaux,
1996). Requirements to make the partner present to the clinic to obtain treatment
should be waived in favor of supplying the index client with dual partner treatment
and instructions for safe use.
3.

Laboratory Testing

In general it makes sense not to universally screen for infections that have
minimal or no incidence in the studied population. In order to select RTIs for
universal screening, baseline data on incidence or prevalence of various infections
must be available. In this case, the prevalence rates of 0% for syphilis and 0.3% for
gonorrhea, that were found, do not justify universal testing of all clients in family
planning clinics, in this community for these two STDs.
Another important recommendation also aimed at cost effectiveness is, “Do
not perform tests that have poor predictive value of actual RTIs”. Cervical
leukocytosis (increased PMNs) was not found to be associated with increased rates
of chlamydial infections. Since chlamydia was the RTI with the highest prevalence
(10.3%), it should continue to be screened for to increase the understanding of this
infection that had never been previously recognized in the target population.
Screening for chlamydial infections should adhere to the protocol established in the
national guidelines (CDC and Prevention, 1993). HCPs should be provided with
follow-up reports of the results of their work demonstrating a higher prevalence of
chlamydial infections than any of the other tested RTIs. However, the laboratory test
for chlamydia is prohibitively expensive and facilities do not exist yet in the
laboratories of primary health centers. Experts from the national STD working group
suggested to use “increase of PMNs over 30" as a proxy indicator for providing
treatment of chlamydia. In the international literature, the test for increased PMNs
was not recognized as a valid predictor of chlamydia. Therefore, it is necessary to
investigate further the association between an increase of PMNs and chlamydia
infection.
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Similarly the “whiff test” performed by mixing KOH with vaginal discharge,
should be discontinued. If this is performed at all, it should be performed according
to the study protocols on a glass slide with an immediate “whiff”, not on the
speculum. Since exact data are not available for the sensitivity and specificity of this
test (Wentworth, 1991), and the results in this study had a low sensitivity and
specificity when compared to the microscopic clue cell test, it would be reasonable
to eliminate this step in the clinical evaluation for future studies.
Replace Gram stains with wet mount microscopy for more rapid evidence of
the presence or absence of candidiasis, bacterial vaginosis and trichomoniasis. The
results of the wet mount should be available before the client leaves the clinic. This
may involve the procurement of a microscope if unavailable, and a trained staff
person to read the slides. The preliminary results of wet mount microscopy can be
used by the HCP to interpret the common (32.4%) yet inconclusive finding of
cervical erythema, which can be related to a fungal and protozoal infection as well
as a bacterial infection. At a minimum, with “wet mount”, more clients should be
able to leave the clinic with a correct diagnosis for the cause of vaginitis.
Finally the outmoded practice of applying any disinfectant to the vulva or
vagina before inserting a speculum should be discontinued. It is an unnecessary
procedure for a pelvic exam and may interfere with the ability to detect infections
from wet mounts and also compromise endocervical samples.
4.

HCP training and behavior change.

As expected, HCP behavior change did not take place after a single training
event. An example of the prolonged and repeated efforts required to change HCP
practices was observed by one of the research assistant during the first three weeks
the study. Experienced physicians would ask her where and how specimens for lab
testing should be obtained. Such a request may represent not only a knowledge
deficit, but also the need for reassurance that they were complying with the protocols
of the study. Considering that these experienced physicians had received two 1- hour
classes focusing on this topic during the initial “Round Table Discussion” session,
a third competency based training for specimen collection on pelvic models, followed
by on-site supervised
practice with volunteer clients, their need for repeated coaching during the first three
weeks of the study demonstrates the need for a massive infusion of training before
a change in practice can be realized.
Compared to the physicians the midwives were much less confident about
making a clinical diagnosis. This is understandable, considering their more limited
experience and education. Indonesian nursing curriculums, as elsewhere, embrace
the theory of “nursing diagnoses”, which preclude etiological diagnostic
conclusions. This fact, along with the struggle (evident among some physicians also)
61

to make an initial diagnosis motivated the development of an RTI/STD Case
Management Manual (see Appendix L). This training manual utilized the exact case
management protocols (Protocol VI, Appendix D) previously distributed during the
initial “Round Table Discussion”, but each RTI specific protocol was accompanied
by photographs to provide a visual example for future reference. All training should
have a firm foundation in the basic clinical protocols and visual references were
found to be very useful.
Training did not seem to “trickle-down” to other HCPs on staff. The hospital
physicians work with nurses and midwives who perform intakes, referring the FP
clients to the appropriate HCP. During a busy clinic, one of the trained physicians
attempted to delegate the clinical evaluation to an untrained midwife who declined
to perform it with the statement, “I don’t have the training, I don’t know how to do
it”.
It is recommended that training must be:
C
C
C
C

C
C

5.

Based on a foundation (written protocol);
Presented in a variety of formats, i.e. didactic, written, visual, case study;
On-going, until an acceptable level of behavioral change is demonstrated;
Not only competency based instruction and practice on models, but also at
the clinic site with each HCP/client interaction accompanied by mentoring/
coaching from a person with experience in applying the protocols.
Repeated practice in recording the written results of an evaluation on a
standardized form to reinforce the components of an appropriate evaluation;
In the context of strong expectations and support from respected leaders in
the institution and field of study to facilitate acceptance and cooperation.
Additional recommendations

In closing, to implement the appropriate integrated reproductive health care
package, inter-sectoral cooperation between the top strategic planning levels and the
primary health care operational levels needs to be improved. In the near future,
health programs must address more attention to maternal morbidity, in addition to
maternal mortality issues.
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RTI/STD CLINICAL EVALUATION

Appendix A

Name:________________________________________________Date: ________________________
Marital Status: S M D
Study #___________________________________________________
LMP:________________BCM_____________________________Allergies:_____________________________________

Antibiotics in the last 14 days ? _________________
History
NO
1. Age: younger than 25 years?
2. Past history of STD?.
3. More than 1 sex partner ?*
4 Sexual intercourse without condoms?*
5. An unusual vaginal discharge?(bad odor, green/yellow color, itch) *
6. Pain with urination?*
7. Lower abdominal pain?*
8. Bleeding after intercourse?*
9. Genital sores or lumps?*
10. Does your husband/partner have : *
a. Unusual discharge from his penis ?
b. Sores or lumps on penis ?
c. Any sex partners other than you ?
* = the past 3 months
Exam
Neg. Findings
1. Systemic exam: Skin
2.
:.Abdomen
3. Ext. Genital : Inguinal palpation
4.
: Inflammation
5.
: Urethral discharge
6.
: Ulcers
7.
: Lesions
8. Vagina
: Inflammation
9.
: Abnormal discharge
10.
: Lesions/ulcers
11. Cervix
: Ectopy
12.
: Erythema/inflammation
13.
: Mucopus
14.
: Friability
15.
: Cervical motion tenderness
16. Uterus
: size/shape.
17. Adnexa
: Mass

YES

Comments:

Pos. Findings

Laboratory
Obtained Neg. Findings Pos. Findings
Microscope:
1.
: Greater than 30 PMNs/HPF
2.
:GNID
3.
: Hyphae or pseudohyphae
4.
: Clue cells
5.
: Motile Trichomonads
6.
: + Amine odor with KOH
7.
: Cultures Gonorrhea
8.
: Chlamydia (Eliza)
9.
: RPR

Describe

Describe

VDRL:

TPHA:

Diagnosis:_____________________________________________________________________________________________________
Treatment
Is pregnancy a possibility ? (Circle one)
YES
NOT SURE
NO
______1 No treatment indicated
______2. Rx :_______________________________________________________________________________________________
______3. Additional tests/referrals:______________________________________________________________________________
______4. Return to clinic :_____________________________________________________________________________________
______5. Partner exam, Rx, and referral plans:_____________________________________________________________________
______6. Counseled re. RTI/STD etiology, Rx, management, & prevention.
______7. Dispensed condoms with instructions.
Examined by :
__________________________________

Completed by :
____________________________

0

LOG FRAME
Objectively Verifiable Indicators
Goal
To facilitate the development and initial implementation
of National policies supportive of HIV/AIDS control
based on the documented effectiveness of interventions
which reduce HIV/AIDS in the demonstration areas.
Purpose
To reach ordinary housewives/women who are generally
unaware of RTI/STD symptoms and potential sequelae
through an integrated RH care services at one PHC
centre, and one public hospital service.
Outputs
1. Strengthen the skills of HC/FP
providers in STD risk assessment, including
diagnosis, treatment and counseling.

1. Upgraded RTI/STD laboratory services.

1. Formulation of a strategy for
integrating STD risk assessment into
family planning services.

Purpose Indicator
Relevant MOH - Sub Directorates and donor agencies will
review the findings and initiate further planning for the
integration of STD services into Reproductive Health Care.
1. Protocols for STD management developed by mid
October 1996.
2. Provider observation checklist/instrument developed
by end of October 1996.
3. Questionnaire for provider need assessment
developed by end of October 1996.
4. Base-line data report completed by mid Nov. 1996.
5. Implementation plan completed by end of Nov 1996.
6. Training of HC/FP providers in two study sites
completed by mid December 1996.
7. Weekly monitoring carried out at study sites.
8. Report with recommendations prepared by end of
June 1997
1. Lab test protocols developed by mid Oct 1996
2. Lab. Current performance observed by mid Nov. 1996.
3. Training needs of personnel assessed by mid Nov.
1996.
4. Training provided to lab. Staff by mid Dec. 1996.
5. Logistic and service delivery upgrading completed by
end of February 1996.
1. Committee of MOH officials directly involved in
MCH/FP services formed (#) by end of October 1996.
2. Advisory committee meetings held every other month,
by November 1996.
3. Strategic plan developed by Advisory Committee and
disseminated to relevant Directorates and donors by
June 1997.

1

Data

Government planning documents.
1.
2.
3.
4.
5.
6.
7.
8.

Written protocols developed.
Observation checklist developed.
Questionnaire developed.
Base-line report submitted to HAPP.
Implementation plan submitted to HAPP.
Training reports and training materials.
Monitoring reports.
Report submitted to HAPP

1.
2.
3.
4.
5.

Written protocols developed.
Current performance reported.
Training needs identified.
Training evaluation report
Logistic and cost estimate reported to HAPP.

Written recommended strategy for integrating STD risk
assessment into FP services.

Important Assumptions

LOG FRAME
Objectively Verifiable Indicators
1.1
•
•
•

Carry out preparatory work
develop protocols
develop instruments
set up field activities

1.2 Pre-intervention baseline data
1.3 Develop recording/reporting system for STD
management.
1.4 Prepare for and carry out training of FP workers
in selected facilities.

1.5 Monitor the use of protocols and completion of
record keeping.

11 Evaluate the impact of the intervention.
21 Carry out laboratory assessment.

2

Data
(a) 1 week discussion to review;
(a) 1 week writing of protocols & instrument;
( c) 1 week pre-test
(a) 1 week revision of protocols & instrument;
(a) Printing of protocols & instruments.
(a) 1 week direct observation.
(a) Recording & Reporting system documentation
(retrospective 6 months prior to the study).
(a) Training on risk assessment for all FP clients;
(a) Training on Pelvic; Exams, and detection of
Cervicitis;
(a) Training on treatment guidelines;
(a) Training on client follow-up instruction, and
counseling to obtain treatment compliance, partner
referral and risk reduction behavior.
(a) 6 months observation of the usage of new
protocols;
(a) 6 regular meetings with counter-part to examine
records, discuss problems, and refresh KAP;
(a) 6 supervisory visits by Advisory Board Members to
raise awareness of HC/FP.providers of the
importance of protocols usage.
(a) Writing of compiled documents based on weekly
progress reports.
(a) Analysis of data collected.
(b) Writing overall final report.
(a) 6 months direct observation;
(a) Regular open discussion with laboratory personnel;
(a) Logistic inventory documentation (past 6 months,
current state, and what is needed in the future.

Important Assumptions

LOG FRAME
Objectively Verifiable Indicators
21 Arrange the acquisition of needed
supplies and equipment.
21 Develop reporting/recording system for laboratory
test ordered by FP services.
21 Establish scale of charges for laboratory tests.

Data
(a) List of supplies/equipment to purchase is
completed by mid October 1996;
(a) Procurement completed by February 1997.
(a) RR system mechanism established by June 1997.
(a) Record of price/cost charged to clients for
laboratory test and client’s ability & willingness to
pay.
(a) List of identified personnel needs to improve skills.

21 Carry out training needs assessment among
laboratory personnel.
21 Provide training for laboratory personnel.

(a) Training on STD laboratory-Test (wet mount) &
interpretation;
(a) 6 months observation of implementing new
laboratory protocols on Wet-Mount test;
(a) 6 regular meetings with laboratory personnel to
examine records and discuss problems;
(a) 6 supervisory visits by Advisory Boards members
to raise awareness of laboratory personnel on the
importance of protocols usage.
(a) Analysis of data collected.
(b) Writing of overall report.
(a) Preparatory (2 days) workshop to obtain MOH
officials inputs;
(a) Develop supervisory checklist for field visit;
(c ) Develop time-plan;
(d) Arrange visits with counterpart.
(a) Advisory Boards Members will visit the study sites;
(a) Supervisory checklist will be used to record
progress and to help counterparts solve daily
problems.
(a) Analysis of problems encountered;
(a) Inventory of suggestions or solutions
recommended/ practiced;
(a) Strategy recommended and endorsed by relevant
MOH officials.

21 Monitor and supervise the implementation of
upgraded STD laboratory tests.

21 Prepare post-intervention report on
laboratory test activity results.
31 Develop an Advisory Committee

31 Intervention implementation and monitoring

31 Formulation of a strategy to integrate STD risk
assessment in FP services.

3

Important Assumptions

PEDOMAN TEKNIS DALAM UJI COBA
PENCEGAHAN DAN PENANGGULANGAN
PENYAKIT MENULAR SEKSUAL MELALUI
PELAYANAN KIA DI TINGKAT PELAYANAN
DASAR

Direktorat Bina Kesehatan Keluarga
Ditjen Binkesmas Depkes RI

Disajikan pada:
Pertemuan Persiapan Uji Coba Pencegahan dan Penanggulangan PMS
melalui Pelayanan KIA di Tingkat Pelayanan Dasar
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I.
Contraceptive Education
Optimum reproductive health and infectious disease prevention are very dependent on the individual behavior
of contraceptive choice. All FP clients will receive a contraceptive method information review of the most
frequently used methods in Jakarta: oral contraceptives (OC’s), hormonal injections, intrauterine devices
(IUD’s), hormonal implants, condoms and surgical sterilization. The informational content will include a
description of the contraceptive, it’s mechanism of action, effectiveness rates, and a comparison of the
method’s advantages and disadvantages. The following outlines provides summary points for each commonly
used contraceptive in the study area. Methods are presented in their order of use in the population studied.
A.
B.
C.
D.
E.
F.

Oral Contraceptives
Hormon Injection
IUDs
Hormonal Implants
Condoms
Surgical Sterilization

1
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Table 1. Contraceptive Method Review
Birth Control
Pills

Hormonal
Injections

Intrauterine Device
(IUD)

Hormonal Implant

Condoms

Surgical
Sterilization

Description

Hormones, usually
estrogen and
progestin, taken by
mouth daily for 21 or
28 days

The hormone,
progestin, is injected
into a muscle in the
upper arm/buttocks
every three months

A small plastic object
which may contain copper
or hormones that is
inserted into the uterus
and left in place for one
year, (some brands may
be left in longer)

Six slender rubber capsules
(match stick in size), that are
surgically inserted under the
skin in the arm and slowly
release the hormone
progestin over a 5 year
period

A thin latex covering for the penis
that collects semen after a man
ejaculates

The fallopian tubes
are surgically blocked
either by cutting, tying,
clipping or applying
electrical cautery

Method of
Action

Primarily by stopping
ovulation

-Inhibits ovulation and
thickens cervical mucus
-Prevents implantation
uterus by disrupting
development of uterine
membrane

-Prevents implantation of
the egg in the uterus
and/or
-Prevents spermatozoa
from reaching fallopian
tubes

-Inhibit ovulation and
thickens cervical mucus
-Prevents implantation in the
uterus by disrupting
development of uterine
membrane

The condom acts as a barrier
preventing direct contact with
semen, genital lesions or
infectious discharge. The condom
blocks the passage of sperm from
the penis into the vagina

The fallopian tube
blockage prevents
sperm and
eggs uniting

Effectiveness

98 - 99%

More than 99% effective

98-99%

More than 99% effective

89 - 90% effectiveness can be
increased with concurrent use of
intravaginal spermicide

More than 99,5%
effective

Advantages

1. Reversible
2. Decreased
menstrual cramps
and pain
3. Protects against
PID
4. Can be used for
emergency
contraception

1. No estrogen
2. Decreased menstrual
cramps and pain
3. Decreased risk of
developing
endometrial cancer,
ovarian cancer and
PID
4. Reversible, but not
immediately
5. Doesn’t interfere with
breast-feeding

1. Doesn’t interfere with
breast-feeding
2. Reversible
3. Easy to use

1. No estrogen
2. Decreased
menstrual cramps
and pain
3. Reversible with
surgical removal
4. Low risk of ectopic
pregnancy
5. Easy to use
6. Doesn’t interfere with
breast feeding

1. Prevents the transmission
of STD’s and HIV
2. Effective, if used correctly
2. Easy to obtain
3. Inexpensive
4. Hygienic
5. Involves both men and
women
6. No systemic side effects
7. Doesn’t interfere with
breast feeding

1. Highly effective
2. Permanent
3. Nothing to buy or
remember
3. Partner
compliance not
required
4. No interruption in
love making
5. Very private/
personal
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Table 1. Contraceptive Method Review

Disadvantages
and Cautions

Birth Control Pills

Hormonal Injection

Intrauterine Device
(IUD)

Hormonal Implant

Condoms

1. Pills must be taken
daily
2. Spotting the first 2
months
3. Temporary nausea*
4. Headaches*
5. Depression*
6. Cervical ectopy and
chlamydia
infections (if
exposed)
7. No protection
against other STDs,
including HIV
8. Fluid retention
9. Gallbradder
disease**
10. Benign liver
tumors**
11. Circulatory
complications which
may be dangerous,
particularly for
people who
smoke**

1. No protection from
STDs, including HIV
2. Menstrual cycle
disturbance, (increased
spotting and
amenorrhea)
3. Weight gain, (1 kg. per
year)
4. Breast tenderness*
5. Decreased bone density
6. Must return every three
months

1. PID. Especially if
gonorrhea &/
chlamydia
is not recognized and
treated before insertion
2. HIV, increased risk of
transmission if
exposed
3. No protection from
other
STDs, including HIV
4. Menstrual problems
(increased bleeding
and cramping)*
5. Expulsions*
6. Risk of uterine
perforation during
insertion**

1. No protection from
STDs including HIV
2. Menstrual cycle
disturbance, (increased
spotting and amenorrhea)
3. Weight gain - less than
2.5 kg. in 5 years
4. Breast tenderness*
5. Difficult removal
6. Local infection at implant
site*
7. Increased rate of benign
ovarian cysts**

1. Interruption at foreplay
to put condom on penis
2. Latex allergies
3. Male involvement
4. Embarrassment
5. Breakage

Surgical
Sterilization
1. Permanent
2. Reversibility
difficult and
expensive
3. No protection
against STDs
and HIV
4. Sterilization
procedure is
difficult
5. Requires
hospitalization
6. Surgical risksinfection,
bleeding,
anesthesia, etc

*
rare
**
very rare
Adapted from :
Hatcher, R. et al, 1994. Contraceptive Technology and
JHPIEHO, 1994. International Family Planning Guide A Prototypic Reference Manual.
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II.
Diseases of
Women’s Reproductive Organs
All study participants will also receive information on infectious diseases that are specific to reproductive
health. An inclusive review of every potential pathogen and disease related to the reproductive tract is
beyond the scope of this initial study. The diseases that will be discussed will include RTI’s that may be
endogenous, iatrogenic, and or sexually transmitted. Some sexually transmitted infections may be acquired
non-sexually. The specific infections this study will address are:
Trichomoniasis
Bacterial Vaginosis
Candidiasis
Gonorrhea
Chlamydia
Syphilis
Chancroid
Herpes Simplex Virus II (HSV II)
Human Papilloma Virus (HPV)
Human Immunodeficiency Virus (HIV).
An effort will be made to link this theoretical infectious disease knowledge to human sexual behavior. The
purpose of this infectious disease review will be done to enable the FP client to self assess her potential of
RTI infection. A connection between the women’s contraceptive method choice and her protection from an
STD if exposed will also be discussed. See Table 2.

4

Appendix D

Table 2. Contraceptive Linkage with STD Prevention
Contraceptive Method

STD Prevention?

Oral Contraceptives

No

Injections

No

IUDs

No - Plus, carries an increased risk of causing
PID with IUD insertion

Implant

No

Condoms

Yes

Surgical Sterilization

No

Adapted from Cates, W. and Katherine M. Stone. “ Family Planning, Sexually Transmitted Diseases and Contraceptive
Choice: a Literature Update-Part I.” Family Planning Perspectives, March/April 1992, 24: 75-84.

Each RTI informational session will include a review of:
#

#
#
#
#

The causative organism;
Potential for sexual transmission;
Signs and symptoms of the disease;
Summary of potential complications;
Ability to be treated.

See also Table 3 for a description teaching content.
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Table 3. Diseases of Women’s Reproductive Organs*
Disease

Caused by

Sexually
Transmitted
?

Signs & Symptoms

Potential Complications

Is Disease
Treatable?

Trichomoniasis

Trichomonas
Vaginalis;
(protozoa)

Yes

1. Abnormal vaginal
discharge: green,
yellow color, foamy,
foul odor
2. Vulvar swelling,
itching, and discomfort

1. Skin can become excoriated
2. Pregnancy may be associated
with premature deliveries
3. Facilitates HIV infection

Yes

Bacterial Vaginosis
(BV)

A syndrome
caused by
several species
of bacteria

Not most of
the time

1. Excessive “fishy”
smelling vaginal
discharge
2. Occasionally has
vulvar itching

1. Pregnancy may be
associated with premature
deliveries
2. May increase the chance of
tubal infections

Yes

Candidiasis
(“yeast”)

Candida
albicans;
(fungus)

Not most of
the time

1. Curdy white “spoiled
milk” vaginal
discharge
2. Itching
3. Redness and swelling
of the vulva

1. Skin can become excoriated
2. Facilitates HIV infection

Yes
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Table 3. Diseases of Women’s Reproductive Organs
Disease

Caused by:

Sexually
Transmitted
?

Signs & Symptoms

Potential Complications

Is Disease
Treatable?

Gonorrhea

Neisseria GC ;
a bacteria

Yes

Can be asymptomatic, or
1. Abnormal vaginal
discharge
2. Pelvic pain

1. PID ( pelvic inflammatory disease)
2. Future sterility
3. Eye infections in newborns that can
cause blindness
4. Facilitates HIV infection

Yes

Chlamydia

Chlamydia
trachomatis;
a bacterium

Yes

1. Most infections are
asymptomatic
2. Abnormal vaginal
discharge
3. Pelvic pain
4. Bleeding after
intercourse

1. PID
2. Future sterility
3. Tubal pregnancy
4. Chronic pelvic pain
5. Serious eye infections &/or
pneumonia in the newborn
6. Facilitates HIV infection

Yes
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Table 3. Diseases of Women’s Reproductive Organs
Disease

Caused by:

Sexually
Transmitted
?

Signs & Symptoms

Potential Complications

Is Disease
Treatable?

Syphilis

Treponema
pallidum;
a spirochete

Yes

A chronic and systemic
infection with 3 stages:
1. Primary-painless
genital sore called a
“chancre”
2. -Secondarygeneralized skin rash,
or
-Latent time without
symptom
3. Tertiary-neurologic,
cardiovascular, &/or
skin

1. Can seriously damage the brain &
heart if not treated
2. During pregnancy can be passed
to the unborn baby & cause
miscarriages &/or birth defects
3. Facilitates HIV infection

Yes

Chancroid

Hemophilus
ducreyi;
a bacteria

Yes

Often asymptomatic, or
1. Single painful sore
2. Painful swollen lump
in the groin that can
rupture

1. Sore can become infected and
cause tissue death
2. Sore facilitates HIV infection
if exposed

Yes
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Table 3. Diseases of Women’s Reproductive Organs
Disease

Caused by:

Sexually
Transmitted ?

Signs & Symptoms

Potential Complications

Is Disease
Treatable?

Genital Herpes
(HSV II)

Herpes
Simplex
Virus

Yes

Initial infections:
1. Painful single or multiple
blisters on the genitals
2. Blisters pop & leave sores
that crust, then disappear
Recurrent outbreaks:
1. Blisters as described above,
but not as painful which can
be triggered by stress,
menstruation, alcohol
consumption

1. Nerve pain
2. Can be transmitted to a newborn
at birth if active lesions are
present and cause a serious
systemic infection to the baby
which could result in death
3. Facilitates HIV infection

No, but antiviral
meds can shorten
pain& length of
outbreak

Genital warts
(HPV)

Human
Papilloma
virus

Yes

1. Single or multiple fleshy
wart-like growths on the
genitals

1. Lesions may enlarge and grow
together
2. Some types of HPV may be
related to cervical cancer

Only to remove
the wart, it doesn’t
kill HPV
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Table 3. Diseases of Women’s Reproductive Organs
Disease
HIV/AIDS

Caused by:

Sexually
Transmitted ?

Human
Immunodeficiency
Virus

Yes, also by
-Blood
transfusion
-Injection
-Maternal fetal
transmission in
pregnancy or
perinatally

Signs & Symptoms
1. May have a flu-like illness 2
weeks after infection
2. Recover and be
asymptomatic
for 5 - 10 yrs followed by:
3. Minor symptoms: fever, night
sweats, yeast infections,
fatigue, & weight loss, which
progresses to:
4. Multiple illnesses: cancers,
neurologic diseases,
bacterial, viral, fungal, &
parasitic infections

Potential Complications
1. If pregnant, HIV also may be
spread to the unborn baby
2. End stage HIV infection =
“AIDS”: causing severe
illnesses and death

Is Disease
Treatable?
No, however, new
combinations of
antiviral
medications may
prolong the
asymptomatic
period of infection
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III.
Taking an Effective
Reproductive Health History
A comprehensive reproductive health history is the foundation for the provision of quality health care for the
woman seeking FP services. It must include relevant data that will :
#
#
#
#
#
#

focus the direction of clinical services to meet the needs of the client;
support future contact with the client if laboratory or examination results indicate the need for followup;
identify previous contraceptive problems;
reveal contraindications for specific contraceptive use;
direct the HCP to identify potential RTI’s, (this process is often referred to as “risk assessment”);
support effective and safe use of prescriptive medications.

The content of a woman’s reproductive health history is of an intense personal nature. It involves highly
confidential information about her pregnancy, contraceptive and sexual history. Therefore, it is imperative
that the interviewing HCP is perceived as an advocate and not an interrogator. This will require skill and tact
from the HCP performing the interview. To support a philosophical position of client advocacy, the HCP must
demonstrate the following communication principals to the FP client:
#
#
#
#
#
#

greet the client warmly and with respect;
interview clients in a private environment;
establish confidentiality;
use understandable language;
ask questions in a non threatening, non judgmental manner;
listen carefully.

It is always best to conduct a reproductive health history when the patient is fully dressed and prior to the start
of the physical examination. Even though the eventual answer to most of the history questions is either a “no”
or a “yes”, it will behave the HCP to frame these questions in an open ended style.
The HCP will attempt to gain knowledge of the client’s particular:
#
#
#
#
#
#

obstetric history and current potential pregnancy status;
contraceptive history;
medical history (critical for contraceptive and pharmaceutical contraindications);
risk markers (age, marital status, past history of STDs, contraceptive behavior);
RTI/STD symptomatology;
perceptions of her partner’s potential for STD symptomatology and risk behavior.
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IV.
Providing a Reproductive Health
Physical Examination
All study participants will receive physical examinations (PE) as part of their clinical evaluation. The
standardized PE will be targeted toward contraceptive and RTI assessment, diagnosis, and treatment.
The four main components of a PE will include a generalized reproductive assessment, external genital
exam, speculum exam, and a bimanual exam. Prior to starting the PE, the HCP will give a verbal
explanation of the exam procedures and purpose to the client. Any questions or concerns the client has
regarding the procedures will be discussed and answered to her satisfaction. The principal that should
guide all PE procedures performed on the client should be service delivery via interactive education as
opposed to task accomplishment. The following outline describes PE procedures and rationales. An
empty bladder before an exam will help reduce discomfort.
A.

Generalized Reproductive Target Organ Assessment
1.
2.

B.

Skin. The HCP will inspect skin for rashes, with special attention to rule out macularpapular rashes of the trunk, palms, and feet characteristic of secondary syphilis.
Abdomen. Palpate while client is supine for hepatomegaly, organomegaly, &/or
abnormal tenderness and pain

External Genitalia
This part of the PE is performed while the client is undressed from the waist down, covered in
a disposable or clean drape and in the lithotomy position. The examiner must have his or her
predominant hand gloved in a clean, previously unused or disinfected glove. Effective visual
inspection requires the presence of an additional light source, like a goose neck lamp, which can
be aimed at the clients genitalia. The HCP will then visually inspect and palpate the external
genitals for the presence or absence of any signs of :
1.

2.
3.

Inguinal area.
Palpation must be done with a gloved hand to rule out lymphadenopathy.
Inflammation
Erythema, edema, excoriation.
Urethral discharge
After separating and retracting the labiums majora and minora, strip the urethra with a
gloved middle finger by milking the anterior vaginal wall once, and observe for discharge
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4.

5.

6.

7.

C.

Ulceration
Note the approximate number, size, distribution pattern, and client’s perception of pain
to the ulcer when it is palpated with a sterile cotton swab. Describe the margin style of
the ulcer border.
Vesicles
Note again the quality and characteristics as described above. Review the client’s
history for any pattern recurrence (HSV II).
Lesions
Describe the type and quality of skin lesions. If suspicious lesions are verruciform (wart
like), but not classic, the area can be swabbed with acetic acid (one part plain vinegar
to three parts uncontaminated water) to render any HPV lesions to turn a more visible
white than the surrounding area.
Additional Findings
Document any additional areas of variation.

Speculum Exam
Using an educational approach to task performance, describe techniques the examined woman
can use to minimize discomfort during speculum insertion and placement i.e. advising her that
abducting her knees to a wide angle opens the perineal muscles as opposed to constricting them
when the knees are adducted (Note: never tell a woman to “relax” during a pelvic exam).
It’s easy for the examiner to say this, but it is not educational, doesn’t promote relaxation, and
doesn’t give the woman the skills to cope with future pelvic examinations.
Always use a clean speculum that has been sterilized since it’s previous client use. If possible,
warm the unlubricated speculum with warm , uncontaminated, water prior to insertion. Test the
speculum temperature on the inner thigh of the examined woman and determine if the
temperature of the speculum is satisfactory to her. Adjust the temperature if necessary.
Insert the gloved index finger of the predominate hand into the vagina and locate the cervix to
determine the angle of speculum insertion. Next, lower the posterior vaginal floor with the same
inserted gloved index finger. Slide the closed speculum over the internal finger, and withdraw
the gloved index finger. With your “external” or non-predominate hand, open the blades of the
speculum until the cervix is visible, then secure the speculum to allow visual inspection of the
vagina and cervix. The vagina and cervix can now be inspected for signs of:
1.

Vaginal mucosa inflammation
Erythema, edema

2.

Abnormal vaginal discharge
The following clinical signs signal the judgement of abnormal vaginal discharge:
a.
curdy white exudate (like spoiled milk), (suspect candidiasis);
b.
foul (fishy) smelling homogenous white or greyish discharge that coats the walls
of the vagina, (suspect Bacterial Vaginosis).
c.
frothy gray or green discharge with a strawberry cervix, (suspect
Trichomoniasis).

.
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All of the above mentioned types of abnormal vaginal discharge may or may not be accompanied
by signs of tissue inflammation, although inflammation signs are usually more common in cases
of candidiasis or trichomoniasis. The symptomatic complaint of vulvar pruritis can also be found
in any of these three vaginal RTI’s, although it is more classically indicative of either candidiasis
or trichomoniasis. The existence of any abnormal vaginal discharge must be accompanied by
wet mount microscopy to confirm or rule out a RTI diagnosis of candidiasis, bacterial vaginosis
or trichomoniasis. Clinical findings can be misleading and only microscopy can be relied on for
diagnosis.
Obtain wet mount specimens at this time
3.

Ulcers
As previously described in “External Genitalia”.

4.

Lesions
Also as previously described.

5.

Cervical ectopy
The cervix should be inspected after any excessive vaginal discharge has been
removed with a clean disposable scopette. Cervical ectopy is detected by noting the
junction between smooth columnar tissue and “grape-like” endocervical tissue. Ectopy
is more common in oral combined contraceptive use due to the influence of estrogen.
Obtain any indicated cervical specimens at this time

D.

6.

Cervical erythema
A reddened, angry appearance.

7.

Cervical friability
The cervix bleeds easily when touched with a sterile swab.

8.

Cervical mucopus
A tenacious cloudy or yellow discharge from the cervical os.

9.

Additional findings
Describe any additional variations.

Bimanual Exam
The bimanual exam is necessary to rule out uterine enlargement suggestive of pregnancy as
well as uterine and or adnexal masses indicating the need for additional evaluation to rule out
pathology. After careful removal of the speculum, the first two fingers of the vaginal examining
hand are lubricated and inserted into the vagina. Locate and palpate the cervix. Proceed with
an assessment of the pelvic organs.
1.

Cervical Motion Tenderness (CMT)
Can be demonstrated if moving the cervix side to side causes pain.
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2.

Uterus size
Can be determined by locating the fundus with the outside hand while palpating the
abdomen medially in the direction of the cervical neck. Record the size of the uterus in
centimeters. Note any abnormal uterine mobility or contour.

3.

Uterus position
Record one of the following uterine positions:
a.
Anteverted (AV);
b.
Midline (Mid);
c.
Retroverted (RV).

4.

Uterine tenderness
Note the presence or absence of unusual pain when palpating the uterus.

5.

Ovaries/Adnexa
The abdominal hand produces pressure on the lower abdomen and the fingers of the
vaginal hand are swept to the side to evaluate the adnexal structures of the fallopian
tubes and ovaries. Only the ovaries should be palpable in a normal exam, and often they
are not even felt. A normal ovary in a menstruating woman measures approximately
3x3x2 cm. Any enlargement above 5 to 6 cm is an abnormal (ABN) finding.

6.

Adnexal pain
Note unusual tenderness.

7.

Rectal
It is not necessary to do a rectal-vaginal exam if the uterus is anteverted, because
adequate palpation of the posterior fundus is possible. If the uterus is midline or
retroverted, inform the client that you will examine her rectally. Change gloves, and with
a well lubricated middle finger in the rectum and the index finger in the vaginal vault,
evaluate for nodularity and polyps. Pressure from the abdominal hand brings the uterus
down so that it’s entire posterior surface can be palpated with the rectal finger.

8.

Additional findings
Record any additional abnormalities.
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V.
Laboratory Tests
Laboratory specimens to aid in the diagnosis of an RTI will be obtained by clinical staff at the study site.
All clients enrolled in the study should have specimens collected as described in Table 4.
Table 4. Summary of Laboratory Tests for Specific Infections
Organism/Syndrome

Lab Tests

Testing Site

Trichomoniasis

Saline Wet Mount

Clinic,

Bacterial Vaginosis

Saline Wet Mount or
Gram-stain

Clinic, with
Referral lab validation
of Gram stains.

Candidiasis

KOH Wet Mount or
Gram-stain

Clinic, with
Referral lab validation
of Gram stain.

Chlamydia

ELISA (not confirmatory)

Referral lab.

Gonorrhea

Gram-stain (Not confirmatory)

Clinic, with referral
lab validation.
Referral lab

Cervical Culture (Confirmatory)
Syphilis

Rapid Plasma Reagin - RPR or VDRL
TPHA if RPR/VDRL is +

Referral Lab

HIV

ELISA and Western Blot

This study will not
include HIV
screening. If in the
judgement of the
HCP, this screening is
indicated, outside
referral to existing
alternative test sites
will be recommended.

Cervical Specimens
Endocervical swabs will be obtained on all enrolled clients. Endocervical specimens should especially
be obtained to back-up a judgement of MPC, which is a clinical diagnosis based on the visible presence
of either cervical erythema, friability, and or mucopus. If any of these three clinical signs are present
along with the presence of cervical ectopy, a higher index of suspicion of MPC should be maintained.
The two most frequent etiologies of MPC are infections with N. Gonorrhoeae or Chlamydia Trachomatis.
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These two specimens should be collected in the following order:
one swab for the gonorrhea culture and Gram-stain, followed by a separate dacron swab for the
chlamydia enzyme test.
An outline for procedural steps necessary to accomplish the collection of endocervical specimens follows.
1.

Cervical preparation
Use a large swab or scopette to remove any vaginal discharge from the os, use great care to
avoid contaminating the endocervical specimen with vaginal discharge.

2.

Endocervical swab for gonorrhea culture and gram stain
Insert sterile cotton swab 1-2 cm, into the endocervical canal (past the squamo-columnar
junction). Rotate the swab 5 to 10 times to permit the absorption of exudate.

3.

Swab color check
Check the color of the swab and be aware that a yellow exudate indicates an increased number
of polymorphonuclear (PMN) leukocytes.

4.

Gonorrhea culture
Immediately inoculate the swab onto the culture plate using a “Z” streak for a modified Thayer
Martin (MTM) plate. Cross streak the inoculated plate immediatly with a sterile, wire loop and
place in a candle extinction jar.

5.

Gram-stain slide preparation

Roll (don’t rub), the swab onto a clean dry glass slide labeled with the patients ID. All aspects
of the swab head should come in contact with the slide. Smears should cover at least one
square centimeter of the slide. They should be air dried and heat fixed. Slides should be
carefully stained by the Gram method and examined for the presence of characteristic gram
negative intracellular diplococci.
6.

Chlamydia enzyme specimen
Use only the sterile swab that comes with the commercially pre-packaged test kit. Insert this
swab 1 - 2 cm into the endocervical canal (past the squamo-columnar junction). Rotate the
swab against the wall of the endocervical canal several times for 10 - 30 seconds. Withdraw
the swab without touching any vaginal surfaces and place it in the appropriate transport medium.

Note: Do not prep or wash the vulva or vagina with any solution prior to the collection of vaginal or
endocervical specimens.
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Wet Mount Microscopy
All clients will have vaginal discharge specimens analyzed within the clinic site by wet mount microscopy
or Gram stain. HCP’s which may include the examining doctor, midwife, or nurse can perform this simple
“in-house” test if existing staffing patterns do not include a laboratory technologist.
A wet mount specimen will consist of a small amount of vaginal fluid collected on a clean cotton swab
from the vaginal fornix during the speculum exam. Separate slides will be prepared for saline and 10%
potassium hydroxide (KOH) analysis. Place a sample of vaginal discharge on one of the glass slides and
combine with 2 drops of normal saline then cover with a glass cover slip (combine the reagent +
discharge by mixing with the wooden tip of the swab, not the cotton). Place a second sample of vaginal
discharge on a separate slide and combine with 2 drops of 10% potassium hydroxide (KOH). The HCP
will note during this process the presence or absence of a positive (+) amine (fishy) odor. This is
commonly referred to as the “Whiff test” and is suggestive of the RTI, bacterial vaginosis.
The HCP will microscopically under low power and scan the prepared slides for the presence or absence
of:
#
Hyphae, pseudohyphae or budding yeast (candidiasis), &/or:
#
motile trichomonads (trichomoniasis), &/or;
#
clue cells (bacterial vaginosis), &/or;
#
increased number of white blood cells, more than 30 WBC’s/HPF (inflammatory vaginitis i.e.,
trichomoniasis or candidiasis, as well as a mucopurulent cervicitis).
During the microscopic scan, it is important to scan the slides thoroughly and remember that the
identification of one vaginal pathogen does not rule out the discovery of a second or third organism,
indicative of concurrent, multiple infections.

Gram Stain
A direct Gram stain of vaginal fluid may also be used to detect the presence of vaginal yeast and clue
cells. Use a cotton-tipped applicator to transfer vaginal fluid to a glass microscope slide, heat fix, Gram
stain and examine under oil immersion.
Note:
If a Gram stain is performed as a screen for Neisseria gonorrhoeae, the specimen must be collected
from the endocervix with careful technique to avoid vaginal discharge contamination. Prepare a thin
uniform smear by gently rolling the swan on a slide. Slides should be scanned by the zig-zag method
for at least 2 minutes before caulling them negative for gram-negative intra cellular diplococci (GNID).
The description GNID should be used only when typical pairs of gram-negative, kidney beam-shaped
diplococci are found within polymorphonuclear leucocytes. Since the sensitivity of a Gram stain from
an endocervix is so low (50-70%, Adimora et all. 1994) a culture should always be used to diagnose
cases of N. gonorrheae in women.
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Serology
1.

Syphilis
All participants will have a 5 ml. sample of blood ascetically drawn for syphilis serology using
the RPR as a screen. In the event that an RPR is reactive, a titrated VDRL will be automatically
run and if positive, the same sample of blood will be retested for confirmation by TPHA.

2.

HIV
It is beyond the scope of this initial study to provide serological testing for HIV. If, in the
judgement of the HCP this further testing is indicated, the patient will be advised that she should
obtain serological testing in an alternate test site.

Laboratory Logistical Requirements
Both permanent and consumable supplies will be necessary to obtain vaginal wet mount, endocervical,
and serological specimens. The following lists describe the projected supplies required to complete the
tests.
Wet Mount Microscopy:
#
Microscope
#
Frosted glass slides
#
Glass cover slips
#
Cotton swabs
#
Normal saline solution
#
10% potassium hydroxide (KOH)
Gram-stain specimens: (For male partners)
#
Frosted glass slides
#
Sterile urethal swabs
#
Crystal violet solution (85% dye)
#
Ethanol (95%)
#
Ammonium oxalate
#
Distilled water
#
Iodine crystals
#
Potassium iodine
#
Sodium bicarbonate 5% aqueous solution
#
Acetone
#
Safranin O
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Gonorrhea cultures:
#
Refrigerator to store culture plates
#
Anaerobic Incubator
#
Culture plates
Chlamydia tests:
#
Prepackaged comprehensive test kits
Serology Tests
#
Vacuum tube
#
Tube 5 cc with red cover (without anticoagulant)
#
Sterile needles
#
Glove hands
#
Cotton with ethanol alcohol
#
Cotton ball
#
Band aid
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VI.
Diagnosis and Case Management
STD Diagnosis
The impact of an STD diagnosis on the client has medical as well as emotional implications. It is of
paramount importance that an STD diagnosis is based on good historical, clinical, and when possible,
laboratory evidence. A conceptual model of STD diagnostic realms recognizes the interdependence of the
three evaluations of history, examination, and laboratory results that must be simultaneously considered to
reach a fair and accurate diagnosis of an STD. Such a diagnosis requires scrupulous attention on the part
of the HCP to the client’s history, chief complaint(s), and demonstration of objective physical signs. The
evidence that is acquired during this process should be documented in a standardized evaluation in the
client’s medical record.
All evaluations must start from the client’s history. The subjective history is a vital foundation for a correct
diagnosis. Next, objective data discovered during the physical examination will serve to guide the HCP in
the collection of laboratory specimens. Data yielded from the physical examination and the laboratory must
be balanced and are often equally important in leading the HCP to a legitimate diagnosis. Particularly in the
case of cervicitis, powers of human observation and laboratory testing are imperfect. In the case of the viral
infections of HSVII and HPV, where no treatment regimens for pathogen eradication are in existence, it is
legitimate to rely of the presence of classically symptomatic signs to conclude an empiric diagnosis.
Please see Table 6 (pp.23-26) for a collective view of optional indicators and mandatory lab results to label
a client with a particular RTI or STD.
Case Management
Indiscriminate and incorrect use of antibiotics have created international concern about the emergence of
drug resistant microorganisms. This crisis underscored the importance of appropriate and ethical prescriptive
practices. When a prescriptive decision is based on evidence gathered from an STD clinical evaluation that
includes investigation of history, symptoms, physical signs and laboratory analysis, the prescriptive choice
is more likely to be an appropriate choice. Prescriptive regimens are made in accordance with
recommendations from the MOH-RI STD Management Guidelines (Daili, et al., 1996).
The range of RTIs targeted by this study will often require sexual partner treatment and evaluation. This is
an important step necessary to reduce or eliminate future reproductive disease for the infected woman and
possible future morbidity and mortality to her unborn children. However, this can only be done with clients’
consent and considerations about the possible risks and benefits. Table 5 compares and contrasts partner
treatment requirements for the RTIs addressed by this study.
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Table 5. Partner Interventions
RTI/STD:

Partner Rx.
is NOT indicated:

Trichomoniasis

Concurrent
partner Rx.
needed:

Medical
evaluation of
partner offered

X

Bacterial Vaginosis

X

Candidiasis

X

Gonorrhea

X

X

Chlamydia

X

X

MPC

X

X

Syphilis

X

X

Chancroid

X

X

HSV II

X

HPV

X

Family planning clients who require sex partner evaluation and treatment will be coached and supported to
develop a plan of partner notification and treatment prior to leaving the clinic. However, this will take into
account clients consent and considerations about the possible risks and benefits of this consent.
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Table 6. RTI/STD Diagnosis and Case Management Protocol*
Trichomoniasis

Bacterial Vaginosis

Candidiasis

Subjective Data:
(History)

May include:
1. Unusual vaginal discharge
-foul odor
-profuse & frothy
-yellow/green color
2. Vulvar itching
3. Dysuria &/or Dyspareunia

May include:
1. Unusual vaginal discharge:
-fishy odor
-grey/white color

May include:
1. Unusual vaginal discharge
- “curdy” white
2. Vulvar itching

Objective Data:
(Exam signs)

May include:
1. Tissue inflammation
2. Malodorous dc
3. Grey/green/yellow vag dc
4. Strawberry cervix

May include:
1. Malodorous discharge
2. Adherent smooth discharge
3. Grey/white discharge

May include:
1. Tissue inflammation
2. “Curdy” white discharge

Lab Results:

May include:
Saline wet mount with motile
trichomonads

May include:
1. Saline wet mount or Gram stain with
clue cells
2. (+) odor with KOH

May include:
1. KOH wet mount with
mycelium/ hyphae or Gram stain

Treatment:
Metronidazole is
contraindicated in the
first trimester of
pregnancy

Rec. Regimen:
#
Metronidazole 2g, single dose

Rec. Regimen:
#
Metronidazole 2g, single dose

Alt. Regimen:
#
Metronidazole 500mg, BID x 7 days

Alt. Regimen:
#
Metronidazole 500 mg, BID x 7
days; or
Ampicillin 500 mg, 4 x 7 days

Rec. Regimen:
Clotrimazol 500 mg intravag single
dose; or
Miconazole/clotrimazol 200mg
intravag daily, x 3 days; or
Nystatin 100,000 IU intravag daily, x
14 days; or
# Ketoconazole 200 mg, x 2 x 1 day;
or
#Itraconazole 200 mg, x 2 x 1 day; or
Fluconazole 150mg oral single dose

Plan for partner Rx and
additional STD testing
for index patient (IP)

1. Concurrent partner Rx.
2. Also test for gonorrhea & chlamydia
3. No ETOH with metronidazole
4. Recommend serology HIV

No ETOH with metronidazole

#
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Table 6. RTI/STD Diagnosis and Case Management Protocol*

Gonorrhea

Chlamydia

MPC-Mucopurulent Cervicitis

Subjective Data:
(History)

May include:
1. Abnormal vaginal discharge;
yellow / white
2. Dysuria
3. Post coital spotting
4. Lower abdominal pain

Asymptomatic infections are very
common; may also include:
1. Abnormal vaginal discharge
2. Dysuria
3. Post coital spotting
4. Lower abdominal pain

May include:
1. Abnormal vaginal discharge
2. Dysuria
3. Post coital spotting
4. Lower abdominal pain

Objective Data:
(Exam Signs)

May include:
1. Increased vaginal discharge
2. Cervix with erythema
3. Cervical ectopy
4. Friable cervix
5. Cervix with cloudy mucopus
6. CMT
7. Tender/painful palpation to uterus
and/or adnexa

May include:
1. Increased vaginal discharge
2. Cervix with erythema
3. Cervical ectopy
4. Friable cervix
5. Cervix with cloudy mucopus
6. CMT
7. Tender/painful palpation to uterus
and/or adnexa

May include:
1. Increased vaginal discharge
2. Cervix with erythema
3. Cervical ectopy
4. Friable cervix
5. Cervix with cloudy mucopus
6. CMT
7. Tender/painful palpation to uterus and
/ or adnexa

Lab Results:

May include:
wet mount >30 WBC’s/HPF
MUST include a (+) culture for
gonorrhea

May include:
wet mount > 30 WBC’s/HPF
MUST include a (+) enzyme test for
chlamydia

May include:
wet mount > 30 WBC’s/HPF, remainder
of the diagnosis is empiric.

Treatment:

Rec.
Regimen:
#
Ciprofloxacin 500 mg single dose;
or
#Ofloxacin 400 mg single dose; or
#Tiamfenikol 3.5 g single dose; or
Ceftriaxone 250 mg IM; or
Canamicyn 2 gr IM single dose; or
Spectinomicyn 2 gr IM single dose

Rec.
Regimen:
#
Doxycycline 100 mg BID x 7 days;
or
#Azitromycin 1 gr single dose; or
#
Tetracycline 500mg QID x 7 days; or
Erythromycin 500 mg QID x 7 days

Rec. Regimen:
Should include regimens equally effective
against Gonorrhea and Chlamydia as
previously described.

1. Partner must be notified, examined,
and treated.
2. Also test for chlamydia.
3. Recommend HIV screening test

1. Partner must be notified,
examined and treated.
2. Also test for gonorrhea
3. Recommend HIV screening test

1. Partner should be examined and
treated IAW IP’s regimen.
2. Also test for gonorrhea and chlamydia.
3. Recommend serology HIV test

#

contraindicated in
pregnancy
Plan for partner Rx and
additional STD testing
for index patient (IP):
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Table 6. RTI/STD Diagnosis and Case Management Protocol*
Syphilis

Chancroid

Subjective Data:
(History)

Asymptomatic infection is common, but may include:
1. Genital ulcer
2. Generalized skin rash

May include:
1. Genital ulcer
2. Tender swollen areas in groin

Objective Data:
(Exam signs)

May include:
1. Single painless ulcer
2. 5 - 15 mm diameter of ulcer
3. Raised round clearly defined ulcer borders
4. Ulcer base: smooth and clean
5. Ulcer: firm and rubbery to touch
6. Lymph glands: firm, non-tender
7. After ulcer heals, appearance of a red symmetrical rash on
trunk, palms, and soles

May include:
1. Multiple painful ulcers
2. 2 - 20 mm diameter of ulcers
3. Rough, irregular ulcer borders
4. Ulcer base: dirty and purulent
5. Ulcer soft to touch.
6. Lymph glands: tender, unilateral buboes

Lab results:

Must include:
A reactive VDRL or RPR with TPHA confirmation. RPR, may
take 3 to 4 months to react after ulcer “chancre” onset

Specific lab confirmation not available at study
site. Diagnose Empirically.

Rec. Regimen for primary syphilis:
Benzathine PCN G, 2.4 million U, IM in a single dose; or
Penicylin Procain 600.000 IU, IM, 10 days
If allergic to Penicylin :
#Tetracycline 500 mg QID x 15 days; or
Erythromycin 500 mg QID x 15 days; or
#Doxycycline 100 mg BID x 15 days

Rec. Regimen:
#Ciprofloxacin 500 mg a single dose; or
#Ofloxacin 400 mg a single dose; or
Azitromycin 1 gr a single dose; or
Erythromycin 500 mg, QID x 7 days; or
Ceftriaxon 250 mg IM a single dose; or
Trimetoprim-Sulfametoksasol 80-400 mg 2 x
BID x 7 days

1. Concurrent partner notification, exam, and Rx is critical.
(Syphilis is a serious systemic disease)
2. Also test for gonorrhea and chlamydia
3. Recommend HIV Elisa testing

1. Concurrent partner notification, exam, and
Rx is indicated.
2. Also test for gonorrhea and chlamydia.
3. Recommend Syphilis and HIV screening test

Treatment
#

See Rx guidelines for
alternate regimens for allergies
and pregnancy

Plan for partner Rx and
additional STD testing for
index patient (IP)

#
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Table 6. RTI/STD Diagnosis and Case Management Protocol*
HSV II

HPV

Subjective Data:
(History)

May include:
1. Initially painful genital sores
2. Dysuria
3. Malaise and myalgia
4. Recurrence of symptoms

May include:
Painless genital warts

Objective Data:
(Exam signs)

May include:
1. Multiple fluid filled blisters that
2. Ulcerate, and are
3. 1 - 5 mm in diameter.

May include:
Verruciform genital lesions.

Lab Results:

Empiric diagnosis

Empiric diagnosis

Treatment:
(Contraindicated in
pregnancy)

*Eradication of virus not possible, but treatment to
relieve symptoms includes:
Initial outbreak:
Acyclovir 200 mg 5 x day for 7-10 days

Eradication of virus not possible, but removal of external
warts may be done by:
#Podophyllin 10 - 25%; or
Trichloracetic Acid (TCA) 40 - 50%;
Liquid Nitrogen 20% - 40 %

Recurrences:
Acyclovir 200 mg 5 x day for 5 days
Plan for partner Rx
1. Partner(s) may benefit from evaluation and
1. Partner (s) may benefit from evaluation and counseling.
and additional STD
counseling.
2. Also test IP for chlamydia.
testing for index
2. Also test IP for gonorrhea, and chlamydia.
3. Recommend for HIV and Syphilis screening test
patient (IP)
3. Recommend for HIV and Syphilis screening test
Note:
*The diagnostic process for HIV is beyond the scope of this initial study patients will be educated (protocol 2) if the HCP judges the individual client
to be at risk and a referral to an alternate test sites will be made
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VII.
RTI/STD Treatment Guidelines
The recommended treatment guidelines have been prepared from a combination of recommendations
from the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC) and
the MOH-RI STD Management Guidelines. Guidelines are given for the confirmed RTIs of
Trichomoniasis, Bacterial Vaginosis, Candidiasis, Neisseria Gonorrhea, Chlamydia Trachomatis, Syphilis,
Chancroid, Herpes Simplex Virus, and Human Papilloma Virus. It is beyond the scope of this study to
make treatment management recommendations for confirmed infections with HIV. Guidelines are also
presented for the clinically recognized syndrome of mucopurulent cervicitis (MPC).
Trichomonas vaginalis:
Recommended regimen
: Metronidazole 2 grams (g) orally in a single dose
Alternative regimen
: Metronidazole 500 milligrams (mg) twice daily for 7 days
Management of sex partners : Treatment of sex partners is recommended
Bacterial Vaginosis:
Recommended regimen
Alternative regimen
Management of sex partners

: Metronidazole 2 g orally in a single dose
: Metronidazole 500 mg orally twice daily for 7 days, or
Ampicillin 500 mg orally four times daily for 7 days
: Routine treatment of sex partners is not recommended

Note:
1. Metronidazole is contraindicated during the first trimester of pregnancy.
2. Do not drink alcohol while taking metronidazole.
Candidiasis:
Recommended regimen

: Clotrimazole 500 mg intravaginally a single dose
: Miconazole or Clotrimazole, 200 mg intravaginally, daily for
3 days; or
Nystatin, 100,000 IU intravaginally, daily for 14 days; or:
Clotrimazole, 500 mg intravaginally, as a single dose
Ketoconazole 200 mg BID, 5 days-oral
Itraconazole 200 mg BID 1 day-oral
Flukonazole 150 mg, single dose-oral
Management of sex partners
: Not usually recommended.
Note : Ketokonazole and Itraconazole are contraindicated for pregnancy.
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Gonorrhea:
Recommended regimens: Ciprofloxacin 500 mg orally in a single dose (Contraindicated in
pregnancy); or
Ofloxacin 400 mg, orally, single dose
Ceftriaxone 250 mg intramuscular (IM) in a single dose; or
Cefixime 400 mg orally in a single dose; or
Spectinomycin 2 g IM in a single dose;
PLUS:
A regimen effective against possible coinfection with Chlamydia Trachomatis, such as Doxycycline
100 mg orally 2 times a day for 7 days. Doxycycline is contraindicated in pregnancy, so use
Erythromycin 500 mg orally 4 times a day for 7 days.
Alternate regimens which may be useful in some countries, depending on the prevalence of resistant
gonococci: Kanamycin 2 g IM in a single dose;
Management of sex partners
: Concurrent partner exam/referral and treatment is indicated.
Note:
Ciprofloxacin and Ofloxacin are contraindicated in pregnancy.
Chlamydia:
Recommended regimens:
Doxycycline 100 mg orally 2 times a day for 7 days; or
Tetracycline 500 mg orally 4 times a day for 7 days; or
Azithromycin 1 g orally in a single dose.
Alternative regimens

: Erythromycin base 500 mg orally 4 times a day for 7 days.

Note:
Tetracycline, Doxycycline and Azithromycin are contraindicated in pregnancy; use
Erythromycin.
Management of sex partners
: Concurrent partner exam/referral and treatment is indicated.
Syphilis: (Primary and Secondary)
Recommended regimens:
Benzathine penicillin G, 2.4 million units IM in a single dose
Alternative regimens:

Procaine Penicillin G, 600.000 IU by IM injection for 10 consecutive
days.
Alternative regimens for penicillin allergic non-pregnant patients:
Doxycycline 100 mg orally 2 times a day for 14 days; or
Tetracycline 500 mg orally 4 times a day for 14 days.
Note:
1.
Syphilis in pregnancy: due to the serious consequences to the fetus, pregnant women
require close surveillance of follow-up serology and epidemiologic investigation to rule out
reinfection. Alternative regimen for penicillin allergic pregnant patients: Erythromycin 500
mg orally 4 times a day for 15 days.
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2.

The Indonesian STD Guidelines (Daili, et. al., 1996) also include a recommendation of
Thiamphenicol treatment for Gonorrhea. However, John S. Moran, MD, MPH, STD Advisor
HAPP/AIDSCAP, May 1997 stated that, “Single dose thiamphenicol regimens have not been
proven to be reliably effective against gonorrhea”..

Management of syphilis sex partners:
All stages of syphilis require concurrent examination and treatment of all
partners
Latent Syphilis (more than 2 years duration or of indeterminate duration):
Recommended regimen : Benzathine penicillin G, 2.4 million units IM injection given weekly for 3

weeks.
Alternative regimen

: Procaine penicillin G, 600.000 IU by IM injection once
a day for 20 consecutive days.

Tertiary Syphilis

All patients with latent syphilis should be evaluated clinically for evidence of tertiary disease (e.g., aortitis,
neuro syphilis, gumma, and iritis). These patients should have a cerebral-spinal fluid (CSF) examination
before treatment. It is beyond the scope of the study clinical sites to provide such service, and as such,
these patients must be referred to a specialist at the hospital level to monitor status, and provide
treatment.
Chancroid:
Recommended regimen
Alternative regimens

Management of sex partners

: Erythromycin base 500 mg orally 4 times a day for 7 days.
: Ciprofloxacin 500 mg orally as a single dose; or
Ceftriaxone 250 mg by IM injection as a single dose; or
Trimethoprim (80 mg)/Sulfamethoxazole (400 mg) 2 tablets
orally, twice a day for 7 days; or
Ofloxacin 400 mg orally, single dose; or
Azithromycin 1 g orally, single dose.
: Concurrent exam/referral and treatment of sex partners is indicated.

Note:
Ciprofloxacin and Ofloxacin are contraindicated in pregnancy
Herpes Simplex Virus:
Recommended regimen for first clinical episode (determined by careful clinical history):
Acyclovir 200 mg orally 5 times a day for 7-10 days.
Recommended regimen for recurrent episodes :
Acyclovir 200 mg orally 5 times a day for 5 days.
.
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Note:
After one year of continuous Acyclovir treatment, the drug should be discontinued to allow assessment
of the patient’s rate of recurrent episodes. Acyclovir must be carefully used in pregnancy. Refer all
pregnant women with herpes to a physician for careful prenatal observation and status evaluation is
indicated to minimize perinatal transmission.
Management of sex partners

: Sex partners of patients who have genital herpes are likely to benefit
from evaluation and counseling. Since acyclovir is a suppressive
treatment and not an eradication of the disease, concurrent partner
treatment is not indicated.

Human Papilloma Virus (HPV) (Genital Warts):
No therapy has been shown to eradicate HPV, therefore the goal of removal should be guided by patient
preference. Current treatment methods range from 22%-94% efficacy in clearing external exophytic warts
with high recurrence rates. Avoid expensive or toxic therapies that can result in scarring.
Recommended Chemical regimens :
C
Podophyllin 10-25% in compound tincture of benzoin. Wash off in 1-4 hours. Repeat
weekly if necessary spread vaseline on the skin around the lesion before applying Podophyllin.
If warts persist after 6 applications, discontinue this method. Avoid normal tissue; or
C
Trichloracetic acid (TCA) (80-90%). Apply only to warts; powder with talc or baking
soda to remove unreacted acid. Repeat weekly if necessary. If warts persist after 6 applications,
other therapies should be considered.
Note:
Podophyllin is contraindicated during pregnancy.
Recommended Physical regimens:
Cryotherapy with liquid nitrogen or cryoprobe; or
Electrocautery; or Surgical removal.
Management of sex partners

: Partners could benefit from evaluation and counseling.
Concurrent treatment is not recommended unless the partner is
symptomatic.
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VIII.
Client Education and Counseling
Educating and counseling the client who receives a diagnosis of RTI/STD is a vital part of disease
prevention for both the individual client and also the greater community. The process of education,
supported by good communication skills, begins with the initial introduction between HCP and client,
continuing through the exam and culminates with dialogue . As with the history and exam, the final
teaching stage of the clinic visit should also be performed in an environment of privacy and confidentiality.
The main goal of STD education is to promote the client’s understanding of:
C
what her diagnosis is
C
how her infection was transmitted
C
steps she can take to manage &/or eradicate the infection
C
options she can use for future prevention from repeat or new STD infection.
Because the reality of an STD diagnosis carries more psychological weight than an infection that is not
sexually transmitted, the opportunity to have an optimum “teachable moment” may be challenged
by emotional reactions that arise from the client as well as from the HCP. Many HCP’s express concern
that a frank discussion of an STD diagnosis will cause the client to feel shame or “loose face”. The most
important start to break this cycle of silence which is the result of a fear of causing shame is for the HCP
to demonstrate comfort and acceptance of the client’s sexuality and diagnosis. Clients will not benefit
or be served by a HCP who is projecting his or her fear onto the client. The correct use of communication
skills and styles will help reduce the intensity of an emotional reaction and allow for a greater exchange
of information. If a HCP is able to demonstrate concern and competence in a receptive and nonjudgmental manner, the client will be more receptive to instructional interventions. Table 7 contrasts
communication behaviors of HCP’s.

Table 7. HCP Communication Behaviors
Negative Impact

Positive Impact

HCP does not personally greet the client
before plunging into chart or exam.

HCP smiles, shakes hand, uses welcoming
words

Does not listen to client (interrupts)

Listens carefully

Uses jargon

Uses clear language

Depersonalizes client

Conveys interest in the client

Angry, hostile, or impatient

Warm, friendly, & accepting

Doesn’t answer questions

Is open to questions
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Teaching Content
A comprehensive, personalized STD teaching plan has many separate teaching points. The HCP should
avoid the temptation of delivering an hour long lecture. The HCP should be mindful of the overall goal
of STD teaching, specifically the client’s understanding of the disease diagnosis, etiology, treatment ,
management, and prevention. By simply asking the client at the start of the education session “what can
I tell you about your infection”, the door can be opened to the “teachable moment” that will be of
greatest service to the client. The following inventory presents components of communicative and
instructional content that should be included in an education session.
Table 8. Inventory of HCP Components of an STD Education Session
1.

Demonstrates professionalism (competence, tolerance).

2.

Emphasizes privacy, confidentiality.

3.

Establishes rapport & demonstrates concern for the client.

4.

Listens to client’s concerns without interrupting.

5.

Uses open ended questions.

6.

Avoids jargon, communicates at the client’s level.

7.

Provides accurate and correct information re. diagnosis, etiology & transmission.

8.

Gives instructions on when, how often, & how long to take medication; the importance of
completing the Rx, and possible side effects.

9.

Ensures any required partner(s) notification, exam & Rx.

10.

Abstain from sexual intercourse for duration of medication (Both client & partner).

11.

Discusses future risk reduction behaviors (A,B,C’s) & dispenses condoms with instructions for
correct use.

12.

Recommends a return clinic visit (RTC) if symptoms worsen or recur.

13.

Ensures that client’s concerns are addressed & that she has an understanding of instructions.

The client’s adherence to treatment recommendations will be higher if the client has been asked to repeat
the instructions, and if the HCP repeats the instructions more than once during the education session.
The importance of education during all health care encounters can not be overestimated. Such a
philosophy is based on the belief that knowledge is power. Sharing this power with the client will
contribute to disease reduction and contribute to health promotion.
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IX.
Infection Control
The integration of RTI/STD services into existing FP clinical practice will require few changes in
infection control procedures. With a greater awareness of the importance of reducing exposure to
blood borne pathogens such as HBV & HIV, all FP clinics should utilize Universal Precautions (UP)
as standard operating procedures in the examination room and the laboratory. A clinical practice that
values and uses UP’s will minimize procedural infections to clients and minimize transmission of
infections to clinic staff. See Table 9 for a review of required UP in daily FP clinical practice.
Table 9. Universal Precautions Highlights

1.
2.
3.
4.
5.
6.

Handle all specimens of blood and body substances as potentially infectious.
Wash hands before and after contact with patients or specimens of blood and body substances.
Wash hands before and after use of gloves.
Do not recap or manipulate needles.
Place used syringes, needles, scalpel blades and other sharp items in puncture-proof
containers marked BIOHAZARD. Do this immediately after use.
For surgical procedures wear laboratory gowns, rubber gloves, protective goggles and masks.

Protective Barriers
Placing a mechanical or chemical barrier between microorganisms and a person is a good way to
prevent the spread of the disease. Protective barriers in infection prevention include:
1. Hand-washing with soap;
2. Wearing gloves, either for surgery or to protect clinic staff when handling contaminated waste
materials or soiled instruments;
3. Using antiseptic solutions for cleaning wounds or preparing the skin prior to invasive procedures,
i.e. injections, IUD or Norplant insertions, and surgery;
4. Decontaminating, cleaning and sterilizing surgical instruments i.e., vaginal speculums, uterine
sounds, trocars, tenacula, and forceps.
Hand-washing is probably the single most important infection prevention practice in a FP clinic.
Hand-washing is indicated:
• before examining a client;
• before putting on sterile gloves for surgical procedures;
• in any situation in which hands may be contaminated;
• after removing gloves (because gloves may have invisible holes or tears).
Gloves must be worn by all staff prior to contact with blood and body fluids from any client. In the FP
clinic, this occurs prior to the start of the pelvic exam. A separate pair of gloves must be used for
each client to avoid cross contamination. Table 10 shows procedure specific glove requirements.
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Table 10 : Glove Requirements For Medical & Surgical Procedures*

Task or Activity:
Measuring blood pressure
Measuring temperature
Giving an injection
Pelvic exam
Contact w. vaginal secretions
IUD insertion & removal
Norplant insertion & removal
Blood drawing
Handling & cleaning contaminated instruments
Handling contaminated specimens or waste
Cleaning blood or body fluid spills

Gloves
Needed?
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes

Hi-Level Disinfected
Gloves (1)

Sterile
Gloves

yes
yes
yes
acceptable (2)
yes (3)
no
no
no

no
no
no
preferable
no
no
no
no

(1) This includes” never used” individual or bulk packaged gloves
(2) When autoclave is not available HLD is the only acceptable alternative
(3) It is not necessary for gloves to be routinely worn by experienced phlebotomists

*Adapted from:

Tietjen et al, 1992. Infection Prevention for Family Planning Service Programs: A
Problem-Solving Reference Manual.
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Antisepsis
Antisepsis is the prevention of infection by killing or inhibiting the growth of microorganisms on the
skin or other body tissues. For the tasks of performing pelvic exams to collect lab specimens for the
diagnosis of RTI/STDs, no antiseptic procedure are indicated. Antisepsis is a very necessary part of
invasive FP practices which in this study includes:
• injections
• IUD insertions
• Norplant insertions.
See the following summary of steps involved in these three procedures that do require antiseptic
applications to the client.
Table 11.

Procedural Specific Antiseptic Steps

Norplant Implants

IUD Insertion

Injection

1. Do not shave
2.

3.

4.
5.

6.

1. Ask about allergic reactions 1. Cleanse skin with 60-90%
before selecting antiseptic
ethyl or isopropyl alcohol (Be
Ask about allergic reaction
solution (iodine)
careful to remove all visible
before antiseptic selection
soil from the proposed
(iodine)
2. If external genitals are visibly
injection site before prepping)
soiled, ask client to wash with
If visibly soiled, thoroughly
soap and water
2. With a fresh cotton swab and
clean the client’s skin with
alcohol solution, wipe the
soap & water before applying 3. Apply antiseptic (Do not use
injection site thoroughly using
antiseptic
alcohol which can dry and
a circular, over lapping
irritate the mucus membrane
motion, starting at the center
Apply antiseptic
and promote the growth of
microorganisms)
3. Allow to dry before giving
Using dry disinfected forceps
injection
& cotton soaked in antiseptic, 4. After inserting the speculum,
thoroughly cleanse skin by
apply solution liberally to the
gently scrubbing. Work from
vagina and cervix
operative site outward in a
circular motion for several 5. If iodophors are used, allow
inches
1-2 minutes before
proceeding (Iodophors
Do not allow antiseptic
require contact time to
solution to pool underneath
release free iodine)
client’s body

7. Allow antiseptic to dry before
beginning procedure (When
iodophors are used, allow 1-2
minutes because they require
contact time to release free
iodine).
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Decontaminating, Cleaning, & Sterilizing Instruments & other Items
The basic process of decontamination to prevent disease transmission from contaminated
instruments is to:
1. Decontaminate with a soak in 0.5% chlorine ( I part bleach to 9 parts water) solution for 10
minutes;
2. Thoroughly wash and rinse instruments with a brush in soapy water;
3. Sterilize at 121 degrees Celsius (250 degrees F) for 20 minutes if unwrapped or 30 minutes if
wrapped.
The most common instruments in FP practice that requires decontamination is the vaginal speculum.
Other instruments that also require sterilization are: uterine sounds, trocars, tenacula, forceps, etc.
The other clinical item that will need routine daily decontamination is the pelvic exam table. This is
done by a 2 step procedure which includes:
1. wiping off the table with a 0.5% chlorine solution.
2. followed by a wash with detergent and water if organic material remains after decontamination
procedures.
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ABBREVIATIONS
A.B.C - Abstinence, Be faithful, Condoms

MID - midline

ABN - abnormal

mm

AIDS - Acquired Immunodeficiency Syndrome

MPC - Mucopurulent Cervicitis

AV

MTM - Modified Thayer Martin

- anteverted

- millimeter

BCM - Birth Control Method

PC

- Post Coital

BID

PE

- Physical Exam

CDC - Centers for Disease Control Prevention

PID

- Pelvic Inflammatory Disease

cm

OC

- Oral Contraceptive

CMT - Cervical Motion Tenderness

QID

- four times a day

dc

- discharge

RPR

- Rapid Plasma Reagin

EAB

- elective abortion

RTI

- Reproductive Tract Infections

ETOH - alcohol

RV

- retroverted

FP

- Family Planning

Rx

- treatment

g

- gram

SAB

- Spontaneous Abortion

Gc

- Gonococcus

STD

- Sexually Transmitted Disease

HCP

- Health Care Provider

TCA

- Trichloracetic Acid

HIV

- Human Immunodeficiency Virus

TID

- three times a day

HPF

- High Power Field

TPHA - Treponema Palidum

HPV

- Human Papilloma Virus

HSV

- Herpes Simplex Virus

U

- unit

IAW

- in accordance with

WBC

- White Blood Cell

IDE

- identification

WHO

- World Health Organization

IM

- intramuscular

WNL

- within normal limits

IP

- Index Patient

IU

- International Unit

IUD

- Intra Uterine Device

KOH

- Potassium Hydroxide

LMP

- Last Menstrual Period

mg

- milligram

- twice a day
- centimeters

Hemagglutination Assay
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ROUND TABLE DISCUSSION AGENDA
24 - 25 January 1997
Koja Hospital
Jakarta, Indonesia

Friday, January 24, 1997, Day 1
Time

Topic

Presenter

9:00-9:15

INTRODUCTORY REMARKS

Dr. Umar Wahid, Director, Koja
Hospital

9:15-9:30

PROJECT REVIEW

Dr. Meiwita B. Iskandar, Ph.D. Resident Advisor, Population Council

9:30-10:00

ESSENTIAL REPRODUCTIVE
HEALTH CARE PACKAGE: The
Linkage of Contraceptive Choice to
RTI/STDs

Dr. Ardi Kaptiningsih, MPH MOH, BINKESGA, Subdirectorate of
OB/GYN

10:00-10:30

THE ROLE OF STDs IN THE
NATIONAL HIV/AIDS PREVENTION
PROGRAM

Dr. H. Sigit Priohutomo, MPH MOH, CDC, Subdirectorate of STDs
and Yaws

10:30-11:00

ESTABLISHING A REPRODUCTIVE
HEALTH SERVICES SYSTEM IN
FAMILY PLANNING SERVICES

Dr. Djajadilaga, DSOG, The Indonesian
OB/GYN Association (POGI Jaya)

11:00-11:30

QUALITY RECORDING &
REPORTING FOR STD MONITORING

Dr. Hariadi Wibisono, MPH MOH, CDC, Subdirectorate of STD
Surveillance

11:30-13:00

Sholat Jumat

13:00-14:00

PRACTICING NON-JUDGEMENTAL
CLIENT COUNSELING

Dr. Frans Sumampouw, DAJ, MPH MOH BINKESGA, Subdirectorate of
Mental Health
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ROUND TABLE DISCUSSION AGENDA
24 - 25 January 1997
Koja Hospital
Jakarta, Indonesia
Saturday, January 25, 1997, Day 2
Time

Topic

Speaker

9:00-9:45

NATIONAL STD GUIDELINES:
Comparison of Syndromic, Clinical
& Etiological Approaches to STD
Case Management

Dr. Sjaiful Fahmi Daili,
DSKK (Dermatovenereologist), National STD
Study Group

9:45-10:30

CLINICAL DIAGNOSIS
THROUGH PHYSICAL
EXAMINATIONS

Dr. Wresti Indriatmi B.
Makes, DSKK, National STD
Stud Group

10:30-11:15

SIMPLE BUT POWERFUL
RTI/STD LABORATORY
TESTS

Dr. Farida Zubier DSKK,
National STD Study Group

11:15-12:15

INDONESIAN RTI/STD
TREATMENT GUIDELINES

Dr. Jubianto Judanarso DSKK
National STD Study Group

12:15-12:45

CREATING CHANGES IN
EXISTING CLINICAL
PRACTICE

Dr. Djajadilaga, DSOG,
Indonesian OB/GYN
Association (POGI Jaya)

12:45-13:15

KOJA HOSPITAL
INTEGRATED
REPRODUCTIVE HEALTH
CARE PACKAGE: a Model
Protocol for a District Hospital
Family Planning Unit

Dr. Basuki Muliono, DSOG,
Department of MCH/FP,
Koja Hospital

Round Table Discussion Synopsis
The two day round table discussion was held in the large conference room of the
Koja Hospital. The facility was comfortably equipped with conference tables, chairs, and
microphones for all speakers and students. The hospital also furnished overhead and slide
projectors, along with technicians to arrange audio-visual equipment. This large conference
room on the fourth floor of the hospital is used as a mosque not only for hospital staff and
2

Appendix E
patients, but for the surrounding community as well. Since this training event was
conducted during the fasting month of Ramadhan, there were no scheduled logistical breaks
for food and drinks. Because the first day of the training was a Friday, it was necessary to
schedule a long break for men during the communal noon prayer. The midwives and female
medical staff took advantage of this time to discuss counseling STD clients.
This initial combined training for medical, midwife, and laboratory staff was attended
by representatives from both KojaHospital and Puskesmas Cilincing. A breakdown of the
attendees by institution included:
Koja Hospital
1 hospital director
3 doctors
2 laboratory technicians
0 midwives

Puskesmas Cilincing
1 medical director
3 midwives
2 laboratory technicians

Dr. Umar Wahid, medical director of RS Koja opened the round table discussion and
established a tone of pride in being involved with a program that would improve services
to clients. He expressed an institutional willingness to work to promote the integration of
STD services into existing family planning care.
The Population Council Resident Advisor introduced the main purpose of the
program and outlined the steps that would be necessary to achieve integration. She also
served as a moderator and discussant for the remainder of the program.
Dr. Ardi reviewed the highlights of the study protocols II and III which encompass
introducing the topic of RTI/STDs to family planning clients, and continuing the discussion
to linking sexual and contraceptive behavior to potential RTI/STD exposure. This leads to
the initial component of a clinical evaluation, taking an effective reproductive health history.
Bridging the two worlds of contraceptive technology and infectious diseases were the main
goals of this presentation. This call for integration provoked the first of many spirited
discussions from one of the doctors who wanted the instructors to realize that several
NGO’s are conducting studies on counseling for STD’s and HIV. He felt that counseling
and client education are difficult and time consuming tasks. Furthermore, he felt that telling
a client she had an STD disturbed the client’s privacy. He went on to discuss his feeling of
discomfort when he felt he was making a client uncomfortable. Other participants
acknowledged that education and counseling require a great deal of the HCP’s time during
a busy schedule of seeing clients. One doctor reported that he prefers to just prescribe a
medicine for treatment without telling the client why it is being prescribed. Several
instructors responded and concluded that HCP’s have an ethical responsibility to not withold
information from the client, regardless of the way it makes the HCP feel.
Dr. Sigit furnished the participants with the most current HIV/AIDS estimates based
on sentinel surveillance research in Indonesia. The participants responded to the information
0
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with a personal concern for occupational safety. This was used as an opportunity to direct
attention to upcoming infection control practices in the clinical setting. Much discussion
ensued about who was responsibile for the resource allocation to purchase barriers,
disinfectants and autoclaves in the field. Dr. Sigit also took the opportunity to teach about
the occupational transmission of HIV/AIDS and emphasized the need for HCPs to follow
universal precautions. A candid discussion about forgetting to comply with universal
precautions when busy followed. Dr. Sigit answered the HCPs questions about national
HIV screening policies and procedures. Dr. Sigit refocused the participant’s attention to
the fact that STDs facilitate HIV transmission as well as a quicker progression to AIDS.
He felt that STD case management could be performed by primary health care providers and
not just STD specialists. He felt that primary health care is the entry point for most contacts
with the medical system, and that client’s deserved to be treated at the point of entry. He
acknowledged that many primary HCPs lack knowledge of STDs. He explored the
advantages and disadvantages of the syndromic model of care for STDs.
Dr. Djajadilaga focused his discussion on how FP could contribute to the
improvement of reproductive health. He also stated his belief that FP should contribute to
STD case management and prevention. He discussed the impact that the 1994 International
Conference on Population and Development in Cairo had on changing the expectations for
quality FP services to include more than just birth spacing. He felt that an improved
program of FP services could reduce maternal mortality rates by 50%. For the successful
introduction of STD case management into FP services, Dr. Djajadilaga felt that there was
a need for greater HCP knowledge, skills as well as access to diagnostic tools like
microscopes for wet mount microscopy. He stressed the critical need for HCP motivation
to include STD case management with FP services. He endorsed the Problem Oriented
Medical Record (POMR) for quality diagnostic services that included the sequential
collection of subjective & objective data, followed by standardized assessment and plans to
treat and educate.
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Training Curricula Implemented as an
Intervention of “Improved Reproductive
Health and STD Service for Women
Presenting
to Family Planning Services in North Jakarta”

January - June
1997
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RTI/STD Case Management
(Trouble Shooting Training)

March 21, 1997- Puskesmas Cilincing
March 27, 1997- Koja Hospital

Participants:

Clinical and laboratory personnel

Objectives:

1)

2)

3)
4)

To provide feedback to health care providers (HCPs) and
laboratory staff about mid-term results of their work in the
program to integrate RTI/STD case management into routine
family planning services.
To identify clinical strengths and weaknesses discovered
during project monitoring of the implementation of the
project protocols.
To receive input from clinical staff about protocol feasibility
and intervention progress.
To review etiologically specific RTI/STD identification for
HCPs, see slide show lesson plan.

Instructors:

Meiwita Iskandar, MD, PhD, project manager
Cathy Vickers, RN, CNP, consultant

Format:

Group discussion

Interactive Slide Presentation Curriculum:
Slide
#

Content

Teaching Point

1

STD symptom chart

may be ASYMPTOMATIC!

2

Female anatomy

Minimal dysuria; normal vaginal environment

3

Male anatomy

Dysuria more anatomically common

4

Exam technique: insertive
finger*

helps locate cervix & reduces speculum
discomfort

5

Speculum insertion*

Cervical visualization must be included for
each evaluation

6

Endocervical swab collection

Sterile cotton for GC, Dacron for chlamydia;
duration- 10 sec. min; rotate x 3.

7

“Z” streak-culture*

gently roll (culture 1st, slide 2nd)

8

Cross streak culture*

Sterile loop, Cipto will do this

9

Gram stain swab

gentle roll

10

Bimanual exam*

to rule out obvious pregnancy/pathology

11

Candle jar*

must be re-lit after each specimen

12

Cultures in candle jar*

media on top to reduce condensation flood

13

BV-external genitalia

“coaty”- smooth, white-grey
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Slide
#

Content

Teaching point

14

Gram stain

normal flora, clear epithelial cell

15

BV- Clue cell, gram stain

pepper on an egg

16

BV- Clue cells, wet mount

done with normal saline

17

TRICH-external genitalia

frothy

18

TRICH-close up of discharge

frothy w. Tissue inflammation

19

Trichomonads on wet mount*

flagellates

20

Trichomonadselectomagnification

flagella obvious

21

TRICH- strawberry cervix

inflamed tissue

22

CANDIDIASISdischarge,external

thick w. Inflammation

23

CANDIDIASISdischarge,speculm

“chunky”-sour milk

24

CANDIDIASISdischarge,speculm

(smooth)-eyes can be fooled-need microscope

25

HYPHAE- Gram stain

circus -skinny balloons

26

HYPHAE- Wet mount*

done with KOH

27

GO-urethra, female

strip with gloved hand

28

GO-urethritis male,colpo.
magnify

yellow & erythema

29

GO- urethritis male

classic yellow drip (Does spouse have dc ?)

30

Cervical culture technique

wipe cervix off first

31

Gram stain w. + GNID

INTRACELLULAR

32

CHLAMYDIA, cartoon time
bomb

Asymptomatic infections common

33

Chlamydial cervix before &
after Rx

8+ tests for CHLAMYDIA first 3 weeks

34

MPC cervix

Rx for GO & CHLAMYDIA

35

MPC-non-gonnoccal

Can’t visually distinguish GO from CHLAM

36

T. Pallidum- spirochete

a systemic access, corkscrew

37

SYPHILIS stages

MUST have serology

38

Chancre- female

clean, rubbery (All genital ulcers need STS)

39

Chancre- male

clean, rubbery (All genital ulcers need STS)
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Slide
#

Content

Teaching Point

40

Secondary syphilis rashfemale

do systemic exams; trunk,abdomen,palms,soles

41

Secondary syphilis rash-male

systemic exams plus STS

42

Untreated syphilis
consequences

FU Rx w. titres for 1 year

43

Fetus and placenta

systemic connection-pregnancy is critical

44

Congenital syphilisabortion**

treatment of pt. & contacts w. close monitor

45

Chancroid-female

dirty, irregular ulcer

46

Chancroid-male

dirty with exudate

47

HERPES (HSV) cartoon

stages with changing appearances

48

HSV - females, primary

painful small papules

49

HSV - female, primary

painful ulcers in various stages

50

Cervical ectopy from HSV

visual ID difficult

51

HSV-primary outbreak, male

vesicles and ulcers- painful

52

Neonatal HSV

very serious

53

Warts (HPV)-external female

varies from discrete to:

54

HPV- external female

moderate

55

HPV- external female

fulminating, coalescing

56

HPV-internal female

refer to GYN, no podophyllin

57

HPV-external male

various sizes

58

HPV-external male

flat warts

59

HPV-external male

flat, spiky

60

RISK REDUCTION

A,B,C- ask, don’t tell, then fill in gaps

61

Condom barrier- they work!!!

Verbally discuss, physically offer

*-slides loaned from PATH
**- slide loaned from Mothercare
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Communication and Infection Control Skills
Supervisory Visit by
Dr. Frans Sumampouw, DAJ, MPH and Midwife Coos Leiwakabessy
April 21, 1997- Puskesmas Cilincing
Participants : Clinical and laboratory personel
Objective:
To offer the midwives a forum to identify problems and successes they
are experiencing in providing RTI/STD case management to family
planning clients.
Dr. Frans Sumampouw, DAJ, MPH - Comminication Skills
1.

Explore with the midwives any problematic areas they may be experiencing in the
areas of:
C
client history taking
C
client education
C
partner notification and treatment
C
initiating a discussion on condoms, and offering them.

2.

Consciousness raising on the subject of privacy.
C

C

3.

Visual privacy:
1)
minimize the number of staff, students, and observers in the exam
room;
2)
restrict entrance of other staff members into the exam room while
an exam is being done. A closed curtain should symbolize “no
entrance” to other staff;
3)
includes medical records and clinical evaluations, they should not
be left out for other clients to see .
Auditory privacy:
1)
especially important when visual privacy is not possible, such as
taking a history in the outside room;
2)
critical when giving results of exam, whether positive or negative;
3)
critical when making a plan for partner treatment;
4)
requires a soft voice.

Reinforce the gathering of the history (questions 1-10c on the clinical evaluation)
by the midwife, not the research assistant.
1)
Is asking the questions (1-10c), getting easier than when the
program started?
2)
How do the midwives introduce the history to the client?
- if a professional explanation is given that the history is an
important part of the evaluation, it will be more acceptable to
the client;
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- Does the introduction of the history always include assurances
that the answers will be kept confidential?
- Have the midwives experienced any negative consequences
from the clients to this part of the evaluation? (Hopefully, the
experience of the midwives or research assistants in the past 10
weeks will bear out the fact that clients are willing and capable
of furnishing the sexual history without loosing face).
3)

If important information is revealed during the history, the midwife
should record it under the “Comments” section. Example: if a client was
referred for an evaluation because she is a contact to a confirmed STD,
this will guide the diagnosis and treatment. It must be recorded on the
history for any additional intervention to occur.

4.

Why is the discussion and provision of condoms not being done for each
client who has a sexually transmitted infection? The client is free to
decline condoms, but they must first be freely talked about and physically
offered before she has an opportunity to choose them or not.

Midwife Kos- Infection Control Skills
Midwife Kos reviewed procedures for speculum sterilization. She stressed
importance of through scrubbing before autoclaving to remove visible contaminants.
She discussed the importance of maintaining an adequate supply of disinfected
speculums. With purchases made trough this study. There are now 12 speculums.
Midwife Kos stressed the importance of not reusing disposable gloves.
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RTI/STD Clinical Evaluation Guide
Health Care Provider Skills Inventory:
U

#

Skill:

1.

Professionally introduces self & establishes rapport with client.

2.

Introduces purpose of program & starts discussion of RTI/STD’s & their link to
contraceptive choice.

3.

Solicits participation in research study using the informed consent principals of:
a) voluntariness; b) anonymity; c) confidentiality; d) privacy.

4.

If client agrees to participate in study, HCP signs consent form.

5.

Obtains a targeted risk assessment history by asking the following questions:
a) Age: younger than 25 years?
b) Past history of STD?
c) More than 1 sex partner (in the past 3 months)?
d) Sexual intercourse without condoms (in the past 3 months)?
e) Unusual vaginal discharge: odor, green/yellow color, itching, etc. (in the past 3
months)?
f) Pain with urination (in the past 3 months)?
g) Lower abdominal pain (in the past 3 months)?
h) Bleeding after intercourse (in the past 3 months)?
i) Genital sores or lumps (in the past 3 months)?
j) Does husband/partner have unusual discharge from penis? (past 3 months)
k) Does husband/partner have sores or lumps on penis? (past 3 months)
l) Does husband/partner have other sex partners?

6.

Visually inspects skin.

7.

Inspects & palpates abdomen.

8.

Inspects & palpates inguinal area.

9.

Performs speculum examination.

10.

Performs bimanual examination.

11.

Obtains laboratory specimens for microscopy, culture, ELISA & serological tests.

12.

Uses infection control practices:

1
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a) washes hands before exam;
b) uses visibly clean speculum;
c) puts on new or disinfected glove before pelvic exam;
d) if rectal exam done, changes glove prior to rectal;
e) washes hands after removing glove;
f) does not re-use glove on another client.
13.

Explains exam findings &/or diagnosis to client.

14.

If diagnosed RTI positive, explains disease to client.

15.

If diagnosed STD positive, explains disease transmission & makes a verbal plan for
partner treatment.

16.

Selects an approved treatment & prescribes the correct amount & length of drug use
if client is diagnosed with a treatable infection.

17.

If a prescription is written, gives instructions on:
a) when to take the drug;
b) length of drug use;
c) the importance of finishing the entire prescription;
d) potential side effects (alcohol & pregnancy).

18.

Assesses the clients understanding of the instructions.

19.

Provides instructions for future RTI/STD prevention:
a) abstinence;
b) monogamy;
c) condoms.

20.

Offers condoms and provides instructions for use.

21.

Demonstrates positive communication skills throughout the entire interaction:
a) open & friendly attitude;
b) uses understandable terminology;
c) conveys an interest in the client;
d) listens carefully;
e) is open to the client’s questions.
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HCP/Client Interaction Observation Form

No.
NO

1.
2.
3.

4.
5.
6.
7.
8.

9.

10.

11.
12.

13.

14.

OBSERVATION

Smiles and greets client respectfully
Asks client’s reason for coming to the clinic
Client’s current status/condition
a. Contraceptive method
b. Last menstruation
c. Current medications
d. Allergies to medications or latex
. OB history and potential of current pregnancy
Reviews contraceptive methods and
relationship with RTI
Review STDs/RTIs that potentially influence
women’s reproductive organs
Past history of STD
Sexual history (in the last 3 months)
a. Sexual intercourse without condoms
b. >1 partner
RTI /STD symptoms (in the last 3 months)
a. Vaginal discharge
b. Vaginal itching
c. Pain with urination
d. Bleeding after intercourse
e. Genital sores or lumps
Perception of partner’s symptoms and risks
a. Unusual discharge from penis
b. Sores or lumps on penis
c. Any partners other than you?
Explains exam before starting procedures
Sterilization
a. Washes hands before exam
b. Visibly clean instruments
c. Puts on new or disinfected glove before
pelvic exam
d. If rectal exam done, changes glove prior to
rectal
e. Washes hands after removing glove
Physical exam
a. Abdomen, skin
b. Inguinal palpation
c. Visualizes external genitalia
d. Speculum exam
e. Bimanual exam
Counseling
a. Explains the diagnosis to client
b. If diagnosed RTI positive, explains disease
transmission
c. If diagnosed STD positive, makes a verbal
plan for partner treatment and evaluation.

(+)

(-)

EXPLANATION
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NO

OBSERVATION

15.

Provides instruction for future RTI prevention
a. Discusses Abstinence
b. Discusses Be Faithful
c. Discusses Condom
a. Offers condoms
b. Provides instructions for condom use
If RTI is positive, gives instruction on infection
treatment
a. Prescribed medication
b. How often to take the drug
c. Length of the drug use
d. Take entire prescription
e. Potential side effect (alcohol and pregnancy)
f. Assess client’s understanding of instruction
HCP demonstrates positive communication
skills
a. Open and friendly
b. Uses understandable terminology
c. Conveys interest in the client
d. Listens carefully
e. Is open to client’s questions

16.
17.

18.

(+)

(-)

EXPLANATION

Research Assistant

(……………………………………)

Instruments\App.D\14/3/97
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STD Treatment Guidelines :
A Partial Comparison of Three Guidelines
Diseases Compared :
Trichomoniasis
Bacterial vaginosis
Candidiasis
Gonorrhea
Chlamydia
Syphilis
Chancroid

Sources :
Daili, Sjaiful Fahmi et.al.(eds). Penatalaksanaan Penyakit Menular Seksual :
Berdasarkan Pendekatan Sindrom, Fasilitas Laboratorium Sederhana,
Laboratorium Khusus. Jakarta : Direktorat Jendral PPM & PLP Departemen
Kesehatan RI dan Kelompok Studi Penyakit Menular Seksual, 1996
(Listed in tables as MOH-RI)
Centers for Disease Control and Prevention. “ 1993 Sexulally Transmitted Disease
Guidelines” MMWR 1993, 42:1-102 (RR-14).
(Listed in tables as CDC-US)
World Health Organization Recommendations. Management of Sexually Transmitted
Diseases. Geneva: WHO, 1994 (Report No. WHO/GPA/TEM/94.1)
(Listed in tables as WHO)
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STD Treatment Guidelines: Trichomoniasis
MOH RI

CDC US

WHO

Metronidazole 2g po
single dose

Metronidazole 2g po
single dose

Metronidazole 2g po single dose

Metronidazole 500
mg po BID x 7 days

Metronidazole 500
mg BID x 7days

Metronidazole 400-500 mg po BID
x 7 days

STD Treatment Guidelines: Bacterial vaginosis
MOH RI

CDC US

WHO

Metronidazole* 2 g
po single dose

Metronidazole 500
mg po BID x 7 days

Metronidazole* 400-500 mg po
BID x 7 days

Metronidazole 500
mg po BID x 7 days

Alt Reg:
Metronidazole* 2 g
po single dose

Metronidazole, 2g po single dose

Ampicillin 500 mg po
QID x 7 days

Alt Reg: Clindamycin
cream** 2%, full
applicator (5g)
intravag @ HS x 7
days
Alt Reg (AR):
Metronidazole gel,
0.75% 1 full
applicator (5g)
intravag, BID x 5
days
AR: Clindamycin 300
mg po BID x 7 days

* Contraindicated in first trimester pregnancy
** Oil based, may weaken latex
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STD Treatment Guidelines: Candidiasis
MOH RI

CDC US

WHO***

Clotrimazole 500 mg
tab/vag x 1 day

Butoconazole 2%
cream 5 g intravag x
3 days **

Nystatin 100,000 IU intravag daily
for 14 days

Miconazole or
Clotrimazole 200 mg
tab/vag per day for 3
days

Clotrimazole 1%
cream 5 g intravag x
7-14 days

Miconazole or Clotrimazole, 200
mg, daily for 3 days

Nystatin 100,000 U
tab/vag Daily x2
weeks

Clotrimazole 100 mg
vag/tab x 7-14 days

Clotrimazole, 500 mg intravag as a
single dose

Ketoconazole* 200
mg p.o BID x 5 days

Clotrimazole 100 mg
vag/tab x 2 tabs x 3
days

Itraconazole* 200 mg
p.o x once

Clotrimazole 500 mg
vag/tab, 1x

Fluconazole 150 mg
p.o. x once

Miconazole 2 %
cream 5 g intravag 7x
days **
Miconazole 200 mg
vag supp daily for
3 days
Miconazole 100 mg
vag supp daily for 7
days **
Tioconazole 6.5%
ointment 5 g intravag,
single dose **
Terconazole 0.4%
cream 5 g intravag x 7
days
Terconazole 0.8%
cream 5 g intravag x 3
days

Terconazole 80 mg
supp daily x 3 days **
*
This drug should not be used by pregnant or lactating women
** These creams and suppositories are oil-based and many weaken latex condoms
and diagphagms
*** Ketoconazole and fluconazole have been studied in variety of oral regimens for
Rx of VVC.
Although effective, they are not recommended as primary therapy because of
cost and toxicity. Oral therapy does not prevent relapse.
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STD Treatment Guidelines: Gonorrhea
MOH RI

CDC US

WHO

Ciprofloxacin* 500 mg
po single dose

Ceftriaxone 125 mg
IM single dose

Ciprofloxacin 500 mg po single
dose

Ofloxacin* 400 mg po
single dose

Cefixime 400 mg po
single dose

Ceftriaxone 250 mg IM single
dose

Thiamphenicol* 3.5 g
po single dose

Ciprofloxacin 500 mg
po single dose

Cefixime 400 mg po single dose

Ceftriaxone 250 mg
IM single dose

Ofloxacin 400 mg po
single dose

Spectinomycin 2 g IM single dose

Kanamycin 2 g IM
single dose

PLUS DUAL RX
FOR CHLAMYDIA

AR: which may be useful in some
countries depending on the
resistance:

Spectinomycin 2 g IM
single dose

Kanamycin 2 g IM single dose
TMP (80mg)/SMZ (400mg), 10
tabs po, once daily for 3 days
Concurrent antichlamydial Rx

STD Treatment Guidelines: Chlamydia
MOH RI

CDC US

WHO

Doxycycline 100 mg
po BID x 7 days

Doxycycline 100 mg
po BID x 7 days

Doxycycline 100 mg po BID x 7
days

Azithromycin 1 g po
single dose

Azithromycin 1 g po
single dose

Tetracycline 500 mg po QID x 7
days

Erythromycin 500 mg
po QID x 7 days

AR: Ofloxacin 300
mg po BID x 7 days

AR: Erythromycin 500 mg QID x
7 days

AR: Erythromycin
base 500 mg po QID
x 7 days

AR: Sulfafurazole 500 mg po QID
x 10 days

AR: Sulfisoxazole
500 mg po QID x 10
days (inferior regimen
to others)
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STD Treatment Guidelines : Syphilis-Primary & Secondary
MOH RI

CDC US

WHO **

Benzathine Penicillin
2.4 million U IM,
single dose, or

Benzathine Penicillin
2.4 million U IM,
single dose*

Benzathine Penicillin 2.4 million U
IM, single dose

Procaine Penicillin
600,000 U IM q.Day x
10 days

if Non-pregnant &
PCN allergic :

(AR) : Aqueous procaine
benzathine PCN G. 1.2 million U
IM daily x 10 days

if allergic can give:

(AR): Doxycycline
100 mg po BID x 14
days

if Non-pregnant & PCN allergic :

Tetracycline 500 mg
po QID x 15 days, or

Tetracycline 500 mg
po QID x 14 days

(AR): Tetracycline 500 mg po
QID x 15 days

Erithromycin 500 mg
po QID x 15 days

if PCN Allergic, &
pregnant,
desensitization then
Rx w. PCN

(AR) : Doxycycline 100 mg po
BID x 15 days

Doxycycline 100 mg
po BID x 15 days

**- recommends this regimen for
primary, secondary or latent
syphilis of not more than 2 years’
duration

* Follow-up exam and labs at 3 AND 6 months
STD Treatment Guidelines : Late Latent Syphilis
Benzathine PCN G 7.2 million U administered in 3 doses of 2.4 million U IM
weekly at 1 week intervals Benzathine PNC G, 2.4 million U IM weekly for 3
weeks
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STD Treatment Guidelines :Chancroid
MOH RI

CDC US

WHO

Ciprofloxacin 500 mg po
single dose, or,

Azithromycin 1 g po
single dose, or,

Erythromycin 500 mg po TID
x 7 days, or

Ofloxacin 400 mg po single
dose, or,

Ceftriaxone 250 mg
IM single dose, or

(AR) : Ciprofloxacin 500 mg
po single dose

Azithromycin 1 g po single
dose, or,

Erythromycin base
500 mg po QID x 7
days, or

Ceftriaxone 250 mg IM single
dose

Erythromycin 500 mg po
QID x 7 days, or

Spectinomycin 2 g IM single
dose

Ceftriaxone 250 mg IM
single dose, or

TMP(80 mg)/SMZ (400 mg),
2 tabs BID x 7 days*

TMP/SMZ 80/400 mg, 2
tabs BID x 7 days
* TMP/SMZ has been shown to be less effective in some parts of Asia and Africa. It
should only be used in areas where in vitro resistant rates are low and monitored
at regular levels. Where compliance is likely, Erythromycin is definitely the
treatment of choice.

RTI/STD Treatment Cost Implication
No

Disease

1 Trichomoniasis

Drug
Metronidazole 500 mg, orally

2 Bacterial vaginosis 1) Metronidazol 500 mg, orally

Dose/Person
2 grams, single dose
500 mg BID for 7 days

2) Ampicillin 500 mg, orally

2 grams, single dose
500 mg BID for 7 days
500 mg QID for 7 days

1) Clotrimazole 500 mg, vaginal tablet
2) Nystatin 10,000 IU, vaginal tablet
3) Ketokonazole 200 mg, orally
4) Itrakonazole 200 mg, orally
5) Fluconazole150 mg, orally

single dose
1 times daily for 14 days
2 times daily for 5 days
2 times daily for 1 day
single dose

1) Ciprofloxacin 500 mg, orally
2) Ofloxacin 400 mg, orally
3) Thiamphenicol 3.5 g, orally
4) Seftriaxone 250 mg, IM
5) Kanamycin 2 gr, IM
6) Spectinomycin 2 gr, IM

single dose
single dose
single dose
single dose
single dose
single dose

5 Chlamydia

1) Doxycycline 100 mg, orally
2) Azithromycin 1 g, orally
3) Erythromycin 500 mg, orally

twice a day for 7 days
single dose
4 times a day for 7 days

6 Syphilis

1) Benzathine penicillin G 2.4 m.unit IM
2) Penicillin procaine 600,000 units IM
3) Tetracycline 500 mg, orally
4) Erithromycin 500 mg, orally
5) Doxycycline 100 mg, orally

single dose
1 times a day for 10 days
4 times a day for 15 days
4 times a day for 15 days
2 times a day 15 days

3 Candidiasis

4 Gonorrhea

Range of Cost for Treatment (Rp)
Min.Cost/Unit Tot Min. Cost/Reg. Max.Cost/Unit Tot. Max Cost/Reg.
106
424
1,747
6,988
106
1,484
1,747
24,458
106
106
206
-

424
1,484
5,768
-

1,747
1,747
1,695

6,988
24,458
47,460

18,150

18,150

2,929
7,150
33,908

29,290
14,300
33,908

1,544
427
3,600
19,800

21,616
4,270
7,200
19,800

2,200
4,573
680
7,573
300

2,200
4,573
4,760
7,573
300

10,116
8,639
1,779
13,750
8,800
22,790

10,116
8,639
12,453
13,750
8,800
22,790

243
13,600
443

3,402
13,600
12,404

3,048
33,492
3,960

51,816
33,492
110,880

6,094
398
202
443
243

6094
3,980
12,120
26,580
7,290

-

-

-

922
3,960
3,048

55,320
237,600
91,440

RTI/STD Treatment Cost Implication
No

Disease

Drug

Dose/Person

7 Chancroid

1) Ciprofloxacin 500 mg, orally
2) Ofloxacin 400 mg, orally
3) Azithromycin 1 gr, orally
4) Erythromycin 500 mg, orally
5) Ceftriaxone 250 mg, IM
6) Cotrimoxazole 400 mg tablets orally

single dose
single dose
single dose
4 times a day for 7 days
single dose
2 tablets BID for 7 days

Min.Cost/Unit
2,200
4,573
13,600
443
7,573
88

8 Herpes Simplex
Virus

first clinical episode
1) Acyclovir 200 mg, orally
recurrent episode
1) Acyclovir 200 mg, orally

5 times a day for 7 days

1,100

38,500

5,525

193,375

5 times a day for 5 days

1,100

27,500

5,525

138,125

Note: Unit means per tablet or capsule
Reg. (regimen) means total tablets/capsules for the length of treatment of time needed

Range of Cost for Treatment (Rp)
Tot Min. Cost/Reg. Max.Cost/Unit Tot. Max Cost/Reg.
2,200
10,116
10,116
4,573
8,639
8,639
13,600
33,492
33,492
12,404
3,960
110,880
7,573
55,000
55,000
2,464
1,726
48,328
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ORAL INFORMED CONSENT FORM
Improved Reproductive Health and STD Services
for Women Presenting to Family Planning Services in North Jakarta
Name of Client: _________________________Study Number: _______________
Address: _______________________________Phone:______________________
1. Purpose of the study:
The purpose of this study is to find out more about infections women might get in their reproductive
tract. We would like your help as a participant in a study to learn more about this and be able to
help women who need treatment to receive it.
2. Procedures:
We invite you to be examined by a doctor or midwife who will perform some tests to see if you
might have an infection and need treatment. During the examination some samples of vaginal and
cervical secretions will be taken, and a small amount of blood (5 ml) will be drawn from your arm.
During the examination an observer will be present to observe the health care providers actions.
We will also ask you to answer some questions about your medical and reproductive health history.
The answers to these questions will be kept strictly confidential. Any report from this study will not
use your name.
You can freely decide if you wish to enter the study. If you do not want to participate in the study
you will receive care as usual at the family planning unit. You may withdraw from the study at any
time.
3. Risks and Benefits:
The possible risks and discomfort associated with this study include some possible discomfort
during the internal examination, and when blood is drawn from your arm, and some possible
embarrassment at being asked certain questions. The procedures are not considered to carry any
medical risks.
If you agree to participate in this study, you will receive a comprehensive physical examination and
a series of tests will be done to identify any infections that you might have in your reproductive
tract. You will not have to pay for these tests and you will receive free treatment if an infection is
discovered. If your partner also needs treatment, we will make a plan with you to accomplish this.
As the results of some of the laboratory tests will not be available for a little while, we would like
you to contact us in two weeks' time to check whether these results show that you have an infection
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that did not get properly treated. If you wish, we can also contact you at home to let you know
whether you need to come back to the clinic for follow-up. If you give us permission to contact you
at home, we will not say anything about you to anyone else there.
You are welcome to ask us questions about the study at any time. If you have questions after you
leave the clinic, you may contact Dr. Meiwita Iskandar, Jakarta (tel 520-0494 or 520-0094).

______________________________
Signature of Investigator

_______________
Date

Subjects Statement:
The study described above has been explained to me and I agree to participate in this study. I have
had a chance to ask questions. I know that I can stop participating at any time without loosing any
benefits of the services I already receive in this family planning clinic.

Participants preferred plan for follow-up:

________________________________
Signature of Staff Reading Informed
Consent Form to Potential Participant

instruments\consent\14/3/97

_________________
Date
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PROTOKOL DIAGNOSIS DAN
PENATALAKSANAAN KASUS
INFEKSI SALURAN REPRODUKSI (ISR)/
PENYAKIT MENULAR SEKSUAL (PMS)

“PEMERIKSAAN ISR/PMS DI UNIT KB
SECARA TERPADU”
Di RSUD Koja dan
Puskesmas Kecamatan Cilincing
The Population Council Jakarta dan HIV/AIDS Prevention Project Departemen
Kesehatan RI dibiayai oleh USAID di bawah koordinasi Family Health
International/AIDSCAP bekerjasama dengan
Centers for Disease Control (CDC) A.S

The Population Council-Jakarta
Asia & Near East Operations Research and
Technical Assistance Project
1997
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PROTOKOL DIAGNOSIS DAN
PENATALAKSANAAN KASUS
INFEKSI SALURAN REPRODUKSI (ISR) /
PENYAKIT MENULAR SEKSUAL (PMS)

Daftar pustaka:
1. King, Holmes K., et al. Sexually Transmitted Diseases. 2nd Ed. New York:
Mc graw-Hill, Inc, 1990.
2. Daili, Sjaiful Fahmi, dkk (ed). Penatalaksanaan Penyakit Menular Seksual
Berdasarkan Pendekatan Sindrom ,Fasilitas Laboratorium Sederhana,
Laboratorium Khusus. Dirjen PPM & PLP Depkes RI dan Kelompok Studi
Penyakit Menular Seksual Indonesia. Jakarta 1996.

Foto-foto pada pedoman ini diambil dari:
H. Hunter Handsfield. Color Atlas and Synopsis of Sexually
Transmitted Diseases. Mc Graw Hill, 1992.

Catatan :
Diagnosis untuk HIV tidak termasuk dalam studi ini, tetapi jika petugas kesehatan
menilai bahwa pasien mempunyai risiko terhadap HIV, disarankan merujuk
pasien menurut mekanisme yang berlaku di fasilitas tersebut.
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TRIKOMONIASIS
Riwayat kesehatan

Mungkin terdapat:
1. Cairan vagina yang abnormal :
- berbau
- banyak & berbusa
- tampak kuning/hijau
2. Gatal pada vulva
3. Nyeri pada saat buang air kecil dan/atau
berhubungan seksual

Pemeriksaan fisik

Mungkin terdapat:
1. Peradangan
2. Cairan berbau
3. Cairan vagina tampak abu-abu/hijau/kuning
4. Strawberry cervix

Hasil laboratorium

Tampak:
Motile trichomonads pada preparat basah garam faal

Pengobatan

Regimen pilihan:
#Metronidazol 2 gr per oral, dosis tunggal

# Tidak diberikan kepada wanita
hamil.
# Dilarang minum alkohol saat
pengobatan dengan Metronidazol
Catatan
Metronidazol dapat dipakai untuk
wanita hamil trimester ke - 3
Rujukan pasangan dan
pemeriksaan tambahan untuk
pasien

Regimen alternatif:
#Metronidazol 2 x 500 mg, 7 hari

1. Terapi bersama pasangan
2. Lakukan juga tes Gonore dan Klamidia
3. Dianjurkan rujukan tes serologi HIV
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Gambar 1 : Motile Trichomonads pada preparat basah garam faal
VAGINOSIS BAKTERIAL
Riwayat kesehatan

Mungkin terdapat:
1. Cairan vagina yang abnormal :
- berbau amis
- tampak abu-abu/putih

Pemeriksaan fisik

Mungkin terdapat:
1. Cairan berbau
2. Cairan licin dan lengket
3. Cairan tampak abu- abu/putih

Hasil laboratorium

Tampak:
1. Clue cells pada preparat basah garam faal
2. Bau (+) dengan KOH

Pengobatan

Regimen pilihan:
#Metronidazol 2 gr per oral, dosis tunggal

# Tidak diberikan kepada wanita
hamil.
Regimen alternatif:
# Dilarang minum alkohol saat
pengobatan dengan Metronidazol #Metronidazol 2 x 500 mg per oral, 7 hari atau
Ampisilin 4 x 500 mg per oral, 7 hari
Catatan
Metronidazol dapat dipakai untuk
wanita hamil trimester ke - 3
Rujukan pasangan dan
pemeriksaan tambahan untuk
pasien
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Gambar 4: Clue Cells pada preparat basah garam faal
KANDIDIASIS VULVOVAGINAL
Riwayat kesehatan

Mungkin terdapat:
1. Cairan vagina yang abnormal:
- putih kental seperti susu basi
2. Gatal & kemerahan pada vulva

Pemeriksaan fisik

Mungkin terdapat:
1. Peradangan
2. Cairan putih kental seperti susu basi

Hasil laboratorium

Tampak :
Miselium/Pseudohifa pada preparat basah KOH/Gram

Pengobatan

Regimen pilihan:
Klotrimazol 500 mg intra vagina, dosis tunggal atau
Mikonazol/klotrimazol 1x200 mg intra vagina, 3 hr atau
Nystatin 1 x 100.000 IU intra vagina, 14 hari atau
#Ketokonazole 2 x 200 mg per oral, 5 hari atau
#Itraconazole 2 x 200 mg per oral, 1 hari atau
Flukonazol 150 mg per oral, dosis tunggal.

# Tidak diberikan kepada
wanita hamil, menyusui, dan
anak-anak.

Rujukan pasangan dan
pemeriksaan tambahan
untuk pasien
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Gambar 6: Hifa pada Pewarnaan Gram
GONORE
Riwayat kesehatan

Mungkin terdapat:
1. Cairan vagina tampak kuning/putih
2. Nyeri pada saat buang air kecil
3. Perdarahan setelah hubungan seksual
4. Nyeri perut bagian bawah

Pemeriksaan fisik

Mungkin terdapat:
1. Cairan vagina bertambah banyak
2. Serviks merah
3. Ektopi serviks
4. Serviks rapuh
5. Cairan mukopus keruh
6. Rasa nyeri saat serviks digerakkan
7. Rasa nyeri pada palpasi uterus dan/atau adneksa.

Hasil laboratorium

Mungkin terdapat >30 lekosit/PMN
Tampak :
Diplococcus Gram Negative Intra Sel
Kultur Gonore (+)

Pengobatan

Regimen pilihan:

# Tidak diberikan kepada
wanita hamil, menyusui, dan
anak-anak

#Siprofloksasin 500 mg per oral, dosis tunggal atau
#Ofloksasin 400 mg per oral, dosis tunggal atau
#Tiamfenikol 3,5 gr per oral, dosis tunggal atau
Seftriakson 250 mg IM, dosis tungggal atau
Kanamisin 2 gr IM, dosis tunggal atau
Spektinomisin 2 gr IM, dosis tunggal

Rujukan pasangan dan
pemeriksaan tambahan
untuk pasien

1. Pasangan harus diberitahu, diperiksa dan diobati
2. Lakukan juga tes Klamidia
3. Dianjurkan rujukan tes serologi HIV
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Gambar 8 : Uretritis Gonore
KLAMIDIA GENITAL
Riwayat kesehatan

Umumnya asimtomatik, mungkin terdapat :
1. Cairan vagina kekuningan dan encer
2. Nyeri pada saat buang air kecil
3. Perdarahan setelah hubungan seksual.
4. Nyeri perut bagian bawah.

Pemeriksaan fisik

Mungkin terdapat:
1. Cairan vagina bertambah banyak
2. Serviks merah
3. Ektopi serviks
4. Serviks rapuh
5. Cairan mukopus keruh
6. Rasa nyeri saat serviks digerakkan
7. Rasa nyeri pada palpasi uterus dan/atau adneksa.

Hasil laboratorium

Mungkin terdapat >30 lekosit/PMN
Tampak :
Tes enzim Klamidia (+).

Pengobatan

# Tidak diberikan kepada
wanita hamil, menyusui, dan
anak-anak

Regimen pilihan:
#Doksisiklin 2 x 100 mg per oral, 7 hari atau
#Azitromisin 1 gr per oral, dosis tunggal atau
#Tetrasiklin 4 x 500 mg per oral, 7 hari atau
Eritromisin 4 x 500 mg per oral, 7 hari

Rujukan pasangan dan
pemeriksaan tambahan
untuk pasien

1. Pasangan harus diberitahu, diperiksa dan diobati
2. Lakukan juga tes Gonore
3. Dianjurkan rujukan tes serologi HIV
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Gambar 10 : Servisitis mukopurulen Klamidia
SERVISITIS MUKOPURULEN
Riwayat kesehatan

Mungkin terdapat:
1. Cairan vagina kekuningan dan encer
2. Nyeri pada saat buang air kecil
3. Perdarahan setelah hubungan seksual
4. Nyeri perut bagian bawah

Pemeriksaan fisik

Mungkin terdapat:
1. Cairan vagina bertambah banyak
2. Serviks merah
3. Ektopi serviks
4. Serviks rapuh
5. Cairan mukopus keruh
6. Rasa nyeri saat serviks digerakkan
7. Rasa nyeri pada palpasi uterus dan/atau adneksa

Hasil laboratorium

Mungkin terdapat :
>30 lekosit/PMN, ingat diagnosis empiris

Pengobatan

Regimen pilihan:
Harus termasuk regimen yang efektif terhadap Gonore
dan Klamidia

Rujukan pasangan dan
pemeriksaan tambahan
untuk pasien

1. Pasangan harus diberitahu, diperiksa dan diobati
dengan regimen
2. Lakukan juga tes Gonore dan Klamidia
3. Dianjurkan rujukan tes serologi HIV
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Gambar 12 : Servisitis Mukopurolen Non Gonore
SIFILIS
Riwayat kesehatan

Umumnya asimtomatik. Mungkin terdapat:
1. Ulkus di genitalia
2. Kemerahan di seluruh kulit

Pemeriksaan fisik

Mungkin terdapat:
1. Ulkus tunggal yang tidak sakit
2. Diameter ulkus 5 - 15 mm
3. Tepi ulkus meninggi dan berbatas jelas
4. Dasar ulkus: halus dan bersih
5. Perabaan ulkus: keras
6. Kelenjar limfe: keras, tidak sakit
7. Setelah ulkus sembuh timbul kemerahan yang
simetris pada tubuh, telapak tangan dan telapak kaki

Hasil laboratorium

Harus tampak :

Pengobatan

# Tidak diberikan kepada
wanita hamil, menyusui, dan
anak-anak

Rujukan pasangan dan
pemeriksaan tambahan
untuk pasien

VDRL atau RPR (+) dengan konfirmasi TPHA, yang
memerlukan waktu untuk bereaksi setelah 3-4 bulan
permulaan timbul ulkus
Regimen pilihan
Benzatin Penisilin G 2,4 juta IU, IM, dosis tunggal atau
Penisilin Prokain 600.000 unit IU, IM, 10 hari
Bila alergi Penisilin, dapat diberikan:
#Tetrasiklin 4 x 500 mg per oral, 15 hari atau
Eritromisin 4 x 500 mg per oral, 15 hari atau
#Doksisiklin 2 x 100 mg per oral, 15 hari
1. Sangat penting untuk memberitahu, memeriksa, dan
mengobati pasangannya bersama-sama. (Sifilis
adalah penyakit sistemik yang serius)
2. Lakukan juga tes Gonore dan Klamidia untuk pasien
3. Dianjurkan rujukan tes serologi HIV
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Gambar 14 : Ulkus Sifilis
ULKUS MOLE/CHANCROID
Riwayat kesehatan

1. Ulkus di genitalia
2. Pembengkakan yang sakit di daerah selangkangan /
lipat paha

Pemeriksaan fisik

1.
2.
3.
4.
5.
6.

Hasil laboratorium

Konfirmasi laboratorium spesifik tidak terdapat pada
penelitian ini. Diagnosis berdasarkan riwayat dan gejala
klinis

Pengobatan

Regimen pilihan:

# Tidak diberikan kepada
wanita hamil, menyusui, dan
anak-anak

Ulkus yang multipel yang sakit
Diameter ulkus 2 - 20 mm
Tepi ulkus kasar dan tidak teratur
Dasar ulkus: kotor dan purulen.
Perabaan ulkus: lunak
Mungkin terdapat kelenjar limfe: bubo unilateral dan
sakit

#Siprofloksasin 500 mg per oral, dosis tunggal atau
#Ofloksasin 400 mg per oral, dosis tunggal atau
Azitromisin 1 gr per oral, dosis tunggal atau
Eritromisin 4 x 500 mg per oral, 7 hari atau
Seftriakson 250 mg IU IM, dosis tunggal atau
Trimetoprim-Sulfametoksasol 80 mg - 400 mg,

2 x 2 tablet per oral, 7 hari
Rujukan pasangan dan
pemeriksaan tambahan
untuk pasien

1. Perlu memberitahu, memeriksa, dan mengobati
pasangannya bersama-sama
2. Lakukan juga tes Gonore dan Klamidia untuk pasien
3. Dianjurkan rujukan tes serologi HIV
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Gambar 16: Ulkus Mole/Chancroid
HERPES GENITAL
Riwayat kesehatan

Mungkin terdapat:
1. Luka di genitalia yang pada permulaan sangat sakit.
2. Nyeri pada saat buang air kecil
3. Malaise (rasa tidak enak badan) dan mialgia/rasa
sakit pada otot
4. Terdapat rekurensi

Pemeriksaan fisik

Mungkin terdapat:
1. Vesikel-vesikel berisi air, yang
2. Ulserasi, dan
3. Berdiameter 1-5 mm

Hasil laboratorium

Diagnosis empiris

Pengobatan

Episode pertama
Asiklovir 5 x 200 mg per oral, 7 hari
Bila gejala sistemik berat
Asiklovir 5 mg/kg BB intravena tiap 8 jam, 7 hari
Episode rekurensi
Bila gejala berat dan lama
Asiklovir 5 x 200 mg per oral, 5 hari

Rujukan pasangan dan
pemeriksaan tambahan
untuk pasien

1. Perlu penyuluhan dan konseling pasangan
2. Lakukan juga tes Gonore dan Klamidia untuk pasien
3. Dianjurkan rujukan tes serologi HIV
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Gambar 20 : Erosi tipis multipel pada wanita yang disebabkan oleh Herpes
Genital
KONDILOMA AKUMINATA
Riwayat kesehatan

Mungkin terdapat:
Kutil di genitalia yang tidak sakit

Pemeriksaan fisik

Lesi genitalia yang menyerupai veruka/kutil

Hasil laboratorium

Diagnosis empiris

Pengobatan

Eradikasi: belum ada
Menghilangkan kutil eksternal dapat dilakukan dengan:
#Tinktura Podofilin 10-25% atau
Asam trikloro-asetat 40-50% topikal atau
Asam salisilat 20-40%

# Tidak diberikan kepada
wanita hamil, menyusui

Rujukan pasangan dan
pemeriksaan tambahan
untuk pasien

1. Perlu penyuluhan dan konseling pasangan
2. Lakukan juga tes Klamidia
3. Dianjurkan tes serologi HIV
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Gambar 18 : Kondiloma Akuminata yang disebabkan oleh Human Papililoma
Virus (HPV
TRIKOMONIASIS

Gambar 2 : Cairan vagina yang berbusa pada trikomoniasis
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“Strawberry Cervix”
Gambar 3 : Serviks yang kemerahan pada trikomoniasis (Strawberry Cervix)
VAGINOSIS BAKTERIAL

Gambar 5 : Cairan dari vagina yang licin dan lengket pada Vaginosis Bakterial
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KANDIDIASIS

Gambar 7 : Cairan dari vagina yang bergumpal seperti susu Kandidiasis
Vulvoginal
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GONORE

Gambar 8 : Uretritis gonore

Gambar 9 : Cairan purulen uretritis Gonore pada pria
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KLAMIDIA

Gambar 11 : Servisitis Klamidia
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Sebelum diobati

2 minggu setelah pengobatan lengkap

SERVISITIS MUKOPURULEN

Gambar 13 : Servisitis Mukopurulen pada pemakai IUD

Appendix L

SIFILIS

Gambar 14 : Ulkus Sifilis
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Gambar 15 : Sifilis sekunder, kemerahan yang simetris pada tubuh, telapak
tangan dan telapak kaki
ULKUS MOLE / CHANCROID

Gambar 17 : Ulkus di labia pada Chancroid
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KONDILOMA AKUMINATA

Gambar 19 : Kutil pada genitalia eksterna pada wanita yang disebabkan oleh
Human Papilloma Virus ( HPV)
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RTI/STD Case Study Game
Purpose:
To conduct a secondary training program for HCP’s that demonstrate the need for
improved etiological assessment of RTI/STD syndromes. This style of training reduces the lecture
format and emphasizes an interactive educational session that uses positive reinforcement for the
learners.
Target audience:
Midwives that have received the introductory RTI/STD core training, but
don’t have a history of making etiological judgements and prescriptions.
Instructions:
RTI/STD clinical case scenarios will be individually printed on a deck of
index cards. A facilitator with RTI/STD clinical expertise will shuffle the deck of cards, and allow
a volunteering participant to select a card that is held face down. The facilitator reads the scenario
then guides the participants response to the correct answer. If the volunteering participant does not
have the correct answer, the facilitator may offer the question to another volunteer participant.
Participants who respond with the correct answer, will be awarded a token for each correct answer.
The participant with the most correct answers at the end of the “game” will win a prize, such as a
decorative pewter bowl for the HCP’s office to display condoms for clients in.
Learning objectives: Upon completion of this training activity, the student participant will be able
to correctly:
C
Describe an etiological diagnosis for eight different clinical case presentations;
C
List the appropriate pharmaceutical selections for four separate RTI/STD;
C
Recognize the need to refer a pregnant client with a suspected syphilis infection to a medical
doctor for treatment both for herself and any sexual partner(s);
C
List the RTI/STD’s that require concurrent partner treatment;
C
Recognize the probable exam signs that lead to an etiological diagnosis from a photographs
of classical RTI/STDs;
C
Include a discussion and offer of condoms in all STD client education sessions;
C
Recognize HIV education and testing as an adjunct of STD case management.

Materials:
C
31clinic case study cards
C
50 correct answer tokens (one scenario may have more than one question)
C
Prizes for participants. Consider a first place for the most correct answers, and addtional
awards for morale, i.e., most enthusiastic, 2nd place, etc.
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Case study/question:
1.
A 20 year old woman who contracepts with injections presents to the FP clinic with a
chief complaint of vaginal itching, and a thick chunky white discharge. On exam you
find her vulva to be swollen and red. Her speculum exam reveals a curdy white
discharge. Her vaginal microscopy shows pseudo hyphae.
What is the diagnosis?
Answer:
Candidiasis.
Bonus question: What is the treatment?
Answer:
An antifungal medicine such as miconazole or clotrimasole. If she is not
pregnant and has no history of liver disease, Fluconazole can also be used.
____________________________________________________________________________
2.

A 40 year old woman who contracepts with an IUD, complains of a white discharge that
has a bad odor. She denies vaginal itching. She complains that the discharge is so heavy
it constantly makes her underwear wet. On exam you notice a smooth white discharge.
There is no sign of tissue irritation. When you combine the discharge with KOH, you
notice a strong odor.

What is the probable diagnosis?
Answer:
suspect Bacterial Vaginosis
What should you see on her vaginal microscopy report?
Answer:
Clue cells
Bonus question:
What medicine should you use to treat this infection?
Answer:
If she is not pregnant or allergic, use Metronidazole.
__________________________________________________________________________
3.

A 32 year old woman who contracepts with injections, complains of vaginal discharge
and itching. She tells you that it stains her underwear a green/yellow color. On exam,
her vulva is normal without ulcers, warts, or significant inflammation. Her speculum
exam reveals a frothy grey discharge. There are signs of cervical and vaginal erythema.

What should you expect to see on the normal saline wet mount?
Answer:
Motile Trichomonads.
2
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Bonus question:
What medicine should you use to treat this infection?
Answer:
If she is not pregnant or allergic, use Metronidazole.

4.

A monogamous 27 year old woman who contracepts with pills is not sure if her husband
has sex with other women or not. She complains of bleeding after intercourse. Her
husband is a sailor and is frequently gone from home for long periods of time. Her
external exam reveals a normal genitalia, without signs of inflammation, ulcers or warts.
Her speculum exam shows a sore red cervix that has thick yellow discharge oozing out
of her os. When you gently insert a sterile swab into the endocervix, her cervix bleeds
easily.

What should you do?
Answer:
1. Consider a diagnosis of Mucopurulent cervicitis;
2. Get endocervical specimens for gonorrhea, and chlamydia;
3. Provide treatment for gonorrhea and chlamydia;
4. Make a treatment plan with her for treatment of her sexual partner(s).
__________________________________________________________________________
5.

A 38 year old woman who is 2 months pregnant, presents with a red rash on her chest,
abdomen, palms, and soles of her feet. She doesn’t feel sick. 4 weeks ago she had a
sore on her labia that was as big as a 25 Rupiah coin. It wasn’t painful and disappeared
without any problems. Her husband is a truck driver. She tells you that she is afraid he
might have given her something. Her pelvic exam is normal without any signs of
discharge, ulcers or cervicitis.

What should you do?
Answer:
1. Tell the woman that it is possible that she has an infection that could hurt her
pregnancy if it is not carefully diagnosed and treated. Tell her that it is
important that you have her evaluated by a doctor today.
2. Obtain a blood specimen for syphilis screening (RPR), and also endocervical
specimens to test for gonorrhea and chlamydia.
3. Find a doctor in your clinic or make a same day referral to a doctor to
evaluate this client. Tell the doctor that you suspect “syphilis” as the
cause for this rash, and request same day treatment for the client.
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4. Make a treatment plan for her sexual partner(s).
5. Provide education after she has sent the doctor to be certain she understands
the importance of the treatment recommendations, and to schedule follow-up
evaluations.
__________________________________________________________________________
6.

A 29 year old woman who contracepts with implants complains of a painful sore on her
labia and pain in her groin. Her exam shows a purulent ulcer about 20 mm in diameter
with rough irregular borders. The sore seems very tender. Her left groin has an
erythematous swelling about 1 by 2 cm in diameter.

What is your first thought about what infection this could be?
Answer:
Chancroid.
Name at least 2 other STD’s that can cause genital ulcers to occur:
Answer:
Syphilis, herpes, LGV.
__________________________________________________________________________
7.

An 18 year old woman complains of small blisters on her vulva that come and go. She
has had these blisters 2 other times this year. They are only painful when she urinates,
but the first time they occurred, they were very painful. On her external genital exam,
you notice some firm and tender bilateral inguinal lymphadenopathy when you palpate
the inguinal area with a gloved hand. Her vulva has 5 small ulcers that are moist and red.

What is a possible cause for these genital ulcers?
Answer:
Herpes Simplex Virus II. (Genital herpes)
Can this infection be cured with medication?
Answer:
Since herpes is a virus, it can not be eliminated with a medication. If the
outbreaks are frequent and problematic for the client, she can take an antiviral
drug called “Acyclovir” which will decrease the intensity and duration of the
outbreaks.
____________________________________________________________________________
8.

A 24 year old woman complains of vaginal discomfort and discharge. She reports that
her partner has “bumps” on his penis. Her exam reveals small clusters of rough raised
skin growths on her perineum.

What possible infection has caused these growths?
Answer:
Human Papilloma Virus (genital warts, or, condylomata accuminata).
___________________________________________________________________________
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9.
List as many medications as possible, that are commonly used to treat sexually
transmitted diseases that are not safe to take in the first trimester of pregnancy:
Answer:

Metronidazole
Ciprofloxacin
Fluconazole
Doxycycline.
___________________________________________________________________________
10.
What are two very important things to determine before prescribing any medication to
a woman?
Answer:
1. Is there a possibility of pregnancy?
2. Are there any medical allergies?
____________________________________________________________________________
11.

Is it necessary to also treat the sexual partner of a client you just diagnosed and treated
for:
Bacterial Vaginosis?
____________________________________________________________________________
12.

Is it necessary to also treat the sexual partner of a client you just diagnosed and treated
for:
Candidiasis?
__________________________________________________________________________
13.

Is it necessary to also treat the sexual partner of a client you just diagnosed and treated
for:
Trichomoniasis?
___________________________________________________________________________
14.

Is it necessary to also treat the sexual partner of a client you just diagnosed and treated
for:
Mucopurulent cervicitis?
____________________________________________________________________________
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15.

Is it necessary to also treat the sexual partner of a client you just diagnosed and treated
for:
Gonorrhea?
____________________________________________________________________________
16.

Is it necessary to also treat the sexual partner of a client you just diagnosed and treated
for:
Chlamydia?
____________________________________________________________________________
17.

Is it necessary to also treat the sexual partner of a client you just diagnosed and treated
for:
Syphilis?
____________________________________________________________________________
18.
Photo ID (#2)- Trichomoniasis
____________________________________________________________________________

19.
Photo ID (#5)- Bacterial Vaginosis
____________________________________________________________________________
20.
Photo ID (#7)- Candidiasis
___________________________________________________________________________
21.
Photo ID (#8)-Gonococcal female urethritis
____________________________________________________________________________
22.
Photo ID (#11)- Mucopurulent cervicitis before and after treatment
____________________________________________________________________________
23.
Photo ID (#14)- Primary syphilis chancre - male
____________________________________________________________________________
24.
Photo ID (#15)- Secondary syphilis rash
____________________________________________________________________________
25.
Photo ID (#17)- Chancroid ulcer- female
____________________________________________________________________________
26.

Photo ID (#18)- Human Papilloma Virus-internal
6
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____________________________________________________________________________
27.
Photo ID (#19)- Human Papilloma Virus- external
____________________________________________________________________________
28.
Photo ID (#20)- Ulcers from Herpes Simplex Virus II
____________________________________________________________________________
29.

What additional supplies should always be discussed and offered to dispense with every
STD treatment for future disease prevention?
Answer:
Condoms.
____________________________________________________________________________
30.

Although not a part of this study, what additional blood test might you discuss and refer
clients at risk for STDs to obtain?
____________________________________________________________________________
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Health Facility Assessment
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Health Facility Assessment
Facility Name :
Address
:
Date of survey :

______________________ Phone :
______________________ Fax :
__/__/__

__________________
__________________

Physical Layout

Infection Control

1. Are clients examined in the same room
they give their history in?
________ No
________ Yes

7. Is the exam area clean? (fresh linen,
floor swept, no garbage on floor, etc.)
________ No
________ Yes

2. Is visual privacy maintained in the room
clients give their initial history in?
_________.No
_________ Yes

8. Is the exam table free of visibly
contaminated material &/or dirt?
________ No
________ Yes

3. Is auditory privacy maintained in the
room clients give their initial history in?
________ No
________ Yes

9. Is there a new covering (paper or linen)
on the exam table that is changed after
each patient lays on the table?
_________ No
_________ Yes

4. Is visual privacy maintained in the
examination room?
________ No
________ Yes
5. Is auditory privacy maintained in the
examination room?
________ No
________ Yes
6. Are there RTI/STD educational
materials available in either the
interview or exam area?
________ No
________ Yes, Specify:
__________ posters
__________ flip charts
__________ pamphlets
__________ fact sheets
__________ other

10.Is there running water and a sink in the
exam room?
_________ No
_________ Yes
11.Is there soap for hand washing in the
exam room?
_________ No
_________ Yes
12.Are there towels for drying hands after
washing them in the exam room?
_________ No
_________ Yes, Describe:
________ paper that is
discarded
________ cloth that is
reused
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13. Describe the step by step process for
cleaning and disinfecting vaginal
speculums after they are used
14.What type of syringes and needles are
used in the clinic?
__________ disposable
__________ reusable
15.After a needle has been used to give an
injection, or draw blood, does the staff
re-cap the needle?
__________ No
__________ Yes
16.Where does the staff place the dirty
needle after it has been used?
Equipment Inventory
17.Indicate the presence (+ ) or absence
(0) of the following resources. Make
notes on the working condition of these
items if they are not in good repair.
ITEM

+/0

Condition

Autoclave for
speculums
Exam table with
stirrups
Exam light
Speculum
Trash cans
Light microscope
Incubator
Refrigerator

Type:

Record Keeping and Reporting
Note: Attach an example of a client record
form and of other report forms
used.
18.Is a separate record kept for each client?
__________ No
__________ Yes
19.Are client locators (address, phone,
village) recorded in sufficient detail on
the record to allow for follow-up?
__________ No
__________ Yes
20.In what condition is the record system
maintained?
__________ Well ordered
__________ Partially obscured, still
usable
__________ Disordered, not usable
21.Are records stored in a locked, secure
cabinet?
__________ No
__________ Yes
22.If a communicable disease is diagnosed,
is it recorded or reported anywhere
other than the individual medical
record?
__________ No
__________ Yes
23.Does the clinic maintain epidemiological records to track the rate of
STD's?
__________ No
__________ Yes, if Ayes@ attach a copy
of the form

List of Training Participants
“Improved Reproductive Health and STD Services for
Women Presenting to Family Planning Services in North Jakarta”

No
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
MCH
FP

Name
dr. Umar Wahid (Director)
dr. Basuki Mulyono, DSOG (Head of ObGyn Clinic)
dr. Bambang Çantayuda, DSOG
dr. Mangisi Tambunan, DSOG
dr. Sundari
dr. Gurmukh Sing
Prikatun (midwife)
Nurjanah S (Nurse)
Hayati (Nurse)
dr. Melina Henratna, DSPK (Head of Laboratory Unit)
dr. Tjan Sian Hwa, DSPK (Vice Head of Laboratory Unit)
Sumarni (Lab Technicians)
Ranita (Lab Technicians)
dr. Sri wahyudiyati (Head of Puskesmas Cilincing)
Teji Sulastri (midwife)
Limanis (midwife)
Rusmiyati (midwife)
Sri Nurhidayati (Lab Technicians)
Dyan Shofa Ma’addin (Lab Technicians)
= Mother & Child Health
= Family Planning

Address
Koja Hospital
Koja Hospital
ObGyn Clinic, Koja Hospital
ObGyn Clinic, Koja Hospital
ObGyn Clinic, Koja Hospital
ObGyn Clinic, Koja Hospital
ObGyn Clinic, Koja Hospital
ObGyn Clinic, Koja Hospital
ObGyn Clinic, Koja Hospital
Koja Hospital
Koja Hospital
Koja Hospital
Koja Hospital
Puskesmas Cilincing
MCH/FP Clinic, Puskesmas Cilincing
MCH/FP Clinic, Puskesmas Cilincing
MCH/FP Clinic, Puskesmas Cilincing
Puskesmas Cilincing
Puskesmas Cilincing

